US20220193267A1 - Engineered nucleases useful for treatment of hemophilia a - Google Patents
Engineered nucleases useful for treatment of hemophilia a Download PDFInfo
- Publication number
- US20220193267A1 US20220193267A1 US17/691,648 US202217691648A US2022193267A1 US 20220193267 A1 US20220193267 A1 US 20220193267A1 US 202217691648 A US202217691648 A US 202217691648A US 2022193267 A1 US2022193267 A1 US 2022193267A1
- Authority
- US
- United States
- Prior art keywords
- seq
- sequence
- meganuclease
- factor viii
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101710163270 Nuclease Proteins 0.000 title claims abstract description 161
- 208000009292 Hemophilia A Diseases 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title description 20
- 208000031220 Hemophilia Diseases 0.000 title description 2
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 171
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 79
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 48
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract description 45
- 201000003542 Factor VIII deficiency Diseases 0.000 claims abstract description 45
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 235
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 108700024394 Exon Proteins 0.000 claims description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 48
- 108020004999 messenger RNA Proteins 0.000 claims description 43
- 102000001690 Factor VIII Human genes 0.000 claims description 33
- 108091026890 Coding region Proteins 0.000 claims description 26
- 241000282465 Canis Species 0.000 claims description 19
- 108091033409 CRISPR Proteins 0.000 claims description 17
- 238000010459 TALEN Methods 0.000 claims description 17
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 17
- 210000002889 endothelial cell Anatomy 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 17
- 238000010354 CRISPR gene editing Methods 0.000 claims description 12
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 7
- 101000871817 Homo sapiens 40-kDa huntingtin-associated protein Proteins 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 4
- 102100033646 40-kDa huntingtin-associated protein Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 155
- 230000027455 binding Effects 0.000 description 131
- 108010042407 Endonucleases Proteins 0.000 description 106
- 108020004414 DNA Proteins 0.000 description 105
- 102000004533 Endonucleases Human genes 0.000 description 97
- 208000037516 chromosome inversion disease Diseases 0.000 description 75
- 239000000178 monomer Substances 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 239000013598 vector Substances 0.000 description 31
- 102000040430 polynucleotide Human genes 0.000 description 29
- 108091033319 polynucleotide Proteins 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 239000013603 viral vector Substances 0.000 description 29
- 229960000301 factor viii Drugs 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 238000003776 cleavage reaction Methods 0.000 description 22
- 230000007017 scission Effects 0.000 description 22
- 230000008685 targeting Effects 0.000 description 22
- 239000012634 fragment Substances 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 239000013607 AAV vector Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 210000001766 X chromosome Anatomy 0.000 description 16
- 230000004568 DNA-binding Effects 0.000 description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 15
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 239000005090 green fluorescent protein Substances 0.000 description 15
- 238000004806 packaging method and process Methods 0.000 description 15
- 230000006798 recombination Effects 0.000 description 15
- 238000005215 recombination Methods 0.000 description 15
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 description 14
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 description 14
- 101000709368 Mus musculus S-phase kinase-associated protein 2 Proteins 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 108020004511 Recombinant DNA Proteins 0.000 description 13
- 238000007847 digital PCR Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 10
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 102100028285 DNA repair protein REV1 Human genes 0.000 description 9
- 108091092584 GDNA Proteins 0.000 description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 101150066002 GFP gene Proteins 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002864 sequence alignment Methods 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 230000007018 DNA scission Effects 0.000 description 4
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 208000026552 Severe hemophilia A Diseases 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000006240 membrane receptors Human genes 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000053659 human HAP40 Human genes 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000013271 Hemopexin Human genes 0.000 description 2
- 108010026027 Hemopexin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010057988 ecdysone receptor Proteins 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003007 single stranded DNA break Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 101150072844 APOM gene Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100021619 Ankyrin repeat and SOCS box protein 5 Human genes 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102100037324 Apolipoprotein M Human genes 0.000 description 1
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101150104226 F8 gene Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- 101710191797 Gamma-enolase Proteins 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 102100033550 Histone H2A-Bbd type 1 Human genes 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000754309 Homo sapiens Ankyrin repeat and SOCS box protein 5 Proteins 0.000 description 1
- 101000872104 Homo sapiens Histone H2A-Bbd type 1 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000731738 Homo sapiens Inactive ADP-ribosyltransferase ARH2 Proteins 0.000 description 1
- 101000693234 Homo sapiens PDZ domain-containing protein 4 Proteins 0.000 description 1
- 101001000069 Homo sapiens Protein phosphatase 1 regulatory subunit 12B Proteins 0.000 description 1
- 101000987003 Homo sapiens Tumor protein 63 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100032448 Inactive ADP-ribosyltransferase ARH2 Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100025653 PDZ domain-containing protein 4 Human genes 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100036545 Protein phosphatase 1 regulatory subunit 12B Human genes 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091006279 SLC5A12 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102100037203 Sodium-coupled monocarboxylate transporter 2 Human genes 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- -1 cationic lipids Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 102220232161 rs1085307160 Human genes 0.000 description 1
- 102220232162 rs1085307161 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
Definitions
- the invention relates to the field of molecular biology and recombinant nucleic acid technology.
- the invention relates to engineered nucleases having specificity for a recognition sequence within intron 22 of a Factor VIII gene, and particularly within the int22h-1 sequence.
- engineered nucleases are useful in methods for treating hemophilia A characterized by an inversion of exons 1-22 in the Factor VIII gene.
- Hemophilia A is a common genetic bleeding disorder with an incidence of 1 in 5000 males worldwide. This genetic disease can result from various mutations within the coagulation Factor VIII (F8) gene located on the X chromosome, which include large deletions, insertions, inversions, and point mutations. Clinically, hemophilia A can be classified based on relative Factor VIII activity in the patient's plasma as mild (5-30% activity; 50% of patients), moderate (2-5% activity; 10% of patients), or severe ( ⁇ 1% activity; 50% of patients). Currently, there is no cure for hemophilia A.
- F8 coagulation Factor VIII
- Standard therapy includes the administration of recombinant Factor VIII, but this approach is limited by cost, the requirement for frequent injections, and the formation of Factor VIII-inactivating antibodies in the subject which reduce the effectiveness of therapy. Therefore, a clear need still exists for alternative treatments for hemophilia A. Gene therapy, targeting mutations in the Factor VIII gene, remains an attractive yet elusive approach to treatment.
- Factor VIII is an essential component of the clotting cascade.
- the protein circulates in the body in an inactive form that is attached to von Willebrand factor.
- Factor VIIIa is activated (Factor VIIIa) and separates from von Willebrand factor, then interacts with Factor IXa as part of the clotting cascade which leads to the formation of firbin and stable clotting.
- Factor VIIIa is produced by liver sinusoidal endothelial cells, as well as extra-hepatic, hematopoictic cells throughout the body.
- the Factor VIII gene on the X chromosome is large and structurally complex, comprising ⁇ 180 kb and 26 exons.
- the wild-type Factor VIII gene encodes two proteins.
- the first protein is the full-length Factor VIII protein, which is encoded by the 9030 bases found in exons 1 to 26, and has a circulating form containing 2332 amino acid residues.
- the second protein referred to as Factor VIIIb, is encoded by 2598 bases in 5 exons present in the Factor VIII gene.
- the resulting protein comprises 216 amino acids and has a presently unknown function.
- int22h-1 an ⁇ 9.5 kb segment of intron 22, referred to as int22h-1, recombines with one of two repeat copies (referred to as int22h-2 and int22h-3, respectively) which are positioned approximately 400 kb and 500 kb telomeric to the Factor VIII gene on the X chromosome.
- exons 1-22 of the Factor VIII gene become inverted in the genome relative to exons 23-26, resulting in the expression of a truncated, inactive Factor VIII protein that lacks the amino acids encoded by exons 23-26 (Sauna et al. (2015) Blood 125(2): 223-228).
- the upstream repeat copy involved in exon 1-22 inversion is oriented in the opposite direction as int22h-1.
- int22h-2 and int22h-3 were both in reverse orientation relative to int22h-1, allowing for recombination to occur with either repeat sequence. This was referred to as Type I inversion and Type II inversion.
- int22h-2 and int22h-3 are found in an inverse orientation to one another on the X chromosome, and are part of an imperfect palindrome ( FIG. 1 ). Recombination of sequences within this palindrome allows int22h-2 and in22h-3 to swap places in the genome and, consequently, change their orientation relative to int22h-1.
- the int22h-1 sequence can, in different circumstances, recombine with the int22h-2 repeat or the int22h-3 repeat, depending on which is in the opposite orientation to int22h-1 (Bagnall et al. (2006) Journal of Thrombosis and Haemostasis 4: 591-598).
- intron 22 of the Factor VIII gene contains a CpG island that acts as a bi-directional promoter for two further genes, referred to as F8A1 (Factor VIII-associated 1) and FSB.
- F8A1 Factor VIII-associated 1
- FSB a CpG island that acts as a bi-directional promoter for two further genes, referred to as F8A1 (Factor VIII-associated 1) and FSB.
- the CpG island and the intron-less F8A1 gene (SEQ ID NO: 5) are both contained within the int22h-1 sequence (and consequently, within int22h-2 and in22h-3) and are transcribed in the opposite direction as the Factor VIII gene (Bowen (2002) J. Clin. Pathol: Mol. Pathol. 55: 127-144).
- the sequence of the F8A1 gene is the only region of the human Factor VIII gene that exhibits significant homology to the Factor VIII gene in the canine genome, and particularly in a clinically-relevant population of canines that are Factor VIII-deficient and exhibit an inversion of exons 1-22 in their Factor VIII gene (Lozier et al. (2002) PNAS 99(20): 12991-12996).
- the present invention requires the use of site-specific, rare-cutting endonucleases that are engineered to recognize DNA sequences within the int22h-1 sequence in order to generate a double-strand break and promote recombination between int22h-1 and an inversely-oriented repeat sequence (int22h-2 or int22h-3) positioned telomeric to the Factor VIII gene.
- site-specific, rare-cutting endonucleases that are engineered to recognize DNA sequences within the int22h-1 sequence in order to generate a double-strand break and promote recombination between int22h-1 and an inversely-oriented repeat sequence (int22h-2 or int22h-3) positioned telomeric to the Factor VIII gene.
- ZFNs zinc-finger nucleases
- FokI restriction enzyme a zinc finger DNA-binding domain fused to the nuclease domain of the FokI restriction enzyme.
- the zinc finger domain can be redesigned through rational or experimental means to produce a protein which binds to a pre-determined DNA sequence ⁇ 18 basepairs in length.
- ZFNs have been used extensively to target gene addition, removal, and substitution in a wide range of eukaryotic organisms (reviewed in S. Durai et al., Nucleic Acids Res 33, 5978 (2005)).
- TAL-effector nucleases can be generated to cleave specific sites in genomic DNA.
- a TALEN comprises an engineered, site-specific DNA-binding domain fused to the FokI nuclease domain (reviewed in Mak, et al. (2013) Curr Opin Struct Biol. 23:93-9).
- the DNA binding domain comprises a tandem array of TAL-effector domains, each of which specifically recognizes a single DNA basepair.
- Compact TALENs are an alternative endonuclease architecture that avoids the need for dimerization (Beurdeley, et al. (2013) Nat Commun. 4:1762).
- a Compact TALEN comprises an engineered, site-specific TAL-effector DNA-binding domain fused to the nuclease domain from the I-TevI homing endonuclease. Unlike FokI, I-TevI does not need to dimerize to produce a double-strand DNA break so a Compact TALEN is functional as a monomer.
- a CRISPR endonuclease comprises two components: (1) a caspase effector nuclease, typically microbial Cas9; and (2) a short “guide RNA” comprising a ⁇ 20 nucleotide targeting sequence that directs the nuclease to a location of interest in the genome.
- a caspase effector nuclease typically microbial Cas9
- a short “guide RNA” comprising a ⁇ 20 nucleotide targeting sequence that directs the nuclease to a location of interest in the genome.
- the DNA break-inducing agent is an engineered homing endonuclease (also called a “meganuclease”).
- Homing endonucleases are a group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi. They are frequently associated with parasitic DNA elements, such as group 1 self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys.
- Homing endonucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLIDADG homing endonucleases with a single copy of the LAGLIDADG motif form homodimers, whereas members with two copies of the LAGLIDADG motif are found as monomers.
- I-CreI (SEQ ID NO: 1) is a member of the LAGLIDADG family of homing endonucleases which recognizes and cuts a 22 basepair recognition sequence in the chloroplast chromosome of the algae Chlamydomonas reinhardtii . Genetic selection techniques have been used to modify the wild-type I-CreI cleavage site preference (Sussman et al. (2004), J. Mol. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: e178; Seligman et al. (2002), Nucleic Acids Res. 30: 3870-9, Amould et al. (2006), J. Mol. Biol.
- 1-CreI and its engineered derivatives are normally dimeric but can be fused into a single poly-peptide using a short peptide linker that joins the C-terminus of a first subunit to the N-terminus of a second subunit (Li, et al. (2009) Nucleic Acids Res. 37:1650-62; Grizot, et al. (2009) Nucleic Acids Res. 37:5405-19.)
- a functional “single-chain” meganuclease can be expressed from a single transcript. This, coupled with the extremely low frequency of off-target cutting observed with engineered meganucleases makes them the preferred endonuclease for the present invention.
- the TALEN selected for this study cut within the intron 1 homology region in order to induce an inversion of this shorter sequence with an efficiency of 1.9% and 1.4% in the HEK 293T cells and iPSCs, respectively.
- the authors further demonstrated reversion of exon 1 in the iPSCs at a similar efficiency of 1.3%.
- Park et al. reported the use of a CRISPR/Cas system to induce a reversion of exons 1-22 of the Factor VIII gene in iPSCs obtained from patients suffering from severe hemophilia A (Park et al. (2015) Cell Stem Cell 17: 213-220).
- inversions of exons 1-22 are eight times more prevalent than inversions of exon 1, but emphasized that the exon 1-22 inversion is technically more challenging to revert due in part to the substantially larger size of the inversion (600 kbp compared to 140 kbp) and the presence of three homologs of the int22h-1 sequence on the X chromosome, compared to only two homologs of the int1h-1 sequence. Indeed, Park et al.
- the present invention improves on the art in several aspects. Despite suggestions in the art to avoid targeting recognition sequences within the int22h homology regions, the inventors surprisingly found that targeting recognition sequences within int22h-1 can, in fact, produce an inversion or reversion of exons 1-22 in the Factor VIII with high efficiency. Further, several recognition sequences targeted within the int22h-1 sequence are found within the F8A1 sequence, which the inventors found to be the only region of the Factor VIII gene which shares a high degree of homology with the canine Factor VIII gene. Thus, the methods of the invention are useful not only in human subjects suffering from hemophilia A, but also in the clinically-relevant canine hemophilia A population which also expresses an inversion of exons 1-22. Accordingly, the present invention fulfills a need in the art for further gene therapy approaches to severe hemophilia A.
- the present invention provides engineered nucleases useful for the treatment of hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene.
- the engineered nucleases of the invention recognize and a cleave recognition sequence within an int22h-1 sequence of the Factor VIII gene, thereby promoting recombination between the int22h-1 sequence and an identical, or highly homologous, inverted repeat sequence positioned telomeric to the Factor VIII gene on the X chromosome. Such recombination results in a reversion of exons 1-22 to generate a wild-type Factor VIII gene.
- the present invention also provides pharmaceutical compositions and methods for treatment of hemophilia A which utilize an engineered nuclease having specificity for a recognition sequence positioned within the int22h-1 sequence of the Factor VIII gene.
- the present invention further provides genetically-modified cells which have been modified to correct an inversion of exons 1-22 in the Factor VIII gene, as well as pharmaceutical compositions comprising such genetically-modified cells and methods of using the same for the treatment of hemophilia A.
- the invention provides an engineered meganuclease that recognizes and cleaves a recognition sequence within an int22h-1 sequence of a Factor VIII gene.
- the engineered meganuclease comprises a first subunit and a second subunit, wherein the first subunit binds to a first recognition half-site of the recognition sequence and comprises a first hypervariable (HVR1) region, and wherein the second subunit binds to a second recognition half-site of the recognition sequence and comprises a second hypervariable (HVR2) region.
- HVR1 hypervariable
- HVR2 hypervariable hypervariable
- the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In one such embodiment, the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- the recognition sequence can be within an F8A1 coding sequence of the Factor VIII gene.
- the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.
- the F8A1 coding sequence can comprise SEQ ID NO: 5 or SEQ ID NO: 6.
- the recognition sequence can comprise SEQ ID NO: 7.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 19 or residues 24-79 of any one of SEQ ID NOs: 20-21.
- the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 19 or residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 20-21.
- the HVR1 region can comprise residues 215-270 of SEQ ID NO: 19 or residues 24-79 of any one of SEQ ID NOs: 20-21.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 19 or residues 215-270 of any one of SEQ ID NOs: 20-21.
- the HVR2 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 68, 70, 75, and 77 of SEQ ID NO: 19 or residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 259, 261, 266, and 268 of any one of SEQ ID NOs: 20-21.
- the HVR2 region can comprise residues 24-79 of SEQ ID NO: 19 or residues 215-270 of any one of SEQ ID NOs: 20-21.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 19 or residues 7-153 of SEQ ID NO: 20 or 21, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95, or more, sequence identity to residues 7-153 of SEQ ID NO: 19 or residues 198-344 of SEQ ID NO: 20 or 21.
- the first subunit can comprise residues 198-344 of SEQ ID NO: 19 or residues 7-153 of SEQ ID NO: 20 or 21.
- the second subunit can comprise residues 7-153 of SEQ ID NO: 19 or residues 198-344 of SEQ ID NO: 20 or 21.
- the engineered meganuclease can be a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- the recognition sequence can comprise SEQ ID NO: 9.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 28-31.
- the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 231, 233, 235, 237, 261, 266, and 268 of any one of SEQ ID NOs: 28-31.
- the HVR1 region can comprise residues 215-270 of any one of SEQ ID NOs: 28-31.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 28-31.
- the HVR2 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 28-31.
- the HVR2 region further can comprise a residue corresponding to residue 73 of SEQ ID NO: 30.
- the HVR2 region can comprise residues 24-79 of any one of SEQ ID NOs: 28-31.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 28-31
- the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ 1D NOs: 28-31.
- the first subunit can comprise residues 198-344 of any one of SEQ ID NOs: 28-31.
- the second subunit can comprise residues 7-153 of any one of SEQ ID NOs: 28-31.
- the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- the recognition sequence can comprise SEQ ID NO: 11.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 40 or residues 215-270 of any one of SEQ ID NOs: 41-43.
- the HVR1 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 40 or residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 41-43.
- the HVR1 region can comprise residues 24-79 of SEQ ID NO: 40 or residues 215-270 of any one of SEQ ID NOs: 41-43.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 40 or residues 24-79 of any one of SEQ ID NOs: 41-43.
- the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 40 or residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 41-43.
- the HVR2 region can comprise residues 215-270 of SEQ ID NO: 40 or residues 24-79 of any one of SEQ ID NOs: 41-43.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of SEQ ID NO: 40 or residues 198-344 of any one of SEQ ID NOs: 41-43
- the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 40 or residues 7-153 of any one of SEQ ID NO:s 41-43.
- the first subunit can comprise residues 7-153 of SEQ ID NO: 40 or residues 198-344 of any one of SEQ ID NOs: 41-43.
- the second subunit can comprise residues 198-344 of SEQ ID NO: 40 or residues 7-153 of any one of SEQ ID NOs: 41-43.
- the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- the recognition sequence can comprise SEQ ID NO: 13.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 52-55.
- the HVR1 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 68, 70, 75, and 77 of any one of SEQ ID NOs: 52-55.
- the HVR1 region can comprise residues 24-79 of any one of SEQ ID NOs: 52-55.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 52-55.
- the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 52-55.
- the HVR2 region can comprise residues 215-270 of any one of SEQ ID NOs: 52-55.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ ID NOs: 52-55
- the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 52-55.
- the first subunit can comprise residues 7-153 of any one of SEQ ID NOs: 52-55.
- the second subunit can comprise residues 198-344 of any one of SEQ ID NOs: 52-55.
- the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- the recognition sequence can comprise SEQ ID NO: 15.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 64 or residues 215-270 of any one of SEQ ID NOs: 65-67.
- the HVR1 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 64 or residues 215, 217, 219, 221, 223, 224, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 65-67.
- the HVR1 region can comprise residues 24-79 of SEQ ID NO: 64 or residues 215-270 of any one of SEQ ID NOs: 65-67.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 64 or residues 24-79 of any one of SEQ ID NOs: 65-67.
- the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 64 or residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 65-67.
- the HVR2 region can comprise residues 215-270 of SEQ ID NO: 64 or residues 24-79 of any one of SEQ ID NOs: 65-67.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of SEQ ID NO: 64 or residues 198-344 of any one of SEQ ID NOs: 65-67
- the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 64 or residues 7-153 of any one of SEQ ID NO:s 65-67.
- the first subunit can comprise residues 7-153 of SEQ ID NO: 64 or residues 198-344 of any one of SEQ ID NOs: 65-67.
- the second subunit can comprise residues 198-344 of SEQ ID NO: 64 or residues 7-153 of any one of SEQ ID NOs: 65-67.
- the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- the recognition sequence can comprise SEQ ID NO: 17.
- the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 76-79.
- the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 259, 261, 266, and 268 of any one of SEQ ID NOs: 76-79.
- the HVR1 region can comprise residues 215-270 of any one of SEQ ID NOs: 76-79.
- the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 76-79.
- the HVR2 region can comprise residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 76-79.
- the HVR2 region can comprise residues 24-79 of any one of SEQ ID NOs: 76-79.
- the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 76-79
- the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ ID NOs: 76-79.
- the first subunit can comprise residues 198-344 of any one of SEQ ID NOs: 76-79.
- the second subunit can comprise residues 7-153 of any one of SEQ ID NOs: 76-79.
- the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- the invention provides an isolated polynucleotide comprising a nucleic acid sequence encoding any engineered meganuclease of the invention.
- the isolated polynucleotide can be an mRNA.
- the invention provides a recombinant DNA construct comprising a nucleic acid sequence which encodes any engineered meganuclease of the invention.
- the recombinant DNA construct can be self-cleaving.
- the recombinant DNA construct encodes a viral vector.
- the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an adeno-associated virus (AAV) vector.
- the viral vector can be a recombinant AAV vector.
- the invention provides a viral vector comprising a nucleic acid sequence which encodes any engineered meganuclease of the invention.
- the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an adeno-associated virus (AAV) vector.
- the viral vector can be a recombinant AAV vector.
- the invention provides a pharmaceutical composition for treatment of a subject having hemophilia A.
- hemophilia A is characterized by an inversion of exons 1-22 in a Factor VIII gene.
- the pharmaceutical composition comprises a pharmaceutically acceptable carrier and: (a) a nucleic acid encoding an engineered nuclease, wherein the engineered nuclease is expressed in a target cell in vivo; or (b) an engineered nuclease protein; wherein the engineered nuclease has specificity for a first recognition sequence positioned within an int22h-1 sequence of the Factor VIII gene in the target cell.
- the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In one such embodiment, the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- the first recognition sequence can be within an F8A1 coding sequence.
- the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.
- the F8A1 coding sequence can comprise SEQ ID NO: 5 or SEQ ID NO: 6.
- the engineered nuclease can have specificity for a second recognition sequence that is identical to, or has a high degree of homology with, the first recognition sequence, wherein the second recognition sequence is positioned in a repeat sequence telomeric to the Factor VIII gene in the X chromosome.
- the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence is in reverse orientation relative to the int22h-1 sequence.
- the nucleic acid encoding the engineered nuclease can be an mRNA.
- the pharmaceutical composition comprises a recombinant DNA construct comprising the nucleic acid.
- the recombinant DNA construct can be self-cleaving.
- the pharmaceutical composition comprises a viral vector comprising the nucleic acid.
- the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an AAV.
- the viral vector can be a recombinant AAV vector.
- the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL.
- the engineered nuclease can be an engineered meganuclease.
- the first recognition sequence can comprise SEQ ID NO: 7.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 7.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- the first recognition sequence can comprise SEQ ID NO: 9.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 9.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- the first recognition sequence can comprise SEQ ID NO: 11.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 11.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- the first recognition sequence can comprise SEQ ID NO: 13.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 13.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- the first recognition sequence can comprise SEQ ID NO: 15.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 15.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- the first recognition sequence can comprise SEQ ID NO: 17.
- the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 17.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- the invention provides a method for treating a subject having hemophilia A.
- hemophilia A is characterized by an inversion of exons 1-22 of a Factor VIII gene.
- the method comprises delivering to a target cell in the subject: (a) a nucleic acid encoding an engineered nuclease, wherein the engineered nuclease is expressed in the target cell in vivo; or (b) an engineered nuclease protein; wherein the engineered nuclease is any engineered nuclease of the invention which has specificity for a first recognition sequence positioned within an int22h-1 sequence of the Factor VIII gene in the target cell.
- the method comprises administering to the subject a pharmaceutical composition of the invention described above, which comprises (a) a nucleic acid encoding an engineered nuclease of the invention, wherein the engineered nuclease is expressed in a target cell in vivo; or (b) an engineered nuclease protein of the invention.
- the engineered nuclease, or the nucleic acid encoding the engineered nuclease can be delivered to a target cell which is capable of expressing wild-type Factor VIII, or a progenitor cell which differentiates into a cell which is capable of expressing wild-type Factor VIII.
- the target cell can be a hepatic cell.
- the hepatic cell can be a hepatic sinusoidal endothelial cell.
- the hepatic cell can be a progenitor cell, such as a hepatic stem cell, which differentiates into a hepatic sinusoidal endothelial cell.
- the target cell can be a hematopoietic endothelial cell.
- the target cell can be a progenitor cell which differentiates into a hematopoietic endothelial cell. It is understand that target cells comprise a Factor VIII gene which has an inversion of exons 1-22.
- the engineered nuclease recognizes and cleaves the first recognition sequence to promote recombination between the int22h-1 sequence and the repeat sequence, resulting in reversion of exons 1-22 to generate a wild-type Factor VIII gene.
- the engineered nuclease further recognizes and cleaves the second recognition sequence in the repeat sequence.
- the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL.
- the engineered nuclease can be an engineered meganuclease.
- the first recognition sequence can comprise SEQ ID NO: 7.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 7.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- the first recognition sequence can comprise SEQ ID NO: 9.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 9.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- the first recognition sequence can comprise SEQ ID NO: 11.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 11.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- the first recognition sequence can comprise SEQ ID NO: 13.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 13.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- the first recognition sequence can comprise SEQ ID NO: 15.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 15.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- the first recognition sequence can comprise SEQ ID NO: 17.
- the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 17.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- the subject can be a mammal. In one such embodiment, the subject can be a human. In another such embodiment, the subject can be a canine.
- the invention provides a method for producing a genetically-modified cell comprising a wild-type Factor VIII gene.
- the method comprises: (a) obtaining a cell comprising a Factor VIII gene having an inversion of exons 1-22; and (b) introducing into the cell: (i) a nucleic acid sequence encoding an engineered nuclease, wherein the engineered nuclease is expressed in the cell; or (ii) an engineered nuclease protein; wherein the engineered nuclease has specificity for a first recognition sequence within an int22h-1 sequence of the Factor VIII gene; and wherein the engineered nuclease recognizes and cleaves the first recognition sequence within the int22h-1 sequence to promote recombination between the int22h-1 sequence and a repeat sequence positioned telomeric to the Factor VIII gene; and wherein the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence
- the cell can be a eukaryotic cell.
- the eukaryotic cell can be a pluripotent cell.
- the pluripotent cell can be an induced pluripotent stem (iPS) cell.
- the iPS cell can be a human iPS cell or a canine iPS cell.
- the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4.
- the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- the first recognition sequence can be within an F8A1 coding sequence of the Factor VIII gene.
- the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4.
- the F8A1 coding sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- the engineered nuclease can have specificity for a second recognition sequence that is identical to, or has a high degree of homology with, the first recognition sequence, wherein the second recognition sequence is positioned in a repeat sequence telomeric to the Factor VIII gene in the X chromosome.
- the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence is in reverse orientation relative to the int22h-1 sequence.
- the nucleic acid can be an mRNA.
- the nucleic acid can be introduced into the cell using a recombinant DNA construct.
- the recombinant DNA construct can be self-cleaving.
- the nucleic acid can be introduced into the cell using a viral vector.
- the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an AAV.
- the viral vector can be a recombinant AAV vector.
- the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL.
- the engineered nuclease can be an engineered meganuclease.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 7.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 9.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 11.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 13.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 15.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 17.
- the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- the invention provides a genetically-modified cell, wherein the genetically-modified cell comprises a wild-type Factor VIII gene and is produced according to the methods of the invention described herein, which produce a genetically-modified cell from a cell which comprises a Factor VIII gene having an inversion of exons 1-22.
- the invention provides a pharmaceutical composition for treatment of a subject having hemophilia A.
- hemophilia A is characterized by an inversion of exons 1-22 in a Factor VIII gene.
- the pharmaceutical composition comprises a pharmaceutically acceptable carrier and any genetically-modified cell of the invention, and/or any genetically-modified cell produced according to the methods of the invention, which comprises a wild-type Factor VIII gene.
- the invention provides a method for treating a subject having hemophilia A.
- hemophilia A is characterized by an inversion of exons 1-22 of the Factor VIII gene.
- the method comprises administering to the subject a pharmaceutical composition of the invention which comprises a pharmaceutically acceptable carrier and any genetically-modified cell of the invention.
- a genetically-modified cell comprises a wild-type Factor VIII gene following modification.
- the genetically-modified cell can be delivered to a target tissue.
- the target tissue can be the liver.
- the target tissue can be the circulatory system.
- the genetically-modified cell can be a genetically-modified iPS cell.
- the genetically-modified iPS cell can differentiate into a cell which expresses Factor VIII when it is delivered to the target tissue.
- the genetically-modified iPS cell can differentiate into a hepatic sinusoidal endothelial cell which expresses Factor VIII.
- the genetically-modified iPS cell can differentiate into a hematopoietic cell, such as a hematopoietic endothelial cell, which expresses Factor VIII.
- the subject can be a mammal. In one such embodiment, the subject can be a human. In another such embodiment, the subject can be a canine.
- the invention provides an engineered nuclease, and particularly an engineered meganuclease, described herein for use as a medicament.
- the invention further provides the use of an engineered nuclease, and particularly an engineered meganuclease, described herein in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 in the Factor VIII gene.
- the invention provides an isolated polynucleotide for use as a medicament, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- the invention further provides the use of an isolated polynucleotide in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 in the Factor VIII gene, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- the invention provides a recombinant AAV vector for use as a medicament, wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- the invention further provides the use of a recombinant AAV vector in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene, wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- the invention provides a genetically-modified cell of the invention for use as a medicament, wherein the genetically-modified cell has been modified to comprise a wild-type Factor VIII gene.
- the invention further provides the use of a genetically-modified cell of the invention in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene, wherein the genetically-modified cell has been modified to comprise a wild-type Factor VIII gene.
- FIG. 1A and FIG. 1B Inversion of introns 1-22 in the Factor VIII gene.
- the int22h-2 and int22h-3 repeat sequences are positioned telomeric to the int22h-1 sequence on the X chromosome. Further, int22h-2 and int22h-3 are found in an inverse orientation to one another as part of an imperfect palindrome. Recombination of sequences within this palindrome allows int22h-2 and in22h-3 to swap places in the genome and, consequently, change their orientation relative to int22h-1.
- FIG. 1A shows a configuration in which int22h-3 is in an inverse orientation to int22h-1, allowing for intrachromosomal recombination to occur between these repeat sequences, resulting in the illustrated inversion of exons 1-22.
- FIG. 1B shows a configuration in which int22h-2 is in an inverse orientation to int22h-1, allowing for intrachromosomal recombination to occur between these repeat sequences, resulting in the illustrated inversion of exons 1-22.
- FIG. 2 F8R recognition sequences in the Factor VIII gene.
- Each recognition sequence targeted by a recombinant meganuclease of the invention comprises two recognition half-sites. Each recognition half-site comprises 9 base pairs, separated by a 4 base pair central sequence.
- the F8R 1-2 recognition sequence (SEQ ID NO: 7) comprises two recognition half-sites referred to as F8R1 and F8R2.
- the F8R 3-4 recognition sequence (SEQ ID NO: 9) comprises two recognition half-sites referred to as F8R3 and F8R4.
- the F8R 9-10 recognition sequence (SEQ ID NO: 11) comprises two recognition half-sites referred to as F8R9 and F8R10.
- the F8R 11-12 recognition sequence (SEQ ID NO: 13) comprises two recognition half-sites referred to as F8R11 and F8R12.
- the F8R 13-14 recognition sequence (SEQ ID NO: 15) comprises two recognition half-sites referred to as F8R13 and F8R14.
- the F8R 15-16 recognition sequence (SEQ ID NO: 17) comprises two recognition half-sites referred to as F8R15 and F8R16.
- the recombinant meganucleases of the invention comprise two subunits, wherein the first subunit comprising the HVR1 region binds to a first recognition half-site (e.g., F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15) and the second subunit comprising the HVR2 region binds to a second recognition half-site (e.g., F8R2, F8R4, F8R10, F8R12, F8R14, or F8R16).
- a first recognition half-site e.g., F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15
- a second recognition half-site e.g., F8R2, F8R4, F8R10, F8R12, F8R14, or F8R16.
- the first subunit comprising the HVR1 region can be positioned as either the N-terminal or C-terminal subunit.
- the second subunit comprising the HVR2 region can be positioned as either the N-terminal or C-terminal subunit.
- FIG. 4 Schematic of reporter assay in CHO cells for evaluating recombinant meganucleases targeting recognition sequences found in intron 22 of the Factor VIII gene.
- a CHO cell line was produced in which a reporter cassette was integrated stably into the genome of the cell.
- the reporter cassette comprised, in 5′ to 3′ order: an SV40 Early Promoter; the 5′ 2/3 of the GFP gene; the recognition sequence for an engineered meganuclease of the invention (e.g., the F8R 1-2 recognition sequence); the recognition sequence for the CHO-23/24 meganuclease (WO/2012/167192); and the 3′ 2/3 of the GFP gene.
- Cells stably transfected with this cassette did not express GFP in the absence of a DNA break-inducing agent.
- Meganucleases were introduced by transduction of plasmid DNA or mRNA encoding each meganuclease. When a DNA break was induced at either of the meganuclease recognition sequences, the duplicated regions of the GFP gene recombined with one another to produce a functional GFP gene. The percentage of GFP-expressing cells could then be determined by flow cytometry as an indirect measure of the frequency of genome cleavage by the meganucleases.
- FIGS. 5A-5G Efficiency of recombinant meganucleases for recognizing and cleaving recognition sequences in the int22h-1 sequence of the Factor VIII gene in a CHO cell reporter assay.
- Recombinant meganucleases set forth in SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, and 76-79 were engineered to target the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 3-4 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17), and were screened for efficacy in the CHO cell reporter assay.
- FIG. 5A shows meganucleases targeting the F8R 1-2 recognition sequence.
- FIG. 5B and FIG. 5C show meganucleases targeting the F8R 3-4 recognition sequence.
- FIG. 5D shows meganucleases targeting the F8R 9-10 recognition sequence.
- FIG. 5E shows meganucleases targeting the F8R 11-12 recognition sequence.
- FIG. 5F shows meganucleases targeting the F8R 13-14 recognition sequence.
- FIG. 5G shows meganucleases targeting the F8R 15-16 recognition sequence.
- FIGS. 6A-6F Efficiency of engineered meganucleases for recognizing and cleaving recognition sequences in the int22h-1 sequence of the Factor VIII gene in a CHO cell reporter assay.
- Engineered meganucleases encompassed by the invention were engineered to target the F8R 1-2 (SEQ ID NO: 7), F8R 3-4 (SEQ ID NO: 9), F8R 9-10 (SEQ ID NO: 11), F8R 11-12 (SEQ ID NO: 13), F8R 13-14 (SEQ ID NO: 15), or F8R 15-16 (SEQ ID NO: 17) recognition sequences, and were screened for efficacy in the CHO cell reporter assay at multiple time points over 12 days after nucleofection.
- FIG. 6A shows F8R 1-2 meganucleases targeting the F8R 1-2 recognition sequence.
- FIG. 6B shows F8R 3-4 meganucleases targeting the F8R 3-4 recognition sequence.
- FIG. 6C shows F8R 9-10 meganucleases targeting the F8R 9-10 recognition sequence.
- FIG. 6D shows F8R 11-12 meganucleases targeting the F8R 11-12 recognition sequence.
- FIG. 6E shows F8R 13-14 meganucleases targeting the F8R 13-14 recognition sequence.
- FIG. 6F shows F8R 15-16 meganucleases targeting the F8R 15-16 recognition sequence.
- FIG. 7 Cleavage of F8R recognition sequences in mammalian cells. Meganucleases F8R 1-2 and F8R 3-4 were tested for the ability to cut and cause insertions and/or deletions (indels) at their recognition sites by T7 endonuclease assay in HEK 293 cells.
- Indels insertions and/or deletions
- FIG. 8A and FIG. 8B Inversion of exons 1-22 in the Factor VIII gene of mammalian cells. This experiment determined if cleavage of genomic DNA by F8R 1-2 and F8R 3-4 meganucleases could stimulate an inversion of exons 1-22 in the Factor VIII gene of HEK 293 cells. Genomic DNA was analyzed by PCR using a primer set which could detect normal positioning of exons 1-22 (H1R/H1F) or an inversion of exons 1-22 (H1R/H2/3R).
- FIG. 9 Inversion of exons 1-22 in the Factor VIII gene of mammalian cells. This experiment determined if cleavage of genomic DNA by F8R 9-10, F8R 11-12, F8R 13-14, and F8R 15-16 meganucleases could stimulate an inversion of exons 1-22 in the Factor VIII gene of HEK 293 cells. Genomic DNA was analyzed by PCR using a primer set which could detect normal positioning of exons 1-22 (H1R/H1F) or an inversion of exons 1-22 (H1R/H2/3R). PCR analysis from day 2 and day 8 are provided for each primer set.
- FIG. 10 Inversion of Factor VIII gene by F8R nucleases in 293 cells and determination of efficiency by inverse digital PCR.
- HEK293 cells were transfected with mRNA encoding F8R11-12x.69 or F8R13-14x.13 nucleases, respectively.
- genomic DNA was isolated from cells and inverse digital PCR was performed to determine Factor VIII genome editing.
- FIG. 11 Inversion of Factor VIII gene by F8R nucleases in primary human T cells and determination of editing by long-distance PCR. Normal human T-cells were transfected with mRNA encoding the F8R3-4x.43 nuclease. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing.
- FIGS. 12A-12B Reversion of Factor VIII gene by F8R nucleases in primary human patient T cells and determination of editing by long-distance PCR.
- Hemophilia A patient T-cells were transfected with mRNA encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases, respectively.
- genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing.
- FIG. 12A shows PCR bands corresponding to a wild type Factor VIII gene configuration, as detected using primers H1U and H1D.
- FIG. 12B shows PCR bands corresponding to the hemophilia A-associated Factor VIII gene inversion, as detected using primers H3D and H1D.
- SEQ ID NO: 1 sets forth the amino acid sequence of the wild-type I-CreI meganuclease from Chlamydomonas reinhardtii.
- SEQ ID NO: 2 sets forth the amino acid sequence of the LAGLIDADG motif.
- SEQ ID NO: 3 sets forth the nucleic acid sequence of a human int22h-1 sequence.
- SEQ ID NO: 4 sets forth the nucleic acid sequence of a canine int22h-1 sequence.
- SEQ ID NO: 5 sets forth the nucleic acid sequence of a human F8A1 sequence.
- SEQ ID NO: 6 sets forth the nucleic acid sequence of a canine F8A1 sequence.
- SEQ ID NO: 7 sets forth the nucleic acid sequence of the F8R 1-2 recognition sequence (sense).
- SEQ ID NO: 8 sets forth the nucleic acid sequence of the F8R 1-2 recognition sequence (antisense).
- SEQ ID NO: 9 sets forth the nucleic acid sequence of the F8R 3-4 recognition sequence (sense).
- SEQ ID NO: 10 sets forth the nucleic acid sequence of the F8R 3-4 recognition sequence (antisense).
- SEQ ID NO: 11 sets forth the nucleic acid sequence of the F8R 9-10 recognition sequence (sense).
- SEQ ID NO: 12 sets forth the nucleic acid sequence of the F8R 9-10 recognition sequence (antisense).
- SEQ ID NO: 13 sets forth the nucleic acid sequence of the F8R 11-12 recognition sequence (sense).
- SEQ ID NO: 14 sets forth the nucleic acid sequence of the F8R 11-12 recognition sequence (antisense).
- SEQ ID NO: 15 sets forth the nucleic acid sequence of the F8R 13-14 recognition sequence (sense).
- SEQ ID NO: 16 sets forth the nucleic acid sequence of the F8R 13-14 recognition sequence (antisense).
- SEQ ID NO: 17 sets forth the nucleic acid sequence of the F8R 15-16 recognition sequence (sense).
- SEQ ID NO: 18 sets forth the nucleic acid sequence of the F8R 15-16 recognition sequence (antisense).
- SEQ ID NO: 19 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease.
- SEQ ID NO: 20 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease.
- SEQ ID NO: 21 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease.
- SEQ ID NO: 22 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease F8R1-binding monomer.
- SEQ ID NO: 23 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease F8R1-binding monomer.
- SEQ ID NO: 24 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease F8R1-binding monomer.
- SEQ ID NO: 25 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease F8R2-binding monomer.
- SEQ ID NO: 26 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease F8R2-binding monomer.
- SEQ ID NO: 27 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease F8R2-binding monomer.
- SEQ ID NO: 28 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease.
- SEQ ID NO: 29 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease.
- SEQ ID NO: 30 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease.
- SEQ ID NO: 31 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease.
- SEQ ID NO: 32 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease F8R3-binding monomer.
- SEQ ID NO: 33 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease F8R3-binding monomer.
- SEQ ID NO: 34 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease F8R3-binding monomer.
- SEQ ID NO: 35 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease F8R3-binding monomer.
- SEQ ID NO: 36 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease F8R4-binding monomer.
- SEQ ID NO: 37 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease F8R4-binding monomer.
- SEQ ID NO: 38 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease F8R4-binding monomer.
- SEQ ID NO: 39 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease F8R4-binding monomer.
- SEQ ID NO: 40 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease.
- SEQ ID NO: 41 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease.
- SEQ ID NO: 42 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease.
- SEQ ID NO: 43 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease.
- SEQ ID NO: 44 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease F8R9-binding monomer.
- SEQ ID NO: 45 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease F8R9-binding monomer.
- SEQ ID NO: 46 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease F8R9-binding monomer.
- SEQ ID NO: 47 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease F8R9-binding monomer.
- SEQ ID NO: 48 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease F8R10-binding monomer.
- SEQ ID NO: 49 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease F8R10-binding monomer.
- SEQ ID NO: 50 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease F8R10-binding monomer.
- SEQ ID NO: 51 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease F8R10-binding monomer.
- SEQ ID NO: 52 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease.
- SEQ ID NO: 53 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease.
- SEQ ID NO: 54 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease.
- SEQ ID NO: 55 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease.
- SEQ ID NO: 56 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease F8R11-binding monomer.
- SEQ ID NO: 57 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease F8R11-binding monomer.
- SEQ ID NO: 58 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease F8R11-binding monomer.
- SEQ ID NO: 59 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease F8R11-binding monomer.
- SEQ ID NO: 60 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease F8R12-binding monomer.
- SEQ ID NO: 61 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease F8R12-binding monomer.
- SEQ ID NO: 62 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease F8R12-binding monomer.
- SEQ ID NO: 63 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease F8R12-binding monomer.
- SEQ ID NO: 64 sets forth the amino acid sequence of the F8R 13-14x.13 meganuclease.
- SEQ ID NO: 65 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease.
- SEQ ID NO: 66 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease.
- SEQ ID NO: 67 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease.
- SEQ ID NO: 68 sets forth the amino acid sequence of the F8R 13-14x.13 meganucicase F8R13-binding monomer.
- SEQ ID NO: 69 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease F8R13-binding monomer.
- SEQ ID NO: 70 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease F8R13-binding monomer.
- SEQ ID NO: 71 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease F8R13-binding monomer.
- SEQ ID NO: 72 sets forth the amino acid sequence of the F8R 13-14x.13 meganuclease F8R14-binding monomer.
- SEQ ID NO: 73 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease F8R14-binding monomer.
- SEQ ID NO: 74 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease F8R14-binding monomer.
- SEQ ID NO: 75 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease F8R14-binding monomer.
- SEQ ID NO: 76 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease.
- SEQ ID NO: 77 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease.
- SEQ ID NO: 78 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease.
- SEQ ID NO: 79 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease.
- SEQ ID NO: 80 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease F8R15-binding monomer.
- SEQ ID NO: 81 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease F8R15-binding monomer.
- SEQ ID NO: 82 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease F8R15-binding monomer.
- SEQ ID NO: 83 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease F8R15-binding monomer.
- SEQ ID NO: 84 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease F8R16-binding monomer.
- SEQ ID NO: 85 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease F8R16-binding monomer.
- SEQ ID NO: 86 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease F8R16-binding monomer.
- SEQ ID NO: 87 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease F8R16-binding monomer.
- SEQ ID NO: 88 sets forth the nucleic acid sequence of the U1 primer.
- SEQ ID NO: 89 sets forth the nucleic acid sequence of the D1 primer.
- SEQ ID NO: 90 sets forth the nucleic acid sequence of the U3 primer.
- SEQ ID NO: 91 sets forth the nucleic acid sequence of the FWD1 primer.
- SEQ ID NO: 92 sets forth the nucleic acid sequence of the REV1 primer.
- SEQ ID NO: 93 sets froth the nucleic acid sequence of the FWD3 primer.
- SEQ ID NO: 94 sets forth the nucleic acid sequence of the H1U primer.
- SEQ ID NO: 95 sets forth the nucleic acid sequence of the H1D primer.
- SEQ ID NO: 96 sets forth the nucleic acid sequence of the H3D primer.
- a can mean one or more than one.
- a cell can mean a single cell or a multiplicity of cells.
- nuclease and “endonuclease” are used interchangeably to refer to naturally-occurring or engineered enzymes which cleave a phosphodiester bond within a polynucleotide chain.
- the term “meganuclease” refers to an endonuclease that binds double-stranded DNA at a recognition sequence that is greater than 12 base pairs.
- the recognition sequence for a meganuclease of the invention is 22 base pairs.
- a meganuclease can be an endonuclease that is derived from I-CreI, and can refer to an engineered variant of I-CreI that has been modified relative to natural I-CreI with respect to, for example, DNA-binding specificity, DNA cleavage activity, DNA-binding affinity, or dimerization properties. Methods for producing such modified variants of I-CreI are known in the art (e.g.
- a meganuclease as used herein binds to double-stranded DNA as a heterodimer.
- a meganuclease may also be a “single-chain meganuclease” in which a pair of DNA-binding domains are joined into a single polypeptide using a peptide linker.
- the term “homing endonuclease” is synonymous with the term “meganuclease.”
- Meganucleases of the invention are substantially non-toxic when expressed in cells without observing deleterious effects on cell viability or significant reductions in meganuclease cleavage activity when measured using the methods described herein.
- single-chain meganuclease refers to a polypeptide comprising a pair of nuclease subunits joined by a linker.
- a single-chain meganuclease has the organization: N-terminal subunit—Linker—C-terminal subunit.
- the two meganuclease subunits will generally be non-identical in amino acid sequence and will recognize non-identical DNA sequences.
- single-chain meganucleases typically cleave pseudo-palindromic or non-palindromic recognition sequences.
- a single-chain meganuclease may be referred to as a “single-chain heterodimer” or “single-chain heterodimeric meganuclease” although it is not, in fact, dimeric.
- the term “meganuclease” can refer to a dimeric or single-chain meganuclease.
- linker refers to an exogenous peptide sequence used to join two meganuclease subunits into a single polypeptide.
- a linker may have a sequence that is found in natural proteins, or may be an artificial sequence that is not found in any natural protein.
- a linker may be flexible and lacking in secondary structure or may have a propensity to form a specific three-dimensional structure under physiological conditions.
- a linker can include, without limitation, those encompassed by U.S. Pat. No. 8,445,251.
- a linker may have an amino acid sequence comprising residues 154-195 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79.
- TALEN refers to an endonuclease comprising a DNA-binding domain comprising 16-22 TAL domain repeats fused to any portion of the FokI nuclease domain.
- Compact TALEN refers to an endonuclease comprising a DNA-binding domain with 16-22 TAL domain repeats fused in any orientation to any portion of the I-TevI homing endonuclease.
- zinc finger nuclease or “ZFN” refers to a chimeric endonuclease comprising a zinc finger DNA-binding domain fused to the nuclease domain of the FokI restriction enzyme.
- the zinc finger domain can be redesigned through rational or experimental means to produce a protein which binds to a pre-determined DNA sequence ⁇ 18 basepairs in length, comprising a pair of nine basepair half-sites separated by 2-10 basepairs. Cleavage by a zinc finger nuclease can create a blunt end or a 5′ overhand of variable length (frequently four basepairs).
- CRISPR refers to a caspase-based endonuclease comprising a caspase, such as Cas9, and a guide RNA that directs DNA cleavage of the caspase by hybridizing to a recognition site in the genomic DNA.
- megaTAL refers to a single-chain endonuclease comprising a transcription activator-like effector (TALE) DNA binding domain with an engineered, sequence-specific horning endonuclease.
- TALE transcription activator-like effector
- the term “recombinant” or “engineered” means having an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein.
- a nucleic acid the term “recombinant” or “engineered” means having an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion.
- Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion.
- a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous host is not considered recombinant.
- wild-type refers to the most common naturally occurring allele (i.e., polynucleotide sequence) in the allele population of the same type of gene, wherein a polypeptide encoded by the wild-type allele has its original functions.
- wild-type also refers a polypeptide encoded by a wild-type allele. Wild-type alleles (i.e., polynucleotides) and polypeptides are distinguishable from mutant or variant alleles and polypeptides, which comprise one or more mutations and/or substitutions relative to the wild-type sequence(s).
- Wild-type nucleases are distinguishable from recombinant or non-naturally-occurring nucleases.
- wild-type can also refer to a cell, an organism, and/or a subject which possesses a wild-type allele of a particular gene, or a cell, an organism, and/or a subject used for comparative purposes.
- the term “genetically-modified” refers to a cell or organism in which, or in an ancestor of which, a genomic DNA sequence has been deliberately modified by recombinant technology. As used herein, the term “genetically-modified” encompasses the term “transgenic.”
- modification means any insertion, deletion, or substitution of an amino acid residue in the recombinant sequence relative to a reference sequence (e.g., a wild-type or a native sequence).
- the term “recognition sequence” refers to a DNA sequence that is bound and cleaved by an endonuclease.
- a recognition sequence comprises a pair of inverted, 9 basepair “half sites” which are separated by four basepairs.
- the N-terminal domain of the protein contacts a first half-site and the C-terminal domain of the protein contacts a second half-site. Cleavage by a meganuclease produces four basepair 3′ “overhangs”.
- “Overhangs”, or “sticky ends” are short, single-stranded DNA segments that can be produced by endonuclease cleavage of a double-stranded DNA sequence.
- the overhang comprises bases 10-13 of the 22 basepair recognition sequence.
- the recognition sequence comprises a first CNNNGN sequence that is recognized by the I-TevI domain, followed by a non-specific spacer 4-16 basepairs in length, followed by a second sequence 16-22 bp in length that is recognized by the TAL-effector domain (this sequence typically has a 5′ T base).
- Cleavage by a Compact TALEN produces two basepair 3′ overhangs.
- the recognition sequence is the sequence, typically 16-24 basepairs, to which the guide RNA binds to direct Cas9 cleavage.
- Cleavage by a CRISPR produced blunt ends.
- the DNA binding domains typically recognize an 18-bp recognition sequence comprising a pair of nine basepair “half-sites” separated by 2-10 basepairs and cleavage by the nuclease creates a blunt end or a 5′ overhang of variable length (frequently four basepairs).
- target site or “target sequence” refers to a region of the chromosomal DNA of a cell comprising a recognition sequence for a nuclease.
- DNA-binding affinity means the tendency of a meganuclease to non-covalently associate with a reference DNA molecule (e.g., a recognition sequence or an arbitrary sequence). Binding affinity is measured by a dissociation constant, K d . As used herein, a nuclease has “altered” binding affinity if the K d of the nuclease for a reference recognition sequence is increased or decreased by a statistically significant (p ⁇ 0.05) amount relative to a reference nuclease.
- the term “specificity” means the ability of a meganuclease to recognize and cleave double-stranded DNA molecules only at a particular sequence of base pairs referred to as the recognition sequence, or only at a particular set of recognition sequences.
- the set of recognition sequences will share certain conserved positions or sequence motifs, but may be degenerate at one or more positions.
- a highly-specific meganuclease is capable of cleaving only one or a very few recognition sequences. Specificity can be determined by any method known in the art.
- a meganuclease has “altered” specificity if it binds to and cleaves a recognition sequence which is not bound to and cleaved by a reference meganuclease (e.g., a wild-type) under physiological conditions, or if the rate of cleavage of a recognition sequence is increased or decreased by a biologically significant amount (e.g., at least 2 ⁇ , or 2 ⁇ -10 ⁇ ) relative to a reference meganuclease.
- a reference meganuclease e.g., a wild-type
- homologous recombination refers to the natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976).
- the homologous DNA sequence may be an endogenous chromosomal sequence or an exogenous nucleic acid that was delivered to the cell.
- non-homologous end-joining refers to the natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the untemplated addition or deletion of DNA sequences at the site of repair. In some instances, cleavage at a target recognition sequence results in NHEJ at a target recognition site.
- Nuclease-induced cleavage of a target site in the coding sequence of a gene followed by DNA repair by NHEJ can introduce mutations into the coding sequence, such as frameshift mutations, that disrupt gene function.
- engineered nucleases can be used to effectively knock-out a gene in a population of cells.
- sequence similarity As used herein with respect to both amino acid sequences and nucleic acid sequences, the terms “percent identity,” “sequence identity,” “percentage similarity,” “sequence similarity” and the like refer to a measure of the degree of similarity of two sequences based upon an alignment of the sequences which maximizes similarity between aligned amino acid residues or nucleotides, and which is a function of the number of identical or similar residues or nucleotides, the number of total residues or nucleotides, and the presence and length of gaps in the sequence alignment. A variety of algorithms and computer programs are available for determining sequence similarity using standard parameters.
- sequence similarity is measured using the BLASTp program for amino acid sequences and the BLASTn program for nucleic acid sequences, both of which are available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/), and are described in, for example, Altschul et al. (1990), J. Mol. Biol. 215:403-410; Gish and States (1993), Nature Genet. 3:266-272; Madden et al. (1996), Meth. Enzymol.266:131-141; Altschul et al. (1997), Nucleic Acids Res. 25:33 89-3402); Zhang et al. (2000), J. Comput. Biol.
- the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins corresponds to or aligns with the amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (e.g., using the BLASTp program).
- the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.
- the term “recognition half-site,” “recognition sequence half-site,” or simply “half-site” means a nucleic acid sequence in a double-stranded DNA molecule which is recognized by a monomer of a homodimeric or heterodimeric meganuclease, or by one subunit of a single-chain meganuclease.
- hypervariable region refers to a localized sequence within a meganuclease monomer or subunit that comprises amino acids with relatively high variability.
- a hypervariable region can comprise about 50-60 contiguous residues, about 53-57 contiguous residues, or preferably about 56 residues.
- the residues of a hypervariable region may correspond to positions 24-79 or positions 215-270 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79.
- a hypervariable region can comprise one or more residues that contact DNA bases in a recognition sequence and can be modified to alter base preference of the monomer or subunit.
- a hypervariable region can also comprise one or more residues that bind to the DNA backbone when the meganuclease associates with a double-stranded DNA recognition sequence. Such residues can be modified to alter the binding affinity of the meganuclease for the DNA backbone and the target recognition sequence.
- a hypervariable region may comprise between 1-20 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity.
- a hypervariable region comprises between about 15-18 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity.
- variable residues within a hypervariable region correspond to one or more of positions 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 72, 73, 75, and 77 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79.
- variable residues within a hypervariable region correspond to one or more of positions 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 263, 264, 266, and 268 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79.
- the terms “Factor VIII gene,” “F8 gene,” and the like refer to a gene located on the X chromosome which encodes the coagulation Factor VIII protein.
- the Factor VIII gene identified by NCBI as Gene ID No. 2157, is located from base pair 154,835,788 to base pair 155,026,934 on the X chromosome.
- the Factor VIII gene can be the gene identified by NCBI Reference Sequence: NM 001003212.1. It is understood that the term “Factor VIII gene” can include both a wild-type Factor VIII gene and a Factor VIII gene which comprises naturally-occurring polymorphisms and/or mutations that allow for the production of a functional Factor VIII protein.
- int22h-1 and int22h-1 sequence refer to a sequence positioned within intron 22 of the Factor VIII gene having a size of approximately 9.5 kb (Bagnall et al. (2006) Journal of Thrombosis and Haemostasis 4:591-598) and can further refer to the human sequence identified by GenBank as Accession No. AY619999.1.
- the int22h-1 sequence is characterized as comprising a CpG island, a coding sequence for the H2AFB1 histone protein, and a coding sequence for the Factor VIII-Associated 1 protein (F8A1; also referred to as the intron 22 protein).
- the int22h-1 sequence is further characterized as being identical to, or having high homology with, at least one repeat sequence that is positioned telomeric to the Factor VIII gene on the X chromosome.
- two repeat sequences referred to as int22h-2 and int22h-3, are positioned telomeric to the Factor VIII gene on the X chromosome.
- the human int22h-1 sequence can comprise SEQ ID NO: 3.
- the canine int22h-1 sequence can comprise SEQ ID NO: 4.
- the terms “F8A1 coding sequence” and “intron 22 protein coding sequence” are used interchangeably and refer to a sequence positioned within the int22h-1 sequence which encodes the F8A1 protein.
- the F8A1 coding sequence is intronless and is transcribed in the opposite direction as the Factor VIII gene.
- the wild-type human F8A1 coding sequence can comprise SEQ ID NO: 5.
- the wild-type canine F8A1 coding sequence can comprise SEQ ID NO: 6, which has ⁇ 75% homology to the human F8A1 coding sequence.
- F8A1 coding sequence includes a wild-type F8A1 sequence and an F8A1 sequence comprising naturally-occurring polymorphisms and/or mutations that allow for the production of a functional F8A1 protein.
- the terms “inversion” and “inversion of exons 1-22” refer to a mutation of a Factor VIII gene wherein an intra-chromosomal homologous recombination event occurs between the int22h-1 sequence of the Factor VIII gene and an identical or closely related, inversely oriented, repeat sequence positioned telomeric to the Factor VIII gene on the X chromosome, which results in an inversion of exons 1-22 with respect to exons 23-26.
- reversion refers to an intra-chromosomal homologous recombination event in a cell comprising an inversion of exons 1-22 of the Factor VIII gene, wherein a double-strand break is produced within the int22h-1 sequence to promote recombination with a repeat sequence telomeric to the Factor VIII gene on the X chromosome. Such recombination results in the corrected orientation of exons 1-22 and the production of a functional, wild-type Factor VIII gene.
- a recombinant construct comprises an artificial combination of nucleic acid fragments, including, without limitation, regulatory and coding sequences that are not found together in nature.
- a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source and arranged in a manner different than that found in nature.
- Such a construct may be used by itself or may be used in conjunction with a vector.
- a “vector” or “recombinant DNA vector” may be a construct that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art.
- Vectors can include, without limitation, plasmid vectors and recombinant AAV vectors, or any other vector known in that art suitable for delivering a gene encoding a meganuclease of the invention to a target cell. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleotides or nucleic acid sequences of the invention.
- a “vector” can also refer to a viral vector.
- Viral vectors can include, without limitation, retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors (AAV).
- control refers to a cell that provides a reference point for measuring changes in genotype or phenotype of a genetically-modified cell.
- a control cell may comprise, for example: (a) a wild-type cell, i.e., of the same genotype as the starting material for the genetic alteration which resulted in the genetically-modified cell; (b) a cell of the same genotype as the genetically-modified cell but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest); or, (c) a cell genetically identical to the genetically-modified cell but which is not exposed to conditions or stimuli or further genetic modifications that would induce expression of altered genotype or phenotype.
- a “self-cleaving” recombinant DNA construct refers to a DNA construct which comprises at least one coding sequence for an endonuclease and at least one recognition sequence for the same endonuclease.
- the endonuclease recognizes and cleaves the recognition sequence, resulting in linearization of the DNA construct.
- the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins corresponds to or aligns with the amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (e.g., using the BLASTp program).
- the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.
- treatment refers to the administration of an engineered nuclease of the invention, or a nucleic acid encoding an engineered nuclease of the invention, to a subject having hemophilia A for the purpose of correcting an inversion of exons 1-22 in the Factor VIII gene in cells which normally express Factor VIII in wild-type subjects.
- Such treatment results in correction of the Factor VIII gene in a number of cells sufficient to increase circulating levels of Factor VIII in the subject, and either partial or complete relief of one or more symptoms of hemophilia A in the subject.
- treatment can further refer to the administration of a genetically-modified cell comprising a wild-type Factor VIII gene to a subject according the method of the invention, wherein the genetically-modified cell is delivered to a target tissue and either produces Factor VIII, or differentiates into a cell which produces Factor VIII, in an amount sufficient to increase the circulating levels of Factor VIII in the subject, resulting in either partial or complete relief of one or more symptoms of hemophilia A.
- an engineered nuclease of the invention, a nucleic acid encoding the same, or a genetically-modified cell of the invention is administered during treatment in the form of a pharmaceutical composition of the invention.
- variable As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range.
- a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values ⁇ 0 and ⁇ 2 if the variable is inherently continuous.
- the present invention is based, in part, on the hypothesis that engineered nucleases can be used to treat hemophilia A by correcting an inversion of exons 1-22 in the Factor VIII gene. More specifically, nucleases can be engineered to recognize and cleave a recognition sequence present within an int22h-1 sequence of the Factor VIII gene to produce a double-strand break. Intra-chromosomal homologous recombination can then occur between the int22h-1 sequence and a repeat sequence which is telomeric to the Factor VIII gene on the X chromosome, resulting in a reversion of exons 1-22 and the production of a functional, wild-type Factor VIII gene in target cells of the subject.
- the invention is also based, in part, on the hypothesis that pluripotent cells (e.g., induced pluripotent stem (iPS) cells) comprising an inversion of exons 1-22 in the Factor VIII gene can be obtained and contacted with an engineered nuclease of the invention (or a nucleic acid encoding the same) in order to correct the Factor VIII gene by the same mechanism described above.
- pluripotent cells e.g., induced pluripotent stem (iPS) cells
- iPS induced pluripotent stem
- the present invention encompasses engineered nucleases, and particularly engineered recombinant meganucleases, which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene.
- the present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating hemophilia A.
- the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins, nucleic acids encoding engineered nucleases, or genetically-modified cells of the invention, and the use of such compositions for the treatment of hemophilia A.
- the invention can be practiced using engineered recombinant meganucleases.
- the invention can be practiced using a CRISPR nuclease or CRISPR Nickase. Methods for making CRISPRs and CRISPR Nickases that recognize pre-determined DNA sites are known in the art, for example Ran, et al. (2013) Nat Protoc. 8:2281-308.
- the invention can be practiced using TALENs or Compact TALENs. Methods for making TALE domains that bind to pre-determined DNA sites are known in the art, for example Reyon et al. (2012) Nat Biotechnol. 30:460-5.
- the invention can be practiced using zinc finger nucleases (ZFNs).
- the invention can be practiced using megaTALs.
- the nucleases used to practice the invention are single-chain meganucleases.
- a single-chain meganuclease comprises an N-terminal subunit and a C-terminal subunit joined by a linker peptide.
- Each of the two domains recognizes half of the recognition sequence (i.e., a recognition half-site) and the site of DNA cleavage is at the middle of the recognition sequence near the interface of the two subunits.
- DNA strand breaks are offset by four base pairs such that DNA cleavage by a meganuclease generates a pair of four base pair, 3′ single-strand overhangs.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 1-2 recognition sequence (SEQ ID NO: 7).
- the F8R 1-2 recognition sequence is positioned within both the int22h-1 sequence and the F8A1 sequence.
- Such recombinant meganucleases are collectively referred to herein as “F8R 1-2 meganucleases.”
- Exemplary F8R 1-2 meganucleases are provided in SEQ ID NOs: 19-22.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 3-4 recognition sequence (SEQ ID NO: 9).
- the F8R 3-4 recognition sequence is positioned within both the int22h-1 sequence and the F8A1 sequence.
- Such recombinant meganucleases are collectively referred to herein as “F8R 3-4 meganucleases.”
- Exemplary F8R 3-4 meganucleases are provided in SEQ ID NOs: 28-31.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 9-10 recognition sequence (SEQ ID NO: 11). Such recombinant meganucleases are collectively referred to herein as “F8R 9-10 meganucleases.” Exemplary F8R 9-10 meganucleases are provided in SEQ ID NOs: 40-43.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 11-12 recognition sequence (SEQ ID NO: 13). Such recombinant meganucleases are collectively referred to herein as “F8R 11-12 meganucleases.” Exemplary F8R 11-12 meganucleases are provided in SEQ ID NOs: 52-55.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 13-14 recognition sequence (SEQ ID NO: 15). Such recombinant meganucleases are collectively referred to herein as “F8R 13-14 meganucleases.” Exemplary F8R 13-14 meganucleases are provided in SEQ ID NOs: 64-67.
- recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 15-16 recognition sequence (SEQ ID NO: 17). Such recombinant meganucleases are collectively referred to herein as “F8R 15-16 meganucleases.” Exemplary F8R 15-16 meganucleases are provided in SEQ ID NOs: 76-79.
- Recombinant meganucleases of the invention comprise a first subunit, comprising a first hypervariable (HVR1) region, and a second subunit, comprising a second hypervariable (HVR2) region. Further, the first subunit binds to a first recognition half-site in the recognition sequence (e.g., the F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15 half-site), and the second subunit binds to a second recognition half-site in the recognition sequence (e.g., the F8R2, F8R4, F8R10, F8R12, F8R14, or F8R16 half-site).
- a first recognition half-site in the recognition sequence e.g., the F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15 half-site
- the second subunit binds to a second recognition half-site in the recognition sequence (e.g., the F
- the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the N-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the C-terminal subunit.
- the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the C-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the N-terminal subunit.
- Exemplary F8R 1-2 meganucleases of the invention are provided in Table 1.
- Exemplary F8R 3-4 meganucleases of the invention are provided in Table 2.
- Exemplary F8R 9-10 meganucleases of the invention are provided in Table 3.
- Exemplary F8R 11-12 meganucleases of the invention are provided in Table 4.
- Exemplary F8R 13-14 meganucleases of the invention are provided in Table 5.
- Exemplary F8R 15-16 meganucleases of the invention are provided in Table 6.
- the invention provides methods for producing genetically-modified cells using engineered nucleases that recognize and cleave recognition sequences found within an intron 22 sequence of a Factor VIII gene.
- the invention further provides methods for treating hemophilia A in a subject by administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an engineered nuclease of the invention (or a nucleic acid encoding the engineered nuclease).
- an engineered nuclease of the invention can be delivered to and/or expressed from DNA/RNA in appropriate cells that comprise an inversion of exons 1-22 in a Factor VIII gene and would typically express Factor VIII in a healthy subject (e.g., hepatic sinusoidal endothelial cells or hematopoietic endothelial cells, or progenitor cells which differentiate into the same).
- a healthy subject e.g., hepatic sinusoidal endothelial cells or hematopoietic endothelial cells, or progenitor cells which differentiate into the same.
- Engineered nucleases of the invention can be delivered into a cell in the form of protein or, preferably, as a nucleic acid encoding the engineered nuclease.
- Such nucleic acid can be DNA (e.g., circular or linearized plasmid DNA or PCR products) or RNA (e.g., mRNA).
- RNA e.g., mRNA
- the engineered nuclease coding sequence is delivered in DNA form, it should be operably linked to a promoter to facilitate transcription of the nuclease gene.
- Mammalian promoters suitable for the invention include constitutive promoters such as the cytomegalovirus early (CMV) promoter (Thomsen et al. (1984), Proc Natl Acad Sci USA.
- CMV cytomegalovirus early
- An engineered nuclease of the invention can also be operably linked to a synthetic promoter.
- Synthetic promoters can include, without limitation, the JeT promoter (WO 2002/012514).
- mRNA encoding an endonuclease is delivered to a cell because this reduces the likelihood that the gene encoding the engineered nuclease will integrate into the genome of the cell.
- Such mRNA encoding an engineered nuclease can be produced using methods known in the art such as in vitro transcription.
- the mRNA is capped using 7-methyl-guanosine.
- the mRNA may be polyadenylated.
- a nucleic acid encoding an endonuclease of the invention can be introduced into the cell using a single-stranded DNA template.
- the single-stranded DNA can further comprise a 5′ and/or a 3′ AAV inverted terminal repeat (ITR) upstream and/or downstream of the sequence encoding the engineered nuclease.
- ITR inverted terminal repeat
- the single-stranded DNA can further comprise a 5′ and/or a 3′ homology arm upstream and/or downstream of the sequence encoding the engineered nuclease.
- genes encoding an endonuclease of the invention can be introduced into a cell using a linearized DNA template.
- a plasmid DNA encoding an endonuclease can be digested by one or more restriction enzymes such that the circular plasmid DNA is linearized prior to being introduced into a cell.
- genes encoding an endonuclease of the invention can be introduced into a cell on a self-cleaving recombinant DNA construct.
- a construct can comprise at least one coding sequence for an endonuclease and at least one recognition sequence for the same endonuclease.
- the endonuclease recognizes and cleaves the recognition sequence, resulting in linearization of the DNA construct.
- Purified nuclease proteins can be delivered into cells to cleave genomic DNA by a variety of different mechanisms known in the art, including those further detailed herein below.
- the target tissue(s) for delivery of recombinant meganucleases of the invention include, without limitation, cells of the liver, preferably hepatic sinusoidal endothelial cells or, alternatively, progenitor cells which differentiate into hepatic sinusoidal endothelial cells.
- Target tissues can also include, without limitation, cells in the circulatory system, preferably hematopoietic endothelial cells or, alternatively, progenitor cells which differentiate into hematopoietic endothelial cells.
- endonucleases of the invention can be delivered as purified protein or as RNA or DNA encoding the endonucleases.
- endonuclease proteins or mRNA, or DNA vectors encoding endonucleases, are supplied to target cells (e.g., cells in the liver or cells in the circulatory system) via injection directly to the target tissue.
- target cells e.g., cells in the liver or cells in the circulatory system
- endonuclease protein, mRNA, or DNA can be delivered systemically via the circulatory system.
- endonuclease proteins are formulated for systemic administration, or administration to target tissues, in a pharmaceutically acceptable carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (21st ed. 2005).
- proteins/RNA/mRNA are typically admixed with a pharmaceutically acceptable carrier.
- the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient.
- the carrier can be a solid or a liquid, or both, and can be formulated with the compound as a unit-dose formulation.
- endonuclease proteins are coupled to a cell penetrating peptide or targeting ligand to facilitate cellular uptake.
- cell penetrating peptides known in the art include poly-arginine (Jearawiriyapaisarn, et al. (2008) Mol Ther. 16:1624-9), TAT peptide from the HIV virus (Hudecz et al. (2005), Med. Res. Rev. 25: 679-736), MPG (Simeoni, et al. (2003) Nucleic Acids Rcs. 31:2717-2724), Pep-1 (Deshayes et al.
- endonuclease proteins are coupled covalently or non-covalently to an antibody that recognizes a specific cell-surface receptor expressed on target cells such that the endonuclease protein/DNA/mRNA binds to and is internalized by the target cells.
- endonuclease protein/DNA/mRNA can be coupled covalently or non-covalently to the natural ligand (or a portion of the natural ligand) for such a cell-surface receptor.
- endonuclease proteins are encapsulated within biodegradable hydrogels for injection or implantation within the desired region of the liver (e.g., in proximity to hepatic sinusoidal endothelial cells or hematopoictic endothelial cells, or progenitor cells which differentiate into the same).
- Hydrogels can provide sustained and tunable release of the therapeutic payload to the desired region of the target tissue without the need for frequent injections, and stimuli-responsive materials (e.g., temperature- and pH-responsive hydrogels) can be designed to release the payload in response to environmental or externally applied cues (Kang Derwent et al. (2008) Trans Am Ophthalmol Soc. 106:206-214).
- endonuclease proteins are coupled covalently or, preferably, non-covalently to a nanoparticle or encapsulated within such a nanoparticle using methods known in the art (Sharma, et al. (2014) Biomed Res Int. 2014).
- a nanoparticle is a nanoscale delivery system whose length scale is ⁇ 1 ⁇ m, preferably ⁇ 100 nm.
- Such nanoparticles may be designed using a core composed of metal, lipid, polymer, or biological macromolecule, and multiple copies of the endonuclease proteins, mRNA, or DNA can be attached to or encapsulated with the nanoparticle core.
- Nanoparticles may be further modified with polymers or lipids (e.g., chitosan, cationic polymers, or cationic lipids) to form a core-shell nanoparticle whose surface confers additional functionalities to enhance cellular delivery and uptake of the payload (Jian et al. (2012) Biomaterials. 33(30): 7621-30).
- Nanoparticles may additionally be advantageously coupled to targeting molecules to direct the nanoparticle to the appropriate cell type and/or increase the likelihood of cellular uptake. Examples of such targeting molecules include antibodies specific for cell-surface receptors and the natural ligands (or portions of the natural ligands) for cell surface receptors.
- the endonuclease proteins or DNA/mRNA encoding the endonucleases are encapsulated within liposomes or complexed using cationic lipids (see, e.g., LipofectamineTM, Life Technologies Corp., Carlsbad, Calif.; Zuris et al. (2015) Nat Biotechnol. 33: 73-80; Mishra et al. (2011) J Drug Deliv. 2011:863734).
- the liposome and lipoplex formulations can protect the payload from degradation, enhance accumulation and retention at the target site, and facilitate cellular uptake and delivery efficiency through fusion with and/or disruption of the cellular membranes of the target cells.
- endonuclease proteins are encapsulated within polymeric scaffolds (e.g., PLGA) or complexed using cationic polymers (e.g., PEI, PLL) (Tamboli et al. (2011) Ther Dcliv. 2(4): 523-536).
- polymeric scaffolds e.g., PLGA
- cationic polymers e.g., PEI, PLL
- Polymeric carriers can be designed to provide tunable drug release rates through control of polymer erosion and drug diffusion, and high drug encapsulation efficiencies can offer protection of the therapeutic payload until intracellular delivery to the desired target cell population.
- endonuclease proteins or DNA/mRNA encoding recombinant meganucleases, are combined with amphiphilic molecules that self-assemble into micelles (Tong et al. (2007) J Gene Med. 9(11): 956-66).
- Polymeric micelles may include a micellar shell formed with a hydrophilic polymer (e.g., polyethyleneglycol) that can prevent aggregation, mask charge interactions, and reduce nonspecific interactions.
- endonuclease proteins or DNA/mRNA encoding endonucleases, are formulated into an emulsion or a nanoemulsion (i.e., having an average particle diameter of ⁇ 1 nm) for administration and/or delivery to the target cell.
- emulsion refers to, without limitation, any oil-in-water, water-in-oil, water-in-oil-in-water, or oil-in-water-in-oil dispersions or droplets, including lipid structures that can form as a result of hydrophobic forces that drive apolar residues (e.g., long hydrocarbon chains) away from water and polar head groups toward water, when a water immiscible phase is mixed with an aqueous phase.
- lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases.
- Emulsions are composed of an aqueous phase and a lipophilic phase (typically containing an oil and an organic solvent). Emulsions also frequently contain one or more surfactants. Nanoemulsion formulations are well known, e.g., as described in US Patent Application Nos. 2002/0045667 and 2004/0043041, and U.S. Pat. Nos. 6,015,832, 6,506,803, 6,635,676, and 6,559,189, each of which is incorporated herein by reference in its entirety.
- endonuclease proteins or DNA/mRNA encoding endonucleases, are covalently attached to, or non-covalently associated with, multifunctional polymer conjugates, DNA dendrimers, and polymeric dendrimers (Mastorakos et al. (2015) Nanoscale. 7(9): 3845-56; Cheng et al. (2008) J Pharm Sci. 97(1): 123-43).
- the dendrimer generation can control the payload capacity and size, and can provide a high drug payload capacity.
- display of multiple surface groups can be leveraged to improve stability, reduce nonspecific interactions, and enhance cell-specific targeting and drug release.
- genes encoding an endonuclease are delivered using a viral vector.
- viral vectors are known in the art and include retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated virus (AAV) vectors (reviewed in Vannucci, et al. (2013 New Microbiol. 36:1-22).
- the viral vectors are injected directly into target tissues.
- the viral vectors are delivered systemically via the circulatory system. It is known in the art that different AAV vectors tend to localize to different tissues. In liver target tissues, effective transduction of hepatocytes has been shown, for example, with AAV serotypes 2, 8, and 9 (Sands (2011) Methods Mol.
- AAV vectors can also be self-complementary such that they do not require second-strand DNA synthesis in the host cell (McCarty, et al. (2001) Gene Ther. 8:1248-54).
- a viral vector used for endonuclease gene delivery is a self-limiting viral vector.
- a self-limiting viral vector can have limited persistence time in a cell or organism due to the presence of a recognition sequence for a recombinant meganuclease within the vector.
- a self-limiting viral vector can be engineered to provide coding for a promoter, an endonuclease described herein, and an endonuclease recognition site within the ITRs.
- the self-limiting viral vector delivers the endonuclease gene to a cell, tissue, or organism, such that the endonuclease is expressed and able to cut the genome of the cell at an endogenous recognition sequence within the genome.
- the delivered endonuclease will also find its target site within the self-limiting viral vector itself, and cut the vector at this target site. Once cut, the 5′ and 3′ ends of the viral genome will be exposed and degraded by exonucleases, thus killing the virus and ceasing production of the endonuclease.
- the endonuclease genes are delivered in DNA form (e.g. plasmid) and/or via a viral vector (e.g. AAV) they must be operably linked to a promoter.
- a viral promoter such as endogenous promoters from the viral vector (e.g. the LTR of a lentiviral vector) or the well-known cytomegalovirus- or SV40 virus-early promoters.
- meganuclease genes are operably linked to a promoter that drives gene expression preferentially in the target cells. Examples of liver-specific promoters include, without limitation, human alpha-1 antitrypsin promoter and apolipoprotein A-II promoter.
- the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and engineered nuclease of the invention, or a pharmaceutically acceptable carrier and an isolated polynucleotide comprising a nucleic acid encoding an engineered nuclease of the invention.
- the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a genetically-modified cell of the invention which can be delivered to a target tissue where the cell can then differentiate into a cell which expresses wild-type Factor VIII.
- Pharmaceutical compositions of the invention can be useful for treating a subject having hemophilia A, wherein the disease is characterized by an inversion of exons 1-22 in a Factor VIII gene.
- compositions can be prepared in accordance with known techniques. See, e.g., Remington, The Science and Practice of Pharmacy (21st ed. 2005).
- endonuclease polypeptides or DNA/RNA encoding the same
- a pharmaceutically acceptable carrier In the manufacture of a pharmaceutical formulation according to the invention, endonuclease polypeptides (or DNA/RNA encoding the same) are typically admixed with a pharmaceutically acceptable carrier and the resulting composition is administered to a subject.
- the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the subject.
- pharmaceutical compositions of the invention can further comprise one or more additional agents or biological molecules useful in the treatment of a disease in the subject. Likewise, the additional agent(s) and/or biological molecule(s) can be co-administered as a separate composition.
- the invention provides recombinant AAV vectors for use in the methods of the invention.
- Recombinant AAV vectors are typically produced in mammalian cell lines such as HEK-293. Because the viral cap and rep genes are removed from the vector to prevent its self-replication to make room for the therapeutic gene(s) to be delivered (e.g. the endonuclease gene), it is necessary to provide these in trans in the packaging cell line. In addition, it is necessary to provide the “helper” (e.g. adenoviral) components necessary to support replication (Cots D, Bosch A, Chillon M (2013) Curr. Gene Ther. 13(5): 370-81).
- helper e.g. adenoviral
- recombinant AAV vectors are produced using a triple-transfection in which a cell line is transfected with a first plasmid encoding the “helper” components, a second plasmid comprising the cap and rep genes, and a third plasmid comprising the viral ITRs containing the intervening DNA sequence to be packaged into the virus.
- Viral particles comprising a genome (ITRs and intervening gene(s) of interest) encased in a capsid are then isolated from cells by freeze-thaw cycles, sonication, detergent, or other means known in the art. Particles are then purified using cesium-chloride density gradient centrifugation or affinity chromatography and subsequently delivered to the gene(s) of interest to cells, tissues, or an organism such as a human patient.
- any endonuclease expressed in the packaging cell line will be capable of cleaving the viral genome before it can be packaged into viral particles. This will result in reduced packaging efficiency and/or the packaging of fragmented genomes.
- Several approaches can be used to prevent endonuclease expression in the packaging cells, including:
- Embodiments of the invention encompass the engineered nucleases described herein, and variants thereof. Further embodiments of the invention encompass isolated polynucleotides comprising a nucleic acid sequence encoding the endonucleases described herein, and variants of such polynucleotides.
- variants is intended to mean substantially similar sequences.
- a “variant” polypeptide is intended to mean a polypeptide derived from the “native” polypeptide by deletion or addition of one or more amino acids at one or more internal sites in the native protein and/or substitution of one or more amino acids at one or more sites in the native polypeptide.
- a “native” polynucleotide or polypeptide comprises a parental sequence from which variants are derived.
- Variant polypeptides encompassed by the embodiments are biologically active.
- the native protein i.e., they continue to possess the desired biological activity of the native protein; i.e., the ability to recognize and cleave recognition sequences found in an int22h-1 sequence in a Factor VIII gene including, for example, the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 3-4 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17).
- Such variants may result, for example, from human manipulation.
- Biologically active variants of a native polypeptide of the embodiments will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%, sequence identity to the amino acid sequence of the native polypeptide or native subunit, as determined by sequence alignment programs and parameters described elsewhere herein.
- a biologically active variant of a polypeptide or subunit of the embodiments may differ from that polypeptide or subunit by as few as about 1-40 amino acid residues, as few as about 1-20, as few as about 1-10, as few as about 5, as few as 4, 3, 2, or even 1 amino acid residue.
- polypeptides of the embodiments may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants can be prepared by mutations in the DNA. Methods for mutagenesis and polynucleotide alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Pat. No. 4,873,192; Walker and Gaastra, eds.
- a “variant” comprises a deletion and/or addition of one or more nucleotides at one or more sites within the native polynucleotide.
- variants of the nucleic acids of the embodiments will be constructed such that the open reading frame is maintained.
- conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the embodiments.
- Variant polynucleotides include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis but which still encode a recombinant meganuclease of the embodiments.
- variants of a particular polynucleotide of the embodiments will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein.
- Variants of a particular polynucleotide of the embodiments can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide.
- deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the polypeptide. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by screening the polypeptide for its ability to preferentially recognize and cleave recognition sequences found within an int22h-1 sequence of a Factor VIII gene.
- F8R 1-2 meganucleases Recombinant meganucleases (SEQ ID NOs: 19-21), collectively referred to herein as “F8R 1-2 meganucleases,” were engineered to recognize and cleave the F8R 1-2 recognition sequence (SEQ ID NO: 7), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence, and more specifically within the F8A1 sequence.
- Each F8R 1-2 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 1-2 meganuclease binds to the F8R1 recognition half-site of SEQ ID NO: 7, while a second subunit binds to the F8R2 recognition half-site (see, FIG. 2 ).
- the F8R 1-binding subunits and F8R2-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R1-binding subunits are highly conserved outside of the HVR1 region.
- F8R2-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R1-binding regions of SEQ ID NOs: 19-21 are provided as SEQ ID NOs: 22-24, respectively.
- Each of SEQ ID NOs: 22-24 share at least 90% sequence identity to SEQ ID NO: 22, which is the F8R1-binding region of the meganuclease F8R 1-2x.27 (SEQ ID NO: 19).
- F8R2-binding regions of SEQ ID NOs: 19-21 are provided as SEQ ID NOs: 25-27, respectively.
- Each of SEQ ID NOs: 25-27 share at least 90% sequence identity to SEQ ID NO: 25, which is the F8R2-binding region of the meganuclease F8R 1-2x.27 (SEQ ID NO: 19).
- F8R 3-4 meganucleases were engineered to recognize and cleave the F8R 3-4 recognition sequence (SEQ ID NO: 9), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence, and more specifically within the F8A1 sequence.
- Each F8R 3-4 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 3-4 meganuclease binds to the F8R3 recognition half-site of SEQ ID NO: 9, while a second subunit binds to the F8R4 recognition half-site (see, FIG. 2 ).
- the F8R3-binding subunits and F8R4-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R3-binding subunits are highly conserved outside of the HVR1 region.
- F8R4-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R3-binding regions of SEQ ID NOs: 28-31 are provided as SEQ ID NOs: 32-35, respectively.
- Each of SEQ ID NOs: 32-35 share at least 90% sequence identity to SEQ ID NO: 32, which is the F8R3-binding region of the meganuclease F8R3-4x.43 (SEQ ID NO: 28).
- F8R4-binding regions of SEQ ID NOs: 28-31 are provided as SEQ ID NOs: 36-39, respectively.
- Each of SEQ ID NOs: 36-39 share at least 90% sequence identity to SEQ ID NO: 36, which is the F8R4-binding region of the meganuclease F8R 3-4x.43 (SEQ ID NO: 28).
- F8R 9-10 meganucleases were engineered to recognize and cleave the F8R 9-10 recognition sequence (SEQ ID NO: 11), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence.
- Each F8R 9-10 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 9-10 meganuclease binds to the F8R9 recognition half-site of SEQ ID NO: 11, while a second subunit binds to the F8R10 recognition half-site (see, FIG. 2 ).
- the F8R9-binding subunits and F8R10-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R9-binding subunits are highly conserved outside of the HVR1 region.
- F8R10-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R9-binding regions of SEQ ID NOs: 40-43 are provided as SEQ ID NOs: 44-47, respectively.
- Each of SEQ ID NOs: 44-47 share at least 90% sequence identity to SEQ ID NO: 44, which is the F8R9-binding region of the meganucicase F8R 9-10x.70 (SEQ ID NO: 40).
- F8R10-binding regions of SEQ ID NOs: 40-43 are provided as SEQ ID NOs: 48-51, respectively.
- Each of SEQ ID NOs: 48-51 share at least 90% sequence identity to SEQ ID NO: 48, which is the F8R10-binding region of the meganuclease F8R 9-10x.70 (SEQ ID NO: 40).
- F8R 11-12 meganucleases (SEQ ID NOs: 52-55), collectively referred to herein as “F8R 11-12 meganucleases,” were engineered to recognize and cleave the F8R 11-12 recognition sequence (SEQ ID NO: 13), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence.
- Each F8R 11-12 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 11-12 meganuclease binds to the F8R11 recognition half-site of SEQ ID NO: 13, while a second subunit binds to the F8R12 recognition half-site (see, FIG. 2 ).
- the F8R11-binding subunits and F8R12-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R11-binding subunits are highly conserved outside of the HVR1 region.
- F8R12-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R11-binding regions of SEQ ID NOs: 52-55 are provided as SEQ ID NOs: 56-59, respectively.
- Each of SEQ ID NOs: 56-59 share at least 90% sequence identity to SEQ ID NO: 56, which is the F8R11-binding region of the meganuclease F8R 11-12x.56 (SEQ ID NO: 52).
- F8R12-binding regions of SEQ ID NOs: 52-55 are provided as SEQ ID NOs: 60-63, respectively.
- Each of SEQ ID NOs: 60-63 share at least 90% sequence identity to SEQ ID NO: 60, which is the F8R12-binding region of the meganuclease F8R 11-12x.56 (SEQ ID NO: 52).
- F8R 13-14 meganucleases Recombinant meganucleases (SEQ ID NOs: 64-67), collectively referred to herein as “F8R 13-14 meganucleases,” were engineered to recognize and cleave the F8R 13-14 recognition sequence (SEQ ID NO: 15), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence.
- Each F8R 13-14 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 13-14 meganuclease binds to the F8R13 recognition half-site of SEQ ID NO: 15, while a second subunit binds to the F8R14 recognition half-site (see, FIG. 2 ).
- the F8R13-binding subunits and F8R14-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R13-binding subunits are highly conserved outside of the HVR1 region.
- F8R14-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R13-binding regions of SEQ ID NOs: 64-67 are provided as SEQ ID NOs: 68-71, respectively.
- SEQ ID NOs: 68-71 share at least 90% sequence identity to SEQ ID NO: 68, which is the F8R13-binding region of the meganuclease F8R 13-14x.13 (SEQ ID NO: 64).
- F8R14-binding regions of SEQ ID NOs: 64-67 are provided as SEQ ID NOs: 72-75, respectively.
- Each of SEQ ID NOs: 72-75 share at least 90% sequence identity to SEQ ID NO: 72, which is the F8R14-binding region of the meganuclease F8R 13-14x. 13 (SEQ ID NO: 64).
- F8R 15-16 meganucleases were engineered to recognize and cleave the F8R 15-16 recognition sequence (SEQ ID NO: 17), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence.
- Each F8R 15-16 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.
- a first subunit in each F8R 15-16 meganuclease binds to the F8R15 recognition half-site of SEQ ID NO: 17, while a second subunit binds to the F8R16 recognition half-site (see, FIG. 2 ).
- the F8R15-binding subunits and F8R16-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively.
- F8R15-binding subunits are highly conserved outside of the HVR1 region.
- F8R16-binding subunits are also highly conserved outside of the HVR2 region.
- the F8R15-binding regions of SEQ ID NOs: 76-79 are provided as SEQ ID NOs: 80-83, respectively.
- Each of SEQ ID NOs: 80-83 share at least 90% sequence identity to SEQ ID NO: 80, which is the F8R15-binding region of the meganuclease F8R 15-16x.14 (SEQ ID NO: 76).
- F8R16-binding regions of SEQ ID NOs: 76-79 are provided as SEQ ID NOs: 84-87, respectively.
- Each of SEQ ID NOs: 84-87 share at least 90% sequence identity to SEQ ID NO: 84, which is the F8R16-binding region of the meganuclease F8R 15-16x.14 (SEQ ID NO: 76).
- each recombinant meganuclease was evaluated using the CHO cell reporter assay previously described (see, WO/2012/167192 and FIG. 4 ).
- CHO cell reporter lines were produced which carried a non-functional Green Fluorescent Protein (GFP) gene expression cassette integrated into the genome of the cells.
- the GFP gene in each cell line was interrupted by a pair of recognition sequences such that intracellular cleavage of either recognition sequence by a meganuclease would stimulate a homologous recombination event resulting in a functional GFP gene.
- GFP Green Fluorescent Protein
- one recognition sequence inserted into the GFP gene was the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 34 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17).
- the second recognition sequence inserted into the GFP gene was a CHO-23/24 recognition sequence, which is recognized and cleaved by a control meganuclease called “CHO-23/24”.
- CHO reporter cells comprising the F8R 1-2 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 1-2 cells.”
- CHO reporter cells comprising the F8R 3-4 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 3-4 cells.”
- CHO reporter cells comprising the F8R 9-10 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 9-10 cells.”
- CHO reporter cells comprising the F8R 11-12 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 11-12 cells.”
- CHO reporter cells comprising the F8R 13-14 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 13-14 cells.”
- CHO reporter cells comprising the F8R 15-16 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 15-16 cells.”
- CHO reporter cells were transfected with plasmid DNA encoding their corresponding recombinant meganucleases (e.g., F8R 1-2 cells were transfected with plasmid DNA encoding F8R 1-2 meganucleases) or encoding the CHO-23/34 meganuclease.
- 4e5 CHO reporter cells were transfected with 50 ng of plasmid DNA in a 96-well plate using Lipofectamine®2000 (ThermoFisher) according to the manufacturer's instructions.
- cells were evaluated by flow cytometry to determine the percentage of GFP-positive cells compared to an untransfected negative control (F8R bs). As shown in FIGS. 5A-5G , all F8R meganucleases were found to produce GFP-positive cells in cell lines comprising their corresponding recognition sequence at frequencies significantly exceeding the negative control.
- the % GFP produced by a number of different F8R meganucleases was relatively consistent over the time course of each study, indicating persistent cleavage activity and a lack of any substantial toxicity in the cells.
- Other F8R meganucleases exhibited some variability in % GFP expression over the time course of the study.
- F8R meganucleases encompassed by the invention can efficiently target and cleave their respective recognition sequences in cells.
- F8R 1-2 and F8R 3-4 were tested for the ability to cut and cause insertions and/or deletions (indels) at their recognition sites by T7 endonuclease assay.
- HEK 293 cells were transfected with 200 ng of mRNA encoding each nuclease. Cells were harvested at 7 days post transfection and gDNA was extracted. This gDNA was used as a template in PCR reactions using primers F8R3-4f.357 and F8R1-2r.467. The resulting PCR product was then analyzed using T7 endonuclease to reveal the presence of indels ( FIG. 7 ).
- FIG. 7 The results were then analyzed using T7 endonuclease to reveal the presence of indels
- FIG. 7 illustrates an agarose gel loaded with PCR/T7 endonuclease reactions from HEK 293 cells that were mock treated (Lane 1 ) or treated with F8R 1-2x.15 (lane 2 ), F8R 1-2x.27 (lane 3 ), F8R 3-4x.43 (lane 4 ), or F8R 3-4x.70 (lane 5 ).
- the lower molecular weight bands in lanes 4 and 5 are indicative of a positive T7 endonuclease result and the presence of indels at the targeted recognition sequences.
- FIG. 8A illustrates an agarose gel loaded with H1R/H1F primed PCR reactions from HEK 293 cells that were mock treated (lane 1 ), or treated with F8R 1-2x.15 (lane 2 ), F8R 1-2x.27 (lane 3 ), F8R 3-4x.43 (lane 4 ), F8R 3-4x.70 (lane 5 ).
- Lane 6 contains a control PCR using untreated human cell gDNA template.
- Lane 7 contains a no template PCR negative control.
- FIG. 8B illustrates an agarose gel loaded with H1R/H2/3R primed PCR reactions from HEK 293 cells that were mock treated (lane 1 ), or treated with F8R 1-2x.15 (lane 2 ), F8R 1-2x.27 (lane 3 ), F8R 3-4x.43 (lane 4 ), F8R 3-4x.70 (lane 5 ).
- Lane 6 contains a control PCR using untreated human cell gDNA template.
- Lane 7 contains a no template PCR negative control.
- the presence of PCR fragments in FIG. 8B is indicative of successful exon 1-22 inversion using F8R meganucleases encompassed by the invention.
- Lane 10 illustrates an agarose gel loaded with H1R/H1F primed PCR reactions (top) and H1R/H2/3R primed PCR reactions (bottom) from HEK 293 cells that were mock treated (lane 1 ), or treated with F8R 9-10x.38 (lane 2 ), F8R 9-10x.70 (lane 3 ), F8R 11-12x.56 (lane 4 ), F8R 11-12x.69 (lane 5 ), F8R 13-14x.3 (lane 6 ), F8R 13-14x.13 (lane 7 ), F8R 15-16x.14 (lane 8 ), or F8R 15-16x.85 (lane 9 ).
- Lane 10 contains a control PCR using untreated human cell gDNA template.
- Lane 11 contains a no template PCR negative control.
- the presence of PCR fragments in H1R/H2/3R primed PCR reactions (lower half of FIG. 9 ) is indicative of successful exon 1-22 inversion using the F8R meganucleases encompassed by the invention.
- F8R nucleases encompassed by this invention can lead to the hemophilia A specific Factor VIII gene inversion in HEK293cells.
- the described method can be used to determine the efficiency of F8R nuclease-mediated Factor VIII gene inversion.
- HEK293 cells (2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6) were transfected with mRNA (5 ⁇ g) encoding F8R11-12x.69 or F8R13-14x.13 nucleases, respectively, using a Bio-Rad GenePulser XCell according to the manufacturer's instructions. At 2 days post-transfection, genomic DNA was isolated from cells and inverse digital PCR was performed to determine Factor VIII genome editing. Genomic DNA isolated from untransfected cells served as a control.
- Genomic DNA was digested to completion with restriction endonuclease Bell. Digested DNA was circularized using T4 DNA ligase and analyzed by inverse digital PCR using the Bio-Rad QX200 Digital PCR System according to the manufacturer's instructions. In normal human genomic DNA, the BcII digest generates an approximately 21 kb fragment encompassing the int22h-1 repeat in intron 22 of the Factor VIII gene as well as an approximately 16 kb fragment encompassing a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- the two circularized BcII fragments described above are amplified with primers flanking the respective Bell sites.
- Primers U1 and D1 bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer U3 binds upstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1. All primers bind the genomic DNA in opposite orientation to conventional PCR and generate amplicons only when the BcII fragments are circularized.
- the U1 primer binding site which is located on the inverted fragment, is reoriented relative to the D1 and U3 primer binding sites.
- the U1/D1 PCR fails to generate a PCR product, while the U3/U1 PCR yields an approximately 0.5 kb amplicon which can be detected with the same TaqMan probe.
- the U1/D1 fragment was still amplified from genomic DNA from F8R nuclease-treated HEK293 cells because the nuclease treatment generated a mixed population of cells with both edited and unedited genomes. Since digital PCR allows parallel analysis of hundreds to thousands of chromosome equivalents, the Factor VIII gene inversion efficiency could be calculated. Out of the total number of Factor VIII genes detected by this assay, 4% and 30% showed an inversion as a result of the activity of nucleases F8R13-14x.13 and F8R11-12x.69, respectively.
- the genomic DNA was amplified between primers FWD1/REV1 and FWD3/FWD1, respectively.
- FWD1 (SEQ ID NO: 91) [5′-CCCTTACAGTTATTAACTACTCTCATGAGGTTCATTCC-3′]
- REV1 (SEQ ID NO: 92) [5′-CCCCGGCACTTGAAAGTAGCAGATGCAAGAAGGGCACA-3′]
- FWD3 (SEQ ID NO: 93) [5′-ACTATAACCAGCACCTTGAACTTCCCCTCTCATA-3′]
- Primers FWD1 and REV1 bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer FWD3 binds upstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- the FWD1 primer binding site which is located on the inverted fragment, is reoriented relative to the REV1 and FWD3 primer binding sites.
- the FWD1/REV1 PCR fails to generate a PCR product while the FWD3/FWD1 PCR yields an approximately 9.7 kb amplicon.
- PCR fragments are analyzed by agarose gel electrophoresis and visualized by ethidium bromide.
- Genomic DNAs from normal human T-cells and normal human T-cells treated with F8R3-4x.43 nuclease were analyzed by long-distance PCR ( FIG. 11 ). Only the FWD1/REV1 fragment was be amplified from genomic DNA isolated from untreated normal human T-cells (lanes 2 and 5 ). Using genomic DNA from F8R3-4x.43 nuclease-treated normal human T-cells as PCR template, both FWD1/REV1 and FWD3/FWD1 primer combinations yield their signature ⁇ 10 kb and ⁇ 9.7 kb amplicons, respectively (lanes 3 and 6 ). The FWD1/REV1 fragment can still be amplified from genomic DNA from F8R3-4x.43 treated normal human T-cells because the nuclease treatment generated a mixed population of cells with edited and unedited genomes.
- the F8R3-4x.43 meganuclease was able to generate an inversion of the Factor VIII gene in human T cells by producing a double strand break within the int22h regions, and this inversion could be detected by long-distance PCR.
- Hemophilia A patient T-cells (1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6) were transfected with mRNA (1 ⁇ g) encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases, respectively, using a Lonza 4D nucleofector according to the manufacturer's instructions. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing. Genomic DNA isolated from patient T-cells transfected with mRNA encoding green fluorescent protein (GFP) served as a control.
- GFP green fluorescent protein
- the genomic DNA was amplified between primers H1U/H1D and H3D/H1D, respectively.
- H1U (SEQ ID NO: 94) [5′-GCCCTGCCTGTCCATTACACTGATGACATTATGCTGAC-3′]
- H1D (SEQ ID NO: 95) [5′-GGCCCTACAACCATTCTGCCTTTCACTTTCAGTGCAATA-3′]
- H3D (SEQ ID NO: 96) [5′-CACAAGGGGGAAGAGTGTGAGGGTGTGGGATAAGAA-3′]
- Primers H1U and H1D bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer H3D binds downstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- the H1U primer binding site which is located on the inverted fragment, is reoriented relative to the H3U and H1D primer binding sites.
- the H1U/H1D PCR yields the 12 kb amplicon, indicating a reversion to the wild-type configuration of the Factor VIII gene.
- PCR fragments were analyzed by agarose gel electrophoresis and visualized by ethidium bromide.
- Genomic DNAs from hemophilia A patient T-cells treated with mRNA encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases (or GFP as a control) were analyzed by long-distance PCR ( FIG. 12 ). Only the H3U/H1D fragment could be amplified from genomic DNA isolated from patient T-cells treated with GFP mRNA (lanes 1 a and 1 b ).
- both H1U/H1D and H3D/H1D primer combinations yielded their signature wild-type ( ⁇ 12 kb) and inversion ( ⁇ 11 kb) amplicons, respectively (lanes 3 a and 3b: F8R3-4x.43; lanes 4 a and 4b: F8R11-12x.69; lanes 5 a and 5b: F8R15-16x.14).
- the H3U/H1D fragment was still being amplified from genomic DNA from F8R nuclease-treated patient T-cells because the nuclease treatment generated a mixed population of cells with edited and unedited genomes.
- F8R meganucleases encompassed by the invention were capable of inducing a reversion of the inverted Factor VIII gene back to a wild-type configuration in hemophilia A patient T-cells in vitro, and this reversion could be detected by long-distance PCR.
Abstract
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating hemophilia A. Further, the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins, nucleic acids encoding engineered nucleases, or genetically-modified cells of the invention, and the use of such compositions for treating of hemophilia A.
Description
- This application claims priority to U.S. Provisional Application No. 62/331,335, entitled “ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A,” filed May 3, 2016, the disclosure of which is hereby incorporated by reference in its entirety.
- The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to engineered nucleases having specificity for a recognition sequence within intron 22 of a Factor VIII gene, and particularly within the int22h-1 sequence. Such engineered nucleases are useful in methods for treating hemophilia A characterized by an inversion of exons 1-22 in the Factor VIII gene.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 2, 2017, is named 182WO1_Sequence_Listing_Final, and is 172,847 bytes in size.
- Hemophilia A is a common genetic bleeding disorder with an incidence of 1 in 5000 males worldwide. This genetic disease can result from various mutations within the coagulation Factor VIII (F8) gene located on the X chromosome, which include large deletions, insertions, inversions, and point mutations. Clinically, hemophilia A can be classified based on relative Factor VIII activity in the patient's plasma as mild (5-30% activity; 50% of patients), moderate (2-5% activity; 10% of patients), or severe (<1% activity; 50% of patients). Currently, there is no cure for hemophilia A. Standard therapy includes the administration of recombinant Factor VIII, but this approach is limited by cost, the requirement for frequent injections, and the formation of Factor VIII-inactivating antibodies in the subject which reduce the effectiveness of therapy. Therefore, a clear need still exists for alternative treatments for hemophilia A. Gene therapy, targeting mutations in the Factor VIII gene, remains an attractive yet elusive approach to treatment.
- Factor VIII is an essential component of the clotting cascade. The protein circulates in the body in an inactive form that is attached to von Willebrand factor. In response to injury, Factor VIII is activated (Factor VIIIa) and separates from von Willebrand factor, then interacts with Factor IXa as part of the clotting cascade which leads to the formation of firbin and stable clotting. A number of studies have suggested that Factor VIII is produced by liver sinusoidal endothelial cells, as well as extra-hepatic, hematopoictic cells throughout the body.
- The Factor VIII gene on the X chromosome is large and structurally complex, comprising ˜180 kb and 26 exons. The wild-type Factor VIII gene encodes two proteins. The first protein is the full-length Factor VIII protein, which is encoded by the 9030 bases found in
exons 1 to 26, and has a circulating form containing 2332 amino acid residues. The second protein, referred to as Factor VIIIb, is encoded by 2598 bases in 5 exons present in the Factor VIII gene. The resulting protein comprises 216 amino acids and has a presently unknown function. - Approximately 45% of severe hemophilia A cases are caused by an intra-chromosomal inversion that involves intron 22 of the Factor VIII gene. This inversion arises when an ˜9.5 kb segment of intron 22, referred to as int22h-1, recombines with one of two repeat copies (referred to as int22h-2 and int22h-3, respectively) which are positioned approximately 400 kb and 500 kb telomeric to the Factor VIII gene on the X chromosome. Following recombination, exons 1-22 of the Factor VIII gene become inverted in the genome relative to exons 23-26, resulting in the expression of a truncated, inactive Factor VIII protein that lacks the amino acids encoded by exons 23-26 (Sauna et al. (2015) Blood 125(2): 223-228).
- The upstream repeat copy involved in exon 1-22 inversion is oriented in the opposite direction as int22h-1. Early studies suggested that int22h-2 and int22h-3 were both in reverse orientation relative to int22h-1, allowing for recombination to occur with either repeat sequence. This was referred to as Type I inversion and Type II inversion. However, more recent evidence indicates that int22h-2 and int22h-3 are found in an inverse orientation to one another on the X chromosome, and are part of an imperfect palindrome (
FIG. 1 ). Recombination of sequences within this palindrome allows int22h-2 and in22h-3 to swap places in the genome and, consequently, change their orientation relative to int22h-1. As a result, the int22h-1 sequence can, in different circumstances, recombine with the int22h-2 repeat or the int22h-3 repeat, depending on which is in the opposite orientation to int22h-1 (Bagnall et al. (2006) Journal of Thrombosis and Haemostasis 4: 591-598). - Of note, intron 22 of the Factor VIII gene contains a CpG island that acts as a bi-directional promoter for two further genes, referred to as F8A1 (Factor VIII-associated 1) and FSB. The CpG island and the intron-less F8A1 gene (SEQ ID NO: 5) are both contained within the int22h-1 sequence (and consequently, within int22h-2 and in22h-3) and are transcribed in the opposite direction as the Factor VIII gene (Bowen (2002) J. Clin. Pathol: Mol. Pathol. 55: 127-144). Interestingly, the inventors have determined that the sequence of the F8A1 gene is the only region of the human Factor VIII gene that exhibits significant homology to the Factor VIII gene in the canine genome, and particularly in a clinically-relevant population of canines that are Factor VIII-deficient and exhibit an inversion of exons 1-22 in their Factor VIII gene (Lozier et al. (2002) PNAS 99(20): 12991-12996).
- The present invention requires the use of site-specific, rare-cutting endonucleases that are engineered to recognize DNA sequences within the int22h-1 sequence in order to generate a double-strand break and promote recombination between int22h-1 and an inversely-oriented repeat sequence (int22h-2 or int22h-3) positioned telomeric to the Factor VIII gene. The inventors have found that nuclease-induced recombination between these regions results in an inversion or reversion of exons 1-22 of the Factor VIII gene.
- Methods for producing engineered, site-specific endonucleases are known in the art. For example, zinc-finger nucleases (ZFNs) can be engineered to recognize and cut pre-determined sites in a genome. ZFNs are chimeric proteins comprising a zinc finger DNA-binding domain fused to the nuclease domain of the FokI restriction enzyme. The zinc finger domain can be redesigned through rational or experimental means to produce a protein which binds to a pre-determined DNA sequence ˜18 basepairs in length. By fusing this engineered protein domain to the FokI nuclease, it is possible to target DNA breaks with genome-level specificity. ZFNs have been used extensively to target gene addition, removal, and substitution in a wide range of eukaryotic organisms (reviewed in S. Durai et al., Nucleic Acids Res 33, 5978 (2005)).
- Likewise, TAL-effector nucleases (TALENs) can be generated to cleave specific sites in genomic DNA. Like a ZFN, a TALEN comprises an engineered, site-specific DNA-binding domain fused to the FokI nuclease domain (reviewed in Mak, et al. (2013) Curr Opin Struct Biol. 23:93-9). In this case, however, the DNA binding domain comprises a tandem array of TAL-effector domains, each of which specifically recognizes a single DNA basepair.
- Compact TALENs are an alternative endonuclease architecture that avoids the need for dimerization (Beurdeley, et al. (2013) Nat Commun. 4:1762). A Compact TALEN comprises an engineered, site-specific TAL-effector DNA-binding domain fused to the nuclease domain from the I-TevI homing endonuclease. Unlike FokI, I-TevI does not need to dimerize to produce a double-strand DNA break so a Compact TALEN is functional as a monomer.
- Engineered endonucleases based on the CRISPR/Cas9 system are also known in the art (Ran, et al. (2013) Nat Protoc. 8:2281-2308; Mali et al. (2013) Nat Methods. 10:957-63). A CRISPR endonuclease comprises two components: (1) a caspase effector nuclease, typically microbial Cas9; and (2) a short “guide RNA” comprising a ˜20 nucleotide targeting sequence that directs the nuclease to a location of interest in the genome. By expressing multiple guide RNAs in the same cell, each having a different targeting sequence, it is possible to target DNA breaks simultaneously to multiple sites in in the genome.
- In the preferred embodiment of the invention, the DNA break-inducing agent is an engineered homing endonuclease (also called a “meganuclease”). Homing endonucleases are a group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi. They are frequently associated with parasitic DNA elements, such as
group 1 self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys. 38: 49-95). Homing endonucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLIDADG homing endonucleases with a single copy of the LAGLIDADG motif form homodimers, whereas members with two copies of the LAGLIDADG motif are found as monomers. - I-CreI (SEQ ID NO: 1) is a member of the LAGLIDADG family of homing endonucleases which recognizes and cuts a 22 basepair recognition sequence in the chloroplast chromosome of the algae Chlamydomonas reinhardtii. Genetic selection techniques have been used to modify the wild-type I-CreI cleavage site preference (Sussman et al. (2004), J. Mol. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: e178; Seligman et al. (2002), Nucleic Acids Res. 30: 3870-9, Amould et al. (2006), J. Mol. Biol. 355: 443-58). Methods for rationally-designing mono-LAGLIDADG homing endonucleases were described which are capable of comprehensively redesigning I-CreI and other homing endonucleases to target widely-divergent DNA sites, including sites in mammalian, yeast, plant, bacterial, and viral genomes (WO 2007/047859).
- As first described in WO 2009/059195, 1-CreI and its engineered derivatives are normally dimeric but can be fused into a single poly-peptide using a short peptide linker that joins the C-terminus of a first subunit to the N-terminus of a second subunit (Li, et al. (2009) Nucleic Acids Res. 37:1650-62; Grizot, et al. (2009) Nucleic Acids Res. 37:5405-19.) Thus, a functional “single-chain” meganuclease can be expressed from a single transcript. This, coupled with the extremely low frequency of off-target cutting observed with engineered meganucleases makes them the preferred endonuclease for the present invention.
- The use of engineered nucleases for gene therapy in severe hemophilia A has been limited. Park et al. described the use of a TALEN to induce an inversion of
exon 1 in the Factor VIII gene in HEK 293T cells and induced pluripotent stem cells (iPSCs) (Park et al. (2014), PNAS 111(25): 9253-9258). Inversions ofexon 1 are also associated with the occurrence of hemophilia A occur due to homologous recombination between an int1h-1 sequence in intron I of the Factor VIII gene and a single homologous region (int1h-2) positioned telomeric to the Factor VIII gene. The TALEN selected for this study cut within theintron 1 homology region in order to induce an inversion of this shorter sequence with an efficiency of 1.9% and 1.4% in the HEK 293T cells and iPSCs, respectively. The authors further demonstrated reversion ofexon 1 in the iPSCs at a similar efficiency of 1.3%. - In a subsequent study, Park et al. reported the use of a CRISPR/Cas system to induce a reversion of exons 1-22 of the Factor VIII gene in iPSCs obtained from patients suffering from severe hemophilia A (Park et al. (2015) Cell Stem Cell 17: 213-220). The authors noted that inversions of exons 1-22 are eight times more prevalent than inversions of
exon 1, but emphasized that the exon 1-22 inversion is technically more challenging to revert due in part to the substantially larger size of the inversion (600 kbp compared to 140 kbp) and the presence of three homologs of the int22h-1 sequence on the X chromosome, compared to only two homologs of the int1h-1 sequence. Indeed, Park et al. specifically targets recognition sequences outside of the int22h-1, int22h-2, and int22h-3 homology regions in order to rule out the possibility that unwanted deletions or inversions involving any two of the three int22 homologs, rather than the desired reversion of the inverted 600-kbp segment, would be induced by cutting within an int22h homology region. Using this approach, the authors observed a reversion frequency of approximately 3.7% in iPS cells. - The present invention improves on the art in several aspects. Despite suggestions in the art to avoid targeting recognition sequences within the int22h homology regions, the inventors surprisingly found that targeting recognition sequences within int22h-1 can, in fact, produce an inversion or reversion of exons 1-22 in the Factor VIII with high efficiency. Further, several recognition sequences targeted within the int22h-1 sequence are found within the F8A1 sequence, which the inventors found to be the only region of the Factor VIII gene which shares a high degree of homology with the canine Factor VIII gene. Thus, the methods of the invention are useful not only in human subjects suffering from hemophilia A, but also in the clinically-relevant canine hemophilia A population which also expresses an inversion of exons 1-22. Accordingly, the present invention fulfills a need in the art for further gene therapy approaches to severe hemophilia A.
- The present invention provides engineered nucleases useful for the treatment of hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene. The engineered nucleases of the invention recognize and a cleave recognition sequence within an int22h-1 sequence of the Factor VIII gene, thereby promoting recombination between the int22h-1 sequence and an identical, or highly homologous, inverted repeat sequence positioned telomeric to the Factor VIII gene on the X chromosome. Such recombination results in a reversion of exons 1-22 to generate a wild-type Factor VIII gene. The present invention also provides pharmaceutical compositions and methods for treatment of hemophilia A which utilize an engineered nuclease having specificity for a recognition sequence positioned within the int22h-1 sequence of the Factor VIII gene. The present invention further provides genetically-modified cells which have been modified to correct an inversion of exons 1-22 in the Factor VIII gene, as well as pharmaceutical compositions comprising such genetically-modified cells and methods of using the same for the treatment of hemophilia A.
- Thus, in one aspect, the invention provides an engineered meganuclease that recognizes and cleaves a recognition sequence within an int22h-1 sequence of a Factor VIII gene. The engineered meganuclease comprises a first subunit and a second subunit, wherein the first subunit binds to a first recognition half-site of the recognition sequence and comprises a first hypervariable (HVR1) region, and wherein the second subunit binds to a second recognition half-site of the recognition sequence and comprises a second hypervariable (HVR2) region.
- In one embodiment, the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In one such embodiment, the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- In another embodiment, the recognition sequence can be within an F8A1 coding sequence of the Factor VIII gene. In such an embodiment, the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6. In another such embodiment, the F8A1 coding sequence can comprise SEQ ID NO: 5 or SEQ ID NO: 6.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 7.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 19 or residues 24-79 of any one of SEQ ID NOs: 20-21.
- In certain embodiments, the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 19 or
residues - In particular embodiments, the HVR1 region can comprise residues 215-270 of SEQ ID NO: 19 or residues 24-79 of any one of SEQ ID NOs: 20-21.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 19 or residues 215-270 of any one of SEQ ID NOs: 20-21.
- In certain embodiments, the HVR2 region can comprise residues corresponding to
residues - In particular embodiments, the HVR2 region can comprise residues 24-79 of SEQ ID NO: 19 or residues 215-270 of any one of SEQ ID NOs: 20-21.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 19 or residues 7-153 of SEQ ID NO: 20 or 21, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95, or more, sequence identity to residues 7-153 of SEQ ID NO: 19 or residues 198-344 of SEQ ID NO: 20 or 21.
- In another such embodiment, the first subunit can comprise residues 198-344 of SEQ ID NO: 19 or residues 7-153 of SEQ ID NO: 20 or 21. In another such embodiment, the second subunit can comprise residues 7-153 of SEQ ID NO: 19 or residues 198-344 of SEQ ID NO: 20 or 21.
- In another such embodiment, the engineered meganuclease can be a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 9.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 28-31.
- In certain embodiments, the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 231, 233, 235, 237, 261, 266, and 268 of any one of SEQ ID NOs: 28-31.
- In particular embodiments, the HVR1 region can comprise residues 215-270 of any one of SEQ ID NOs: 28-31.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 28-31.
- In certain embodiments, the HVR2 region can comprise residues corresponding to
residues - In further embodiments, the HVR2 region further can comprise a residue corresponding to residue 73 of SEQ ID NO: 30.
- In particular embodiments, the HVR2 region can comprise residues 24-79 of any one of SEQ ID NOs: 28-31.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 28-31, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ 1D NOs: 28-31.
- In another such embodiment, the first subunit can comprise residues 198-344 of any one of SEQ ID NOs: 28-31. In another such embodiment, the second subunit can comprise residues 7-153 of any one of SEQ ID NOs: 28-31.
- In another such embodiment, the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 11.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 40 or residues 215-270 of any one of SEQ ID NOs: 41-43.
- In certain embodiments, the HVR1 region can comprise residues corresponding to
residues - In particular embodiments, the HVR1 region can comprise residues 24-79 of SEQ ID NO: 40 or residues 215-270 of any one of SEQ ID NOs: 41-43.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 40 or residues 24-79 of any one of SEQ ID NOs: 41-43.
- In certain embodiments, the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 40 or
residues - In particular embodiments, the HVR2 region can comprise residues 215-270 of SEQ ID NO: 40 or residues 24-79 of any one of SEQ ID NOs: 41-43.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of SEQ ID NO: 40 or residues 198-344 of any one of SEQ ID NOs: 41-43, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 40 or residues 7-153 of any one of SEQ ID NO:s 41-43.
- In another such embodiment, the first subunit can comprise residues 7-153 of SEQ ID NO: 40 or residues 198-344 of any one of SEQ ID NOs: 41-43. In another such embodiment, the second subunit can comprise residues 198-344 of SEQ ID NO: 40 or residues 7-153 of any one of SEQ ID NOs: 41-43.
- In another such embodiment, the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 13.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 52-55.
- In certain embodiments, the HVR1 region can comprise residues corresponding to
residues - In particular embodiments, the HVR1 region can comprise residues 24-79 of any one of SEQ ID NOs: 52-55.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 52-55.
- In certain embodiments, the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 52-55.
- In particular embodiments, the HVR2 region can comprise residues 215-270 of any one of SEQ ID NOs: 52-55.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ ID NOs: 52-55, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 52-55.
- In another such embodiment, the first subunit can comprise residues 7-153 of any one of SEQ ID NOs: 52-55. In another such embodiment, the second subunit can comprise residues 198-344 of any one of SEQ ID NOs: 52-55.
- In another such embodiment, the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 15.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 64 or residues 215-270 of any one of SEQ ID NOs: 65-67.
- In certain embodiments, the HVR1 region can comprise residues corresponding to
residues - In particular embodiments, the HVR1 region can comprise residues 24-79 of SEQ ID NO: 64 or residues 215-270 of any one of SEQ ID NOs: 65-67.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 64 or residues 24-79 of any one of SEQ ID NOs: 65-67.
- In certain embodiments, the HVR2 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 64 or
residues - In particular embodiments, the HVR2 region can comprise residues 215-270 of SEQ ID NO: 64 or residues 24-79 of any one of SEQ ID NOs: 65-67.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of SEQ ID NO: 64 or residues 198-344 of any one of SEQ ID NOs: 65-67, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of SEQ ID NO: 64 or residues 7-153 of any one of SEQ ID NO:s 65-67.
- In another such embodiment, the first subunit can comprise residues 7-153 of SEQ ID NO: 64 or residues 198-344 of any one of SEQ ID NOs: 65-67. In another such embodiment, the second subunit can comprise residues 198-344 of SEQ ID NO: 64 or residues 7-153 of any one of SEQ ID NOs: 65-67.
- In another such embodiment, the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- In another embodiment, the recognition sequence can comprise SEQ ID NO: 17.
- In some such embodiments, the HVR1 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 76-79.
- In certain embodiments, the HVR1 region can comprise residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 259, 261, 266, and 268 of any one of SEQ ID NOs: 76-79.
- In particular embodiments, the HVR1 region can comprise residues 215-270 of any one of SEQ ID NOs: 76-79.
- In some such embodiments, the HVR2 region can comprise an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 76-79.
- In certain embodiments, the HVR2 region can comprise residues corresponding to
residues - In particular embodiments, the HVR2 region can comprise residues 24-79 of any one of SEQ ID NOs: 76-79.
- In one such embodiment, the first subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 198-344 of any one of SEQ ID NOs: 76-79, and the second subunit can comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to residues 7-153 of any one of SEQ ID NOs: 76-79.
- In another such embodiment, the first subunit can comprise residues 198-344 of any one of SEQ ID NOs: 76-79. In another such embodiment, the second subunit can comprise residues 7-153 of any one of SEQ ID NOs: 76-79.
- In another such embodiment, the engineered meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.
- In another such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- In another aspect, the invention provides an isolated polynucleotide comprising a nucleic acid sequence encoding any engineered meganuclease of the invention. In a particular embodiment, the isolated polynucleotide can be an mRNA.
- In another aspect, the invention provides a recombinant DNA construct comprising a nucleic acid sequence which encodes any engineered meganuclease of the invention.
- In one embodiment, the recombinant DNA construct can be self-cleaving.
- In another embodiment, the recombinant DNA construct encodes a viral vector. In such an embodiment, the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an adeno-associated virus (AAV) vector. In a particular embodiment, the viral vector can be a recombinant AAV vector.
- In another aspect, the invention provides a viral vector comprising a nucleic acid sequence which encodes any engineered meganuclease of the invention.
- In one embodiment, the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an adeno-associated virus (AAV) vector. In a particular embodiment, the viral vector can be a recombinant AAV vector.
- In another aspect, the invention provides a pharmaceutical composition for treatment of a subject having hemophilia A. In such an aspect, hemophilia A is characterized by an inversion of exons 1-22 in a Factor VIII gene. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and: (a) a nucleic acid encoding an engineered nuclease, wherein the engineered nuclease is expressed in a target cell in vivo; or (b) an engineered nuclease protein; wherein the engineered nuclease has specificity for a first recognition sequence positioned within an int22h-1 sequence of the Factor VIII gene in the target cell.
- In one embodiment, the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In one such embodiment, the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- In another embodiment, the first recognition sequence can be within an F8A1 coding sequence. In such an embodiment, the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6. In another such embodiment, the F8A1 coding sequence can comprise SEQ ID NO: 5 or SEQ ID NO: 6.
- In another embodiment, the engineered nuclease can have specificity for a second recognition sequence that is identical to, or has a high degree of homology with, the first recognition sequence, wherein the second recognition sequence is positioned in a repeat sequence telomeric to the Factor VIII gene in the X chromosome. In such an embodiment, the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence is in reverse orientation relative to the int22h-1 sequence.
- In another embodiment, the nucleic acid encoding the engineered nuclease can be an mRNA.
- In another embodiment, the pharmaceutical composition comprises a recombinant DNA construct comprising the nucleic acid. In one such embodiment, the recombinant DNA construct can be self-cleaving.
- In another embodiment, the pharmaceutical composition comprises a viral vector comprising the nucleic acid. In one such embodiment, the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an AAV. In a particular embodiment, the viral vector can be a recombinant AAV vector.
- In another embodiment, the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL. In a particular embodiment, the engineered nuclease can be an engineered meganuclease.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 7. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 7. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 9. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 9. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 11. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 11. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 13. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 13. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 15. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 15. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- In another embodiment, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 17. In one such embodiment, the pharmaceutical composition can comprise an engineered meganuclease of the invention (or a nucleic acid encoding the same) which recognizes and cleaves SEQ ID NO: 17. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- In another aspect, the invention provides a method for treating a subject having hemophilia A. In such an aspect, hemophilia A is characterized by an inversion of exons 1-22 of a Factor VIII gene. The method comprises delivering to a target cell in the subject: (a) a nucleic acid encoding an engineered nuclease, wherein the engineered nuclease is expressed in the target cell in vivo; or (b) an engineered nuclease protein; wherein the engineered nuclease is any engineered nuclease of the invention which has specificity for a first recognition sequence positioned within an int22h-1 sequence of the Factor VIII gene in the target cell.
- In one embodiment of the method, the method comprises administering to the subject a pharmaceutical composition of the invention described above, which comprises (a) a nucleic acid encoding an engineered nuclease of the invention, wherein the engineered nuclease is expressed in a target cell in vivo; or (b) an engineered nuclease protein of the invention.
- In another embodiment of the method, the engineered nuclease, or the nucleic acid encoding the engineered nuclease, can be delivered to a target cell which is capable of expressing wild-type Factor VIII, or a progenitor cell which differentiates into a cell which is capable of expressing wild-type Factor VIII. In one such embodiment, the target cell can be a hepatic cell. In a particular embodiment, the hepatic cell can be a hepatic sinusoidal endothelial cell. In another such embodiment, the hepatic cell can be a progenitor cell, such as a hepatic stem cell, which differentiates into a hepatic sinusoidal endothelial cell. In another such embodiment, the target cell can be a hematopoietic endothelial cell. In another such embodiment, the target cell can be a progenitor cell which differentiates into a hematopoietic endothelial cell. It is understand that target cells comprise a Factor VIII gene which has an inversion of exons 1-22.
- In another embodiment of the method, the engineered nuclease recognizes and cleaves the first recognition sequence to promote recombination between the int22h-1 sequence and the repeat sequence, resulting in reversion of exons 1-22 to generate a wild-type Factor VIII gene.
- In another embodiment of the method, the engineered nuclease further recognizes and cleaves the second recognition sequence in the repeat sequence.
- In another embodiment of the method, the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL. In a particular embodiment, the engineered nuclease can be an engineered meganuclease.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 7. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 7. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 9. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 9. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 11. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 11. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 13. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 13. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 15. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 15. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- In another embodiment of the method, wherein the engineered nuclease is an engineered meganuclease, the first recognition sequence can comprise SEQ ID NO: 17. In one such embodiment, the engineered meganuclease can be any engineered meganuclease of the invention which recognizes and cleaves SEQ ID NO: 17. In a particular embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- In another embodiment of the method, the subject can be a mammal. In one such embodiment, the subject can be a human. In another such embodiment, the subject can be a canine.
- In another aspect, the invention provides a method for producing a genetically-modified cell comprising a wild-type Factor VIII gene. The method comprises: (a) obtaining a cell comprising a Factor VIII gene having an inversion of exons 1-22; and (b) introducing into the cell: (i) a nucleic acid sequence encoding an engineered nuclease, wherein the engineered nuclease is expressed in the cell; or (ii) an engineered nuclease protein; wherein the engineered nuclease has specificity for a first recognition sequence within an int22h-1 sequence of the Factor VIII gene; and wherein the engineered nuclease recognizes and cleaves the first recognition sequence within the int22h-1 sequence to promote recombination between the int22h-1 sequence and a repeat sequence positioned telomeric to the Factor VIII gene; and wherein the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence is in reverse orientation relative to the int22h-1 sequence; and wherein recombination causes reversion of exons 1-22 and generation of the genetically-modified cell comprising a wild-type Factor VIII gene.
- In one embodiment, the cell can be a eukaryotic cell. In one such embodiment, the eukaryotic cell can be a pluripotent cell. In such an embodiment, the pluripotent cell can be an induced pluripotent stem (iPS) cell. In a particular embodiment, the iPS cell can be a human iPS cell or a canine iPS cell.
- In another embodiment, the int22h-1 sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In one such embodiment, the int22h-1 sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- In another embodiment, the first recognition sequence can be within an F8A1 coding sequence of the Factor VIII gene. In such an embodiment, the F8A1 coding sequence can have at least 80%, at least 85%, at least 90%, at least 95%, or more, sequence identity to SEQ ID NO: 3 or SEQ ID NO: 4. In a particular embodiment, the F8A1 coding sequence can comprise SEQ ID NO: 3 or SEQ ID NO: 4.
- In another embodiment, the engineered nuclease can have specificity for a second recognition sequence that is identical to, or has a high degree of homology with, the first recognition sequence, wherein the second recognition sequence is positioned in a repeat sequence telomeric to the Factor VIII gene in the X chromosome. In such an embodiment, the repeat sequence is identical to, or has a high degree of homology with, the int22h-1 sequence except that the repeat sequence is in reverse orientation relative to the int22h-1 sequence.
- In another embodiment, the nucleic acid can be an mRNA.
- In another embodiment, the nucleic acid can be introduced into the cell using a recombinant DNA construct. In one such embodiment, the recombinant DNA construct can be self-cleaving.
- In another embodiment, the nucleic acid can be introduced into the cell using a viral vector. In one such embodiment, the viral vector can be a retrovirus, a lentivirus, an adenovirus, or an AAV. In a particular embodiment, the viral vector can be a recombinant AAV vector.
- In another embodiment, the engineered nuclease can be an engineered meganuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL. In a particular embodiment, the engineered nuclease can be an engineered meganuclease.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 7. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 19-21.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 9. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 28-31.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 11. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 40-43.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 13. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 52-55.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 15. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 64-67.
- In another embodiment, the engineered nuclease can be any engineered meganuclease of the invention which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 17. In one such embodiment, the engineered meganuclease can comprise the amino acid sequence of any one of SEQ ID NOs: 76-79.
- In another aspect, the invention provides a genetically-modified cell, wherein the genetically-modified cell comprises a wild-type Factor VIII gene and is produced according to the methods of the invention described herein, which produce a genetically-modified cell from a cell which comprises a Factor VIII gene having an inversion of exons 1-22.
- In another aspect, the invention provides a pharmaceutical composition for treatment of a subject having hemophilia A. In such an aspect, hemophilia A is characterized by an inversion of exons 1-22 in a Factor VIII gene. In different embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and any genetically-modified cell of the invention, and/or any genetically-modified cell produced according to the methods of the invention, which comprises a wild-type Factor VIII gene.
- In another aspect, the invention provides a method for treating a subject having hemophilia A. In such an aspect, hemophilia A is characterized by an inversion of exons 1-22 of the Factor VIII gene. The method comprises administering to the subject a pharmaceutical composition of the invention which comprises a pharmaceutically acceptable carrier and any genetically-modified cell of the invention. Such a genetically-modified cell comprises a wild-type Factor VIII gene following modification.
- In one embodiment of the method, the genetically-modified cell can be delivered to a target tissue. In one such embodiment, the target tissue can be the liver. In another such embodiment, the target tissue can be the circulatory system.
- In another embodiment of the method, the genetically-modified cell can be a genetically-modified iPS cell. In one such embodiment, the genetically-modified iPS cell can differentiate into a cell which expresses Factor VIII when it is delivered to the target tissue. In a particular embodiment, the genetically-modified iPS cell can differentiate into a hepatic sinusoidal endothelial cell which expresses Factor VIII. In another particular embodiment, the genetically-modified iPS cell can differentiate into a hematopoietic cell, such as a hematopoietic endothelial cell, which expresses Factor VIII.
- In another embodiment of the method, the subject can be a mammal. In one such embodiment, the subject can be a human. In another such embodiment, the subject can be a canine.
- In another aspect, the invention provides an engineered nuclease, and particularly an engineered meganuclease, described herein for use as a medicament. The invention further provides the use of an engineered nuclease, and particularly an engineered meganuclease, described herein in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 in the Factor VIII gene.
- In another aspect, the invention provides an isolated polynucleotide for use as a medicament, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention. The invention further provides the use of an isolated polynucleotide in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 in the Factor VIII gene, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- In another aspect, the invention provides a recombinant AAV vector for use as a medicament, wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention. The invention further provides the use of a recombinant AAV vector in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene, wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding an engineered nuclease, and particularly an engineered meganuclease, of the invention.
- In another aspect, the invention provides a genetically-modified cell of the invention for use as a medicament, wherein the genetically-modified cell has been modified to comprise a wild-type Factor VIII gene. The invention further provides the use of a genetically-modified cell of the invention in the manufacture of a medicament for treating hemophilia A, which is characterized by an inversion of exons 1-22 of the Factor VIII gene, wherein the genetically-modified cell has been modified to comprise a wild-type Factor VIII gene.
-
FIG. 1A andFIG. 1B . Inversion of introns 1-22 in the Factor VIII gene. The int22h-2 and int22h-3 repeat sequences are positioned telomeric to the int22h-1 sequence on the X chromosome. Further, int22h-2 and int22h-3 are found in an inverse orientation to one another as part of an imperfect palindrome. Recombination of sequences within this palindrome allows int22h-2 and in22h-3 to swap places in the genome and, consequently, change their orientation relative to int22h-1. As a result, the int22h-1 sequence can, in different circumstances, recombine with the int22h-2 repeat or the int22h-3 repeat, depending on which is in the opposite orientation to int22h-1.FIG. 1A shows a configuration in which int22h-3 is in an inverse orientation to int22h-1, allowing for intrachromosomal recombination to occur between these repeat sequences, resulting in the illustrated inversion of exons 1-22.FIG. 1B shows a configuration in which int22h-2 is in an inverse orientation to int22h-1, allowing for intrachromosomal recombination to occur between these repeat sequences, resulting in the illustrated inversion of exons 1-22. -
FIG. 2 . F8R recognition sequences in the Factor VIII gene. A) Each recognition sequence targeted by a recombinant meganuclease of the invention comprises two recognition half-sites. Each recognition half-site comprises 9 base pairs, separated by a 4 base pair central sequence. The F8R 1-2 recognition sequence (SEQ ID NO: 7) comprises two recognition half-sites referred to as F8R1 and F8R2. The F8R 3-4 recognition sequence (SEQ ID NO: 9) comprises two recognition half-sites referred to as F8R3 and F8R4. The F8R 9-10 recognition sequence (SEQ ID NO: 11) comprises two recognition half-sites referred to as F8R9 and F8R10. The F8R 11-12 recognition sequence (SEQ ID NO: 13) comprises two recognition half-sites referred to as F8R11 and F8R12. The F8R 13-14 recognition sequence (SEQ ID NO: 15) comprises two recognition half-sites referred to as F8R13 and F8R14. The F8R 15-16 recognition sequence (SEQ ID NO: 17) comprises two recognition half-sites referred to as F8R15 and F8R16. -
FIG. 3 . The recombinant meganucleases of the invention comprise two subunits, wherein the first subunit comprising the HVR1 region binds to a first recognition half-site (e.g., F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15) and the second subunit comprising the HVR2 region binds to a second recognition half-site (e.g., F8R2, F8R4, F8R10, F8R12, F8R14, or F8R16). In embodiments where the recombinant meganuclease is a single-chain meganuclease, the first subunit comprising the HVR1 region can be positioned as either the N-terminal or C-terminal subunit. Likewise, the second subunit comprising the HVR2 region can be positioned as either the N-terminal or C-terminal subunit. -
FIG. 4 . Schematic of reporter assay in CHO cells for evaluating recombinant meganucleases targeting recognition sequences found in intron 22 of the Factor VIII gene. For the recombinant meganucleases described herein, a CHO cell line was produced in which a reporter cassette was integrated stably into the genome of the cell. The reporter cassette comprised, in 5′ to 3′ order: an SV40 Early Promoter; the 5′ 2/3 of the GFP gene; the recognition sequence for an engineered meganuclease of the invention (e.g., the F8R 1-2 recognition sequence); the recognition sequence for the CHO-23/24 meganuclease (WO/2012/167192); and the 3′ 2/3 of the GFP gene. Cells stably transfected with this cassette did not express GFP in the absence of a DNA break-inducing agent. Meganucleases were introduced by transduction of plasmid DNA or mRNA encoding each meganuclease. When a DNA break was induced at either of the meganuclease recognition sequences, the duplicated regions of the GFP gene recombined with one another to produce a functional GFP gene. The percentage of GFP-expressing cells could then be determined by flow cytometry as an indirect measure of the frequency of genome cleavage by the meganucleases. -
FIGS. 5A-5G . Efficiency of recombinant meganucleases for recognizing and cleaving recognition sequences in the int22h-1 sequence of the Factor VIII gene in a CHO cell reporter assay. Recombinant meganucleases set forth in SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, and 76-79 were engineered to target the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 3-4 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17), and were screened for efficacy in the CHO cell reporter assay. The results shown provide the percentage of GFP-expressing cells observed in each assay, which indicates the efficacy of each meganuclease for cleaving a target recognition sequence or the CHO-23/24 recognition sequence. A negative control (bs) was further included in each assay.FIG. 5A . shows meganucleases targeting the F8R 1-2 recognition sequence.FIG. 5B andFIG. 5C show meganucleases targeting the F8R 3-4 recognition sequence.FIG. 5D shows meganucleases targeting the F8R 9-10 recognition sequence.FIG. 5E shows meganucleases targeting the F8R 11-12 recognition sequence.FIG. 5F shows meganucleases targeting the F8R 13-14 recognition sequence.FIG. 5G shows meganucleases targeting the F8R 15-16 recognition sequence. -
FIGS. 6A-6F . Efficiency of engineered meganucleases for recognizing and cleaving recognition sequences in the int22h-1 sequence of the Factor VIII gene in a CHO cell reporter assay. Engineered meganucleases encompassed by the invention were engineered to target the F8R 1-2 (SEQ ID NO: 7), F8R 3-4 (SEQ ID NO: 9), F8R 9-10 (SEQ ID NO: 11), F8R 11-12 (SEQ ID NO: 13), F8R 13-14 (SEQ ID NO: 15), or F8R 15-16 (SEQ ID NO: 17) recognition sequences, and were screened for efficacy in the CHO cell reporter assay at multiple time points over 12 days after nucleofection. The results shown provide the percentage of GFP-expressing cells observed in each assay over the 12 day period of analysis, which indicates the efficacy of each meganuclease for cleaving a target recognition sequence or the CHO-23/24 recognition sequence as a function of time.FIG. 6A shows F8R 1-2 meganucleases targeting the F8R 1-2 recognition sequence.FIG. 6B shows F8R 3-4 meganucleases targeting the F8R 3-4 recognition sequence.FIG. 6C shows F8R 9-10 meganucleases targeting the F8R 9-10 recognition sequence.FIG. 6D shows F8R 11-12 meganucleases targeting the F8R 11-12 recognition sequence.FIG. 6E shows F8R 13-14 meganucleases targeting the F8R 13-14 recognition sequence.FIG. 6F shows F8R 15-16 meganucleases targeting the F8R 15-16 recognition sequence. -
FIG. 7 . Cleavage of F8R recognition sequences in mammalian cells. Meganucleases F8R 1-2 and F8R 3-4 were tested for the ability to cut and cause insertions and/or deletions (indels) at their recognition sites by T7 endonuclease assay in HEK 293 cells. -
FIG. 8A andFIG. 8B . Inversion of exons 1-22 in the Factor VIII gene of mammalian cells. This experiment determined if cleavage of genomic DNA by F8R 1-2 and F8R 3-4 meganucleases could stimulate an inversion of exons 1-22 in the Factor VIII gene of HEK 293 cells. Genomic DNA was analyzed by PCR using a primer set which could detect normal positioning of exons 1-22 (H1R/H1F) or an inversion of exons 1-22 (H1R/H2/3R). -
FIG. 9 . Inversion of exons 1-22 in the Factor VIII gene of mammalian cells. This experiment determined if cleavage of genomic DNA by F8R 9-10, F8R 11-12, F8R 13-14, and F8R 15-16 meganucleases could stimulate an inversion of exons 1-22 in the Factor VIII gene of HEK 293 cells. Genomic DNA was analyzed by PCR using a primer set which could detect normal positioning of exons 1-22 (H1R/H1F) or an inversion of exons 1-22 (H1R/H2/3R). PCR analysis fromday 2 andday 8 are provided for each primer set. -
FIG. 10 . Inversion of Factor VIII gene by F8R nucleases in 293 cells and determination of efficiency by inverse digital PCR. HEK293 cells were transfected with mRNA encoding F8R11-12x.69 or F8R13-14x.13 nucleases, respectively. At 2 days post-transfection, genomic DNA was isolated from cells and inverse digital PCR was performed to determine Factor VIII genome editing. -
FIG. 11 . Inversion of Factor VIII gene by F8R nucleases in primary human T cells and determination of editing by long-distance PCR. Normal human T-cells were transfected with mRNA encoding the F8R3-4x.43 nuclease. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing. -
FIGS. 12A-12B . Reversion of Factor VIII gene by F8R nucleases in primary human patient T cells and determination of editing by long-distance PCR. Hemophilia A patient T-cells were transfected with mRNA encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases, respectively. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing.FIG. 12A shows PCR bands corresponding to a wild type Factor VIII gene configuration, as detected using primers H1U and H1D.FIG. 12B shows PCR bands corresponding to the hemophilia A-associated Factor VIII gene inversion, as detected using primers H3D and H1D. - SEQ ID NO: 1 sets forth the amino acid sequence of the wild-type I-CreI meganuclease from Chlamydomonas reinhardtii.
- SEQ ID NO: 2 sets forth the amino acid sequence of the LAGLIDADG motif.
- SEQ ID NO: 3 sets forth the nucleic acid sequence of a human int22h-1 sequence.
- SEQ ID NO: 4 sets forth the nucleic acid sequence of a canine int22h-1 sequence.
- SEQ ID NO: 5 sets forth the nucleic acid sequence of a human F8A1 sequence.
- SEQ ID NO: 6 sets forth the nucleic acid sequence of a canine F8A1 sequence.
- SEQ ID NO: 7 sets forth the nucleic acid sequence of the F8R 1-2 recognition sequence (sense).
- SEQ ID NO: 8 sets forth the nucleic acid sequence of the F8R 1-2 recognition sequence (antisense).
- SEQ ID NO: 9 sets forth the nucleic acid sequence of the F8R 3-4 recognition sequence (sense).
- SEQ ID NO: 10 sets forth the nucleic acid sequence of the F8R 3-4 recognition sequence (antisense).
- SEQ ID NO: 11 sets forth the nucleic acid sequence of the F8R 9-10 recognition sequence (sense).
- SEQ ID NO: 12 sets forth the nucleic acid sequence of the F8R 9-10 recognition sequence (antisense).
- SEQ ID NO: 13 sets forth the nucleic acid sequence of the F8R 11-12 recognition sequence (sense).
- SEQ ID NO: 14 sets forth the nucleic acid sequence of the F8R 11-12 recognition sequence (antisense).
- SEQ ID NO: 15 sets forth the nucleic acid sequence of the F8R 13-14 recognition sequence (sense).
- SEQ ID NO: 16 sets forth the nucleic acid sequence of the F8R 13-14 recognition sequence (antisense).
- SEQ ID NO: 17 sets forth the nucleic acid sequence of the F8R 15-16 recognition sequence (sense).
- SEQ ID NO: 18 sets forth the nucleic acid sequence of the F8R 15-16 recognition sequence (antisense).
- SEQ ID NO: 19 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease.
- SEQ ID NO: 20 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease.
- SEQ ID NO: 21 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease.
- SEQ ID NO: 22 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease F8R1-binding monomer.
- SEQ ID NO: 23 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease F8R1-binding monomer.
- SEQ ID NO: 24 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease F8R1-binding monomer.
- SEQ ID NO: 25 sets forth the amino acid sequence of the F8R 1-2x.27 meganuclease F8R2-binding monomer.
- SEQ ID NO: 26 sets forth the amino acid sequence of the F8R 1-2x.15 meganuclease F8R2-binding monomer.
- SEQ ID NO: 27 sets forth the amino acid sequence of the F8R 1-2x.9 meganuclease F8R2-binding monomer.
- SEQ ID NO: 28 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease.
- SEQ ID NO: 29 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease.
- SEQ ID NO: 30 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease.
- SEQ ID NO: 31 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease.
- SEQ ID NO: 32 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease F8R3-binding monomer.
- SEQ ID NO: 33 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease F8R3-binding monomer.
- SEQ ID NO: 34 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease F8R3-binding monomer.
- SEQ ID NO: 35 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease F8R3-binding monomer.
- SEQ ID NO: 36 sets forth the amino acid sequence of the F8R 3-4x.43 meganuclease F8R4-binding monomer.
- SEQ ID NO: 37 sets forth the amino acid sequence of the F8R 3-4x.70 meganuclease F8R4-binding monomer.
- SEQ ID NO: 38 sets forth the amino acid sequence of the F8R 3-4x.4 meganuclease F8R4-binding monomer.
- SEQ ID NO: 39 sets forth the amino acid sequence of the F8R 3-4L.5 meganuclease F8R4-binding monomer.
- SEQ ID NO: 40 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease.
- SEQ ID NO: 41 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease.
- SEQ ID NO: 42 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease.
- SEQ ID NO: 43 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease.
- SEQ ID NO: 44 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease F8R9-binding monomer.
- SEQ ID NO: 45 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease F8R9-binding monomer.
- SEQ ID NO: 46 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease F8R9-binding monomer.
- SEQ ID NO: 47 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease F8R9-binding monomer.
- SEQ ID NO: 48 sets forth the amino acid sequence of the F8R 9-10x.70 meganuclease F8R10-binding monomer.
- SEQ ID NO: 49 sets forth the amino acid sequence of the F8R 9-10x.38 meganuclease F8R10-binding monomer.
- SEQ ID NO: 50 sets forth the amino acid sequence of the F8R 9-10x.2 meganuclease F8R10-binding monomer.
- SEQ ID NO: 51 sets forth the amino acid sequence of the F8R 9-10x.8 meganuclease F8R10-binding monomer.
- SEQ ID NO: 52 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease.
- SEQ ID NO: 53 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease.
- SEQ ID NO: 54 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease.
- SEQ ID NO: 55 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease.
- SEQ ID NO: 56 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease F8R11-binding monomer.
- SEQ ID NO: 57 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease F8R11-binding monomer.
- SEQ ID NO: 58 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease F8R11-binding monomer.
- SEQ ID NO: 59 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease F8R11-binding monomer.
- SEQ ID NO: 60 sets forth the amino acid sequence of the F8R 11-12x.56 meganuclease F8R12-binding monomer.
- SEQ ID NO: 61 sets forth the amino acid sequence of the F8R 11-12x.69 meganuclease F8R12-binding monomer.
- SEQ ID NO: 62 sets forth the amino acid sequence of the F8R 11-12x.66 meganuclease F8R12-binding monomer.
- SEQ ID NO: 63 sets forth the amino acid sequence of the F8R 11-12x.41 meganuclease F8R12-binding monomer.
- SEQ ID NO: 64 sets forth the amino acid sequence of the F8R 13-14x.13 meganuclease.
- SEQ ID NO: 65 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease.
- SEQ ID NO: 66 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease.
- SEQ ID NO: 67 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease.
- SEQ ID NO: 68 sets forth the amino acid sequence of the F8R 13-14x.13 meganucicase F8R13-binding monomer.
- SEQ ID NO: 69 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease F8R13-binding monomer.
- SEQ ID NO: 70 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease F8R13-binding monomer.
- SEQ ID NO: 71 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease F8R13-binding monomer.
- SEQ ID NO: 72 sets forth the amino acid sequence of the F8R 13-14x.13 meganuclease F8R14-binding monomer.
- SEQ ID NO: 73 sets forth the amino acid sequence of the F8R 13-14x.3 meganuclease F8R14-binding monomer.
- SEQ ID NO: 74 sets forth the amino acid sequence of the F8R 13-14x.1 meganuclease F8R14-binding monomer.
- SEQ ID NO: 75 sets forth the amino acid sequence of the F8R 13-14x.11 meganuclease F8R14-binding monomer.
- SEQ ID NO: 76 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease.
- SEQ ID NO: 77 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease.
- SEQ ID NO: 78 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease.
- SEQ ID NO: 79 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease.
- SEQ ID NO: 80 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease F8R15-binding monomer.
- SEQ ID NO: 81 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease F8R15-binding monomer.
- SEQ ID NO: 82 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease F8R15-binding monomer.
- SEQ ID NO: 83 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease F8R15-binding monomer.
- SEQ ID NO: 84 sets forth the amino acid sequence of the F8R 15-16x.14 meganuclease F8R16-binding monomer.
- SEQ ID NO: 85 sets forth the amino acid sequence of the F8R 15-16x.85 meganuclease F8R16-binding monomer.
- SEQ ID NO: 86 sets forth the amino acid sequence of the F8R 15-16x.4 meganuclease F8R16-binding monomer.
- SEQ ID NO: 87 sets forth the amino acid sequence of the F8R 15-16x.79 meganuclease F8R16-binding monomer.
- SEQ ID NO: 88 sets forth the nucleic acid sequence of the U1 primer.
- SEQ ID NO: 89 sets forth the nucleic acid sequence of the D1 primer.
- SEQ ID NO: 90 sets forth the nucleic acid sequence of the U3 primer.
- SEQ ID NO: 91 sets forth the nucleic acid sequence of the FWD1 primer.
- SEQ ID NO: 92 sets forth the nucleic acid sequence of the REV1 primer.
- SEQ ID NO: 93 sets froth the nucleic acid sequence of the FWD3 primer.
- SEQ ID NO: 94 sets forth the nucleic acid sequence of the H1U primer.
- SEQ ID NO: 95 sets forth the nucleic acid sequence of the H1D primer.
- SEQ ID NO: 96 sets forth the nucleic acid sequence of the H3D primer.
- The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. The issued US patents, allowed applications, published foreign applications, and references, including GenBank database sequences, which are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.
- The present invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. For example, features illustrated with respect to one embodiment can be incorporated into other embodiments, and features illustrated with respect to a particular embodiment can be deleted from that embodiment. In addition, numerous variations and additions to the embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
- All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety.
- As used herein, “a,” “an,” or “the” can mean one or more than one. For example, “a” cell can mean a single cell or a multiplicity of cells.
- As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “and/or” and not the exclusive sense of “either/or.”
- As used herein, the terms “nuclease” and “endonuclease” are used interchangeably to refer to naturally-occurring or engineered enzymes which cleave a phosphodiester bond within a polynucleotide chain.
- As used herein, the term “meganuclease” refers to an endonuclease that binds double-stranded DNA at a recognition sequence that is greater than 12 base pairs. Preferably, the recognition sequence for a meganuclease of the invention is 22 base pairs. A meganuclease can be an endonuclease that is derived from I-CreI, and can refer to an engineered variant of I-CreI that has been modified relative to natural I-CreI with respect to, for example, DNA-binding specificity, DNA cleavage activity, DNA-binding affinity, or dimerization properties. Methods for producing such modified variants of I-CreI are known in the art (e.g. WO 2007/047859). A meganuclease as used herein binds to double-stranded DNA as a heterodimer. A meganuclease may also be a “single-chain meganuclease” in which a pair of DNA-binding domains are joined into a single polypeptide using a peptide linker. The term “homing endonuclease” is synonymous with the term “meganuclease.” Meganucleases of the invention are substantially non-toxic when expressed in cells without observing deleterious effects on cell viability or significant reductions in meganuclease cleavage activity when measured using the methods described herein.
- As used herein, the term “single-chain meganuclease” refers to a polypeptide comprising a pair of nuclease subunits joined by a linker. A single-chain meganuclease has the organization: N-terminal subunit—Linker—C-terminal subunit. The two meganuclease subunits will generally be non-identical in amino acid sequence and will recognize non-identical DNA sequences. Thus, single-chain meganucleases typically cleave pseudo-palindromic or non-palindromic recognition sequences. A single-chain meganuclease may be referred to as a “single-chain heterodimer” or “single-chain heterodimeric meganuclease” although it is not, in fact, dimeric. For clarity, unless otherwise specified, the term “meganuclease” can refer to a dimeric or single-chain meganuclease.
- As used herein, the term “linker” refers to an exogenous peptide sequence used to join two meganuclease subunits into a single polypeptide. A linker may have a sequence that is found in natural proteins, or may be an artificial sequence that is not found in any natural protein. A linker may be flexible and lacking in secondary structure or may have a propensity to form a specific three-dimensional structure under physiological conditions. A linker can include, without limitation, those encompassed by U.S. Pat. No. 8,445,251. In some embodiments, a linker may have an amino acid sequence comprising residues 154-195 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79.
- As used herein, the term “TALEN” refers to an endonuclease comprising a DNA-binding domain comprising 16-22 TAL domain repeats fused to any portion of the FokI nuclease domain.
- As used herein, the term “Compact TALEN” refers to an endonuclease comprising a DNA-binding domain with 16-22 TAL domain repeats fused in any orientation to any portion of the I-TevI homing endonuclease.
- As used herein, the term “zinc finger nuclease” or “ZFN” refers to a chimeric endonuclease comprising a zinc finger DNA-binding domain fused to the nuclease domain of the FokI restriction enzyme. The zinc finger domain can be redesigned through rational or experimental means to produce a protein which binds to a pre-determined DNA sequence ˜18 basepairs in length, comprising a pair of nine basepair half-sites separated by 2-10 basepairs. Cleavage by a zinc finger nuclease can create a blunt end or a 5′ overhand of variable length (frequently four basepairs).
- As used herein, the term “CRISPR” refers to a caspase-based endonuclease comprising a caspase, such as Cas9, and a guide RNA that directs DNA cleavage of the caspase by hybridizing to a recognition site in the genomic DNA.
- As used herein, the term “megaTAL” refers to a single-chain endonuclease comprising a transcription activator-like effector (TALE) DNA binding domain with an engineered, sequence-specific horning endonuclease.
- As used herein, with respect to a protein, the term “recombinant” or “engineered” means having an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein. With respect to a nucleic acid, the term “recombinant” or “engineered” means having an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In accordance with this definition, a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous host, is not considered recombinant.
- As used herein, the term “wild-type” refers to the most common naturally occurring allele (i.e., polynucleotide sequence) in the allele population of the same type of gene, wherein a polypeptide encoded by the wild-type allele has its original functions. The term “wild-type” also refers a polypeptide encoded by a wild-type allele. Wild-type alleles (i.e., polynucleotides) and polypeptides are distinguishable from mutant or variant alleles and polypeptides, which comprise one or more mutations and/or substitutions relative to the wild-type sequence(s). Whereas a wild-type allele or polypeptide can confer a normal phenotype in an organism, a mutant or variant allele or polypeptide can, in some instances, confer an altered phenotype. Wild-type nucleases are distinguishable from recombinant or non-naturally-occurring nucleases. The term “wild-type” can also refer to a cell, an organism, and/or a subject which possesses a wild-type allele of a particular gene, or a cell, an organism, and/or a subject used for comparative purposes.
- As used herein, the term “genetically-modified” refers to a cell or organism in which, or in an ancestor of which, a genomic DNA sequence has been deliberately modified by recombinant technology. As used herein, the term “genetically-modified” encompasses the term “transgenic.”
- As used herein with respect to recombinant proteins, the term “modification” means any insertion, deletion, or substitution of an amino acid residue in the recombinant sequence relative to a reference sequence (e.g., a wild-type or a native sequence).
- As used herein, the term “recognition sequence” refers to a DNA sequence that is bound and cleaved by an endonuclease. In the case of a meganuclease, a recognition sequence comprises a pair of inverted, 9 basepair “half sites” which are separated by four basepairs. In the case of a single-chain meganuclease, the N-terminal domain of the protein contacts a first half-site and the C-terminal domain of the protein contacts a second half-site. Cleavage by a meganuclease produces four
basepair 3′ “overhangs”. “Overhangs”, or “sticky ends” are short, single-stranded DNA segments that can be produced by endonuclease cleavage of a double-stranded DNA sequence. In the case of meganucleases and single-chain meganucleases derived from I-CreI, the overhang comprises bases 10-13 of the 22 basepair recognition sequence. In the case of a Compact TALEN, the recognition sequence comprises a first CNNNGN sequence that is recognized by the I-TevI domain, followed by a non-specific spacer 4-16 basepairs in length, followed by a second sequence 16-22 bp in length that is recognized by the TAL-effector domain (this sequence typically has a 5′ T base). Cleavage by a Compact TALEN produces twobasepair 3′ overhangs. In the case of a CRISPR, the recognition sequence is the sequence, typically 16-24 basepairs, to which the guide RNA binds to direct Cas9 cleavage. Cleavage by a CRISPR produced blunt ends. In the case of a zinc finger, the DNA binding domains typically recognize an 18-bp recognition sequence comprising a pair of nine basepair “half-sites” separated by 2-10 basepairs and cleavage by the nuclease creates a blunt end or a 5′ overhang of variable length (frequently four basepairs). - As used herein, the term “target site” or “target sequence” refers to a region of the chromosomal DNA of a cell comprising a recognition sequence for a nuclease.
- As used herein, the term “DNA-binding affinity” or “binding affinity” means the tendency of a meganuclease to non-covalently associate with a reference DNA molecule (e.g., a recognition sequence or an arbitrary sequence). Binding affinity is measured by a dissociation constant, Kd. As used herein, a nuclease has “altered” binding affinity if the Kd of the nuclease for a reference recognition sequence is increased or decreased by a statistically significant (p<0.05) amount relative to a reference nuclease.
- As used herein, the term “specificity” means the ability of a meganuclease to recognize and cleave double-stranded DNA molecules only at a particular sequence of base pairs referred to as the recognition sequence, or only at a particular set of recognition sequences. The set of recognition sequences will share certain conserved positions or sequence motifs, but may be degenerate at one or more positions. A highly-specific meganuclease is capable of cleaving only one or a very few recognition sequences. Specificity can be determined by any method known in the art. As used herein, a meganuclease has “altered” specificity if it binds to and cleaves a recognition sequence which is not bound to and cleaved by a reference meganuclease (e.g., a wild-type) under physiological conditions, or if the rate of cleavage of a recognition sequence is increased or decreased by a biologically significant amount (e.g., at least 2×, or 2×-10×) relative to a reference meganuclease.
- As used herein, the term “homologous recombination” or “HR” refers to the natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). The homologous DNA sequence may be an endogenous chromosomal sequence or an exogenous nucleic acid that was delivered to the cell.
- As used herein, the term “non-homologous end-joining” or “NHEJ” refers to the natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the untemplated addition or deletion of DNA sequences at the site of repair. In some instances, cleavage at a target recognition sequence results in NHEJ at a target recognition site. Nuclease-induced cleavage of a target site in the coding sequence of a gene followed by DNA repair by NHEJ can introduce mutations into the coding sequence, such as frameshift mutations, that disrupt gene function. Thus, engineered nucleases can be used to effectively knock-out a gene in a population of cells.
- As used herein with respect to both amino acid sequences and nucleic acid sequences, the terms “percent identity,” “sequence identity,” “percentage similarity,” “sequence similarity” and the like refer to a measure of the degree of similarity of two sequences based upon an alignment of the sequences which maximizes similarity between aligned amino acid residues or nucleotides, and which is a function of the number of identical or similar residues or nucleotides, the number of total residues or nucleotides, and the presence and length of gaps in the sequence alignment. A variety of algorithms and computer programs are available for determining sequence similarity using standard parameters. As used herein, sequence similarity is measured using the BLASTp program for amino acid sequences and the BLASTn program for nucleic acid sequences, both of which are available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/), and are described in, for example, Altschul et al. (1990), J. Mol. Biol. 215:403-410; Gish and States (1993), Nature Genet. 3:266-272; Madden et al. (1996), Meth. Enzymol.266:131-141; Altschul et al. (1997), Nucleic Acids Res. 25:33 89-3402); Zhang et al. (2000), J. Comput. Biol. 7(1-2):203-14. As used herein, percent similarity of two amino acid sequences is the score based upon the following parameters for the BLASTp algorithm: word size=3; gap opening penalty=−11; gap extension penalty=−1; and scoring matrix=BLOSUM62. As used herein, percent similarity of two nucleic acid sequences is the score based upon the following parameters for the BLASTn algorithm: word size=11; gap opening penalty=−5; gap extension penalty=−2; match reward=−1; and mismatch penalty=−3.
- As used herein with respect to modifications of two proteins or amino acid sequences, the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins corresponds to or aligns with the amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (e.g., using the BLASTp program). Thus, the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.
- As used herein, the term “recognition half-site,” “recognition sequence half-site,” or simply “half-site” means a nucleic acid sequence in a double-stranded DNA molecule which is recognized by a monomer of a homodimeric or heterodimeric meganuclease, or by one subunit of a single-chain meganuclease.
- As used herein, the term “hypervariable region” refers to a localized sequence within a meganuclease monomer or subunit that comprises amino acids with relatively high variability. A hypervariable region can comprise about 50-60 contiguous residues, about 53-57 contiguous residues, or preferably about 56 residues. In some embodiments, the residues of a hypervariable region may correspond to positions 24-79 or positions 215-270 of any one of SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79. A hypervariable region can comprise one or more residues that contact DNA bases in a recognition sequence and can be modified to alter base preference of the monomer or subunit. A hypervariable region can also comprise one or more residues that bind to the DNA backbone when the meganuclease associates with a double-stranded DNA recognition sequence. Such residues can be modified to alter the binding affinity of the meganuclease for the DNA backbone and the target recognition sequence. In different embodiments of the invention, a hypervariable region may comprise between 1-20 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity. In particular embodiments, a hypervariable region comprises between about 15-18 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity. In some embodiments, variable residues within a hypervariable region correspond to one or more of
positions - As used herein, the terms “Factor VIII gene,” “F8 gene,” and the like, refer to a gene located on the X chromosome which encodes the coagulation Factor VIII protein. In humans, the Factor VIII gene, identified by NCBI as Gene ID No. 2157, is located from base pair 154,835,788 to base pair 155,026,934 on the X chromosome. In canines, the Factor VIII gene can be the gene identified by NCBI Reference Sequence: NM 001003212.1. It is understood that the term “Factor VIII gene” can include both a wild-type Factor VIII gene and a Factor VIII gene which comprises naturally-occurring polymorphisms and/or mutations that allow for the production of a functional Factor VIII protein.
- As used herein, the terms “int22h-1” and “int22h-1 sequence” refer to a sequence positioned within intron 22 of the Factor VIII gene having a size of approximately 9.5 kb (Bagnall et al. (2006) Journal of Thrombosis and Haemostasis 4:591-598) and can further refer to the human sequence identified by GenBank as Accession No. AY619999.1. The int22h-1 sequence is characterized as comprising a CpG island, a coding sequence for the H2AFB1 histone protein, and a coding sequence for the Factor VIII-
Associated 1 protein (F8A1; also referred to as the intron 22 protein). The int22h-1 sequence is further characterized as being identical to, or having high homology with, at least one repeat sequence that is positioned telomeric to the Factor VIII gene on the X chromosome. In humans, two repeat sequences, referred to as int22h-2 and int22h-3, are positioned telomeric to the Factor VIII gene on the X chromosome. In particular embodiments of the invention, the human int22h-1 sequence can comprise SEQ ID NO: 3. In other particular embodiments of the invention, the canine int22h-1 sequence can comprise SEQ ID NO: 4. - As used herein, the terms “F8A1 coding sequence” and “intron 22 protein coding sequence” are used interchangeably and refer to a sequence positioned within the int22h-1 sequence which encodes the F8A1 protein. The F8A1 coding sequence is intronless and is transcribed in the opposite direction as the Factor VIII gene. In one embodiment, the wild-type human F8A1 coding sequence can comprise SEQ ID NO: 5. In another embodiment, the wild-type canine F8A1 coding sequence can comprise SEQ ID NO: 6, which has ˜75% homology to the human F8A1 coding sequence. It is understood that reference to an F8A1 coding sequence includes a wild-type F8A1 sequence and an F8A1 sequence comprising naturally-occurring polymorphisms and/or mutations that allow for the production of a functional F8A1 protein.
- As used herein, the terms “inversion” and “inversion of exons 1-22” refer to a mutation of a Factor VIII gene wherein an intra-chromosomal homologous recombination event occurs between the int22h-1 sequence of the Factor VIII gene and an identical or closely related, inversely oriented, repeat sequence positioned telomeric to the Factor VIII gene on the X chromosome, which results in an inversion of exons 1-22 with respect to exons 23-26.
- As used herein, the term “reversion” refers to an intra-chromosomal homologous recombination event in a cell comprising an inversion of exons 1-22 of the Factor VIII gene, wherein a double-strand break is produced within the int22h-1 sequence to promote recombination with a repeat sequence telomeric to the Factor VIII gene on the X chromosome. Such recombination results in the corrected orientation of exons 1-22 and the production of a functional, wild-type Factor VIII gene.
- The terms “recombinant DNA construct,” “recombinant construct,” “expression cassette,” “expression construct,” “chimeric construct,” “construct,” and “recombinant DNA fragment” are used interchangeably herein and are nucleic acid fragments. A recombinant construct comprises an artificial combination of nucleic acid fragments, including, without limitation, regulatory and coding sequences that are not found together in nature. For example, a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source and arranged in a manner different than that found in nature. Such a construct may be used by itself or may be used in conjunction with a vector.
- As used herein, a “vector” or “recombinant DNA vector” may be a construct that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art. Vectors can include, without limitation, plasmid vectors and recombinant AAV vectors, or any other vector known in that art suitable for delivering a gene encoding a meganuclease of the invention to a target cell. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleotides or nucleic acid sequences of the invention.
- As used herein, a “vector” can also refer to a viral vector. Viral vectors can include, without limitation, retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors (AAV).
- As used herein, a “control” or “control cell” refers to a cell that provides a reference point for measuring changes in genotype or phenotype of a genetically-modified cell. A control cell may comprise, for example: (a) a wild-type cell, i.e., of the same genotype as the starting material for the genetic alteration which resulted in the genetically-modified cell; (b) a cell of the same genotype as the genetically-modified cell but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest); or, (c) a cell genetically identical to the genetically-modified cell but which is not exposed to conditions or stimuli or further genetic modifications that would induce expression of altered genotype or phenotype.
- As used herein, a “self-cleaving” recombinant DNA construct refers to a DNA construct which comprises at least one coding sequence for an endonuclease and at least one recognition sequence for the same endonuclease. When expressed in a cell (i.e., in vivo), the endonuclease recognizes and cleaves the recognition sequence, resulting in linearization of the DNA construct.
- As used herein with respect to modifications of two proteins or amino acid sequences, the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins corresponds to or aligns with the amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (e.g., using the BLASTp program). Thus, the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.
- As used herein, the terms “treatment” or “treating a subject” refers to the administration of an engineered nuclease of the invention, or a nucleic acid encoding an engineered nuclease of the invention, to a subject having hemophilia A for the purpose of correcting an inversion of exons 1-22 in the Factor VIII gene in cells which normally express Factor VIII in wild-type subjects. Such treatment results in correction of the Factor VIII gene in a number of cells sufficient to increase circulating levels of Factor VIII in the subject, and either partial or complete relief of one or more symptoms of hemophilia A in the subject. The terms “treatment” or “treating a subject” can further refer to the administration of a genetically-modified cell comprising a wild-type Factor VIII gene to a subject according the method of the invention, wherein the genetically-modified cell is delivered to a target tissue and either produces Factor VIII, or differentiates into a cell which produces Factor VIII, in an amount sufficient to increase the circulating levels of Factor VIII in the subject, resulting in either partial or complete relief of one or more symptoms of hemophilia A. In some aspects, an engineered nuclease of the invention, a nucleic acid encoding the same, or a genetically-modified cell of the invention is administered during treatment in the form of a pharmaceutical composition of the invention.
- As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 can take the
values - The present invention is based, in part, on the hypothesis that engineered nucleases can be used to treat hemophilia A by correcting an inversion of exons 1-22 in the Factor VIII gene. More specifically, nucleases can be engineered to recognize and cleave a recognition sequence present within an int22h-1 sequence of the Factor VIII gene to produce a double-strand break. Intra-chromosomal homologous recombination can then occur between the int22h-1 sequence and a repeat sequence which is telomeric to the Factor VIII gene on the X chromosome, resulting in a reversion of exons 1-22 and the production of a functional, wild-type Factor VIII gene in target cells of the subject.
- The invention is also based, in part, on the hypothesis that pluripotent cells (e.g., induced pluripotent stem (iPS) cells) comprising an inversion of exons 1-22 in the Factor VIII gene can be obtained and contacted with an engineered nuclease of the invention (or a nucleic acid encoding the same) in order to correct the Factor VIII gene by the same mechanism described above. Such pluripotent cells can then be administered to a subject having hemophilia A, wherein the cells are delivered to a target tissue (e.g., the liver or the circulatory system) and differentiate into cells which express wild-type Factor VIII in the subject.
- Thus, the present invention encompasses engineered nucleases, and particularly engineered recombinant meganucleases, which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating hemophilia A. Further, the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins, nucleic acids encoding engineered nucleases, or genetically-modified cells of the invention, and the use of such compositions for the treatment of hemophilia A.
- 2.2 Nucleases for Recognizing and Cleaving Recognition Sequences Within an int22h-1 Sequence of the Factor VIII Gene
- It is known in the art that it is possible to use a site-specific nuclease to make a DNA break in the genome of a living cell, and that such a DNA break can result in permanent modification of the genome via homologous recombination of the cleaved target site with an identical or highly homologous DNA sequence within the genome.
- Thus, in different embodiments, a variety of different types of endonuclease are useful for practicing the invention. In one embodiment, the invention can be practiced using engineered recombinant meganucleases. In another embodiment, the invention can be practiced using a CRISPR nuclease or CRISPR Nickase. Methods for making CRISPRs and CRISPR Nickases that recognize pre-determined DNA sites are known in the art, for example Ran, et al. (2013) Nat Protoc. 8:2281-308. In another embodiment, the invention can be practiced using TALENs or Compact TALENs. Methods for making TALE domains that bind to pre-determined DNA sites are known in the art, for example Reyon et al. (2012) Nat Biotechnol. 30:460-5. In another embodiment, the invention can be practiced using zinc finger nucleases (ZFNs). In a further embodiment, the invention can be practiced using megaTALs.
- In preferred embodiments, the nucleases used to practice the invention are single-chain meganucleases. A single-chain meganuclease comprises an N-terminal subunit and a C-terminal subunit joined by a linker peptide. Each of the two domains recognizes half of the recognition sequence (i.e., a recognition half-site) and the site of DNA cleavage is at the middle of the recognition sequence near the interface of the two subunits. DNA strand breaks are offset by four base pairs such that DNA cleavage by a meganuclease generates a pair of four base pair, 3′ single-strand overhangs.
- In some examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 1-2 recognition sequence (SEQ ID NO: 7). The F8R 1-2 recognition sequence is positioned within both the int22h-1 sequence and the F8A1 sequence. Such recombinant meganucleases are collectively referred to herein as “F8R 1-2 meganucleases.” Exemplary F8R 1-2 meganucleases are provided in SEQ ID NOs: 19-22.
- In additional examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 3-4 recognition sequence (SEQ ID NO: 9). The F8R 3-4 recognition sequence is positioned within both the int22h-1 sequence and the F8A1 sequence. Such recombinant meganucleases are collectively referred to herein as “F8R 3-4 meganucleases.” Exemplary F8R 3-4 meganucleases are provided in SEQ ID NOs: 28-31.
- In additional examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 9-10 recognition sequence (SEQ ID NO: 11). Such recombinant meganucleases are collectively referred to herein as “F8R 9-10 meganucleases.” Exemplary F8R 9-10 meganucleases are provided in SEQ ID NOs: 40-43.
- In additional examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 11-12 recognition sequence (SEQ ID NO: 13). Such recombinant meganucleases are collectively referred to herein as “F8R 11-12 meganucleases.” Exemplary F8R 11-12 meganucleases are provided in SEQ ID NOs: 52-55.
- In additional examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 13-14 recognition sequence (SEQ ID NO: 15). Such recombinant meganucleases are collectively referred to herein as “F8R 13-14 meganucleases.” Exemplary F8R 13-14 meganucleases are provided in SEQ ID NOs: 64-67.
- In additional examples, recombinant meganucleases of the invention have been engineered to recognize and cleave the F8R 15-16 recognition sequence (SEQ ID NO: 17). Such recombinant meganucleases are collectively referred to herein as “F8R 15-16 meganucleases.” Exemplary F8R 15-16 meganucleases are provided in SEQ ID NOs: 76-79.
- Recombinant meganucleases of the invention comprise a first subunit, comprising a first hypervariable (HVR1) region, and a second subunit, comprising a second hypervariable (HVR2) region. Further, the first subunit binds to a first recognition half-site in the recognition sequence (e.g., the F8R1, F8R3, F8R9, F8R11, F8R13, or F8R15 half-site), and the second subunit binds to a second recognition half-site in the recognition sequence (e.g., the F8R2, F8R4, F8R10, F8R12, F8R14, or F8R16 half-site). In embodiments where the recombinant meganuclease is a single-chain meganuclease, the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the N-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the C-terminal subunit. In alternative embodiments, the first and second subunits can be oriented such that the first subunit, which comprises the HVR1 region and binds the first half-site, is positioned as the C-terminal subunit, and the second subunit, which comprises the HVR2 region and binds the second half-site, is positioned as the N-terminal subunit. Exemplary F8R 1-2 meganucleases of the invention are provided in Table 1. Exemplary F8R 3-4 meganucleases of the invention are provided in Table 2. Exemplary F8R 9-10 meganucleases of the invention are provided in Table 3. Exemplary F8R 11-12 meganucleases of the invention are provided in Table 4. Exemplary F8R 13-14 meganucleases of the invention are provided in Table 5. Exemplary F8R 15-16 meganucleases of the invention are provided in Table 6.
-
TABLE 1 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 1-2 recognition sequence (SEQ ID NO: 7) F8R1 F8R1 *F8R1 F8R2 F8R2 *F8R2 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 1-2x.27 19 198-344 22 100 7-153 25 100 F8R 1-2x.15 20 7-153 23 95.24 198-344 26 95.24 F8R 1-2x.9 21 7-153 24 95.24 198-344 27 95.24 *“F8R1 Subunit %” and “F8R2 Subunit %” represent the amino acid sequence identity between the F8R1-binding and F8R2-binding subunit regions of each meganuclease and the F8R1-binding and F8R2-binding subunit regions, respectively, of the F8R 1-2x.27 meganuclease. -
TABLE 2 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 3-4 recognition sequence (SEQ ID NO: 9) F8R3 F8R3 *F8R3 F8R4 F8R4 *F8R4 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 3-4x.43 28 198-344 32 100 7-153 36 100 F8R 3-4x.70 29 198-344 33 98.64 7-153 37 91.16 F8R 3-4x.4 30 198-344 34 100 7-153 38 98.64 F8R 3-4L.5 31 198-344 35 98.64 7-153 39 97.28 *“F8R3 Subunit %” and “F8R4 Subunit %” represent the amino acid sequence identity between the F8R3-binding and F8R4-binding subunit regions of each meganuclease and the F8R3-binding and F8R4-binding subunit regions, respectively, of the F8R 3-4x.43 meganuclease. -
TABLE 3 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 9-10 recognition sequence (SEQ ID NO: 11) F8R9 F8R9 *F8R9 F8R10 F8R10 *F8R10 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 9-10x.70 40 7-153 44 100 198-344 48 100 F8R 9-10x.38 41 198-344 45 97.96 7-153 49 100 F8R 9-10x.2 42 198-344 46 94.56 7-153 50 91.84 F8R 9-10x.8 43 198-344 47 95.24 7-153 51 98.64 *“F8R9 Subunit %” and “F8R10 Subunit %” represent the amino acid sequence identity between the F8R9-binding and F8R10-binding subunit regions of each meganuclease and the F8R9-binding and F8R10-binding subunit regions, respectively, of the F8R 9-10x.70 meganuclease. -
TABLE 4 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 11-12 recognition sequence (SEQ ID NO: 13) F8R11 F8R11 *F8R11 F8R12 F8R12 *F8R12 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 11-12x.56 52 7-153 56 100 198-344 60 100 F8R 11-12x.69 53 7-153 57 91.84 198-344 61 95.24 F8R 11-12x.66 54 7-153 58 92.52 198-344 62 90.48 F8R 11-12x.41 55 7-153 59 91.84 198-344 63 92.52 *“F8R11 Subunit %” and “F8R12 Subunit %” represent the amino acid sequence identity between the F8R11-binding and F8R12-binding subunit regions of each meganuclease and the F8R11-binding and F8R12-binding subunit regions, respectively, of the F8R 11-12x.56 meganuclease. -
TABLE 5 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 13-14 recognition sequence (SEQ ID NO: 15) F8R13 F8R13 *F8R13 F8R14 F8R14 *F8R14 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 13-14x.13 64 7-153 68 100 198-344 72 100 F8R 13-14x.3 65 198-344 69 94.56 7-153 73 92.52 F8R 13-14x.1 66 198-344 70 93.88 7-153 74 93.2 F8R 13-1.4x.11 67 198-344 71 93.2 7-153 75 93.2 *“F8R13 Subunit %” and “F8R14 Subunit %” represent the amino acid sequence identity between the F8R13-binding and F8R14-binding subunit regions of each meganuclease and the F8R13-binding and F8R14-binding subunit regions, respectively, of the F8R 13-14x.13 meganuclease. -
TABLE 6 Exemplary recombinant meganucleases engineered to recognize and cleave the F8R 15-16 recognition sequence (SEQ ID NO: 17) F8R15 F8R15 *F8R15 F8R16 F8R16 *F8R16 AA Subunit Subunit Subunit Subunit Subunit Subunit Meganuclease SEQ ID Residues SEQ ID % Residues SEQ ID % F8R 15-16x.14 76 198-344 80 100 7-153 84 100 F8R 15-16x.85 77 198-344 81 99.32 7-153 85 93.88 F8R 15-16x.4 78 198-344 82 95.24 7-153 86 91.84 F8R 15-16x.79 79 198-344 83 94.56 7-153 87 92.52 *“F8R15 Subunit %” and “F8R16 Subunit %” represent the amino acid sequence identity between the F8R15-binding and F8R16-binding subunit regions of each meganuclease and the F8R15-binding and F8R16-binding subunit regions, respectively, of the F8R 15-16x.14 meganuclease. - The invention provides methods for producing genetically-modified cells using engineered nucleases that recognize and cleave recognition sequences found within an intron 22 sequence of a Factor VIII gene. The invention further provides methods for treating hemophilia A in a subject by administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an engineered nuclease of the invention (or a nucleic acid encoding the engineered nuclease). In each case, the invention requires that an engineered nuclease of the invention can be delivered to and/or expressed from DNA/RNA in appropriate cells that comprise an inversion of exons 1-22 in a Factor VIII gene and would typically express Factor VIII in a healthy subject (e.g., hepatic sinusoidal endothelial cells or hematopoietic endothelial cells, or progenitor cells which differentiate into the same).
- Engineered nucleases of the invention can be delivered into a cell in the form of protein or, preferably, as a nucleic acid encoding the engineered nuclease. Such nucleic acid can be DNA (e.g., circular or linearized plasmid DNA or PCR products) or RNA (e.g., mRNA). For embodiments in which the engineered nuclease coding sequence is delivered in DNA form, it should be operably linked to a promoter to facilitate transcription of the nuclease gene. Mammalian promoters suitable for the invention include constitutive promoters such as the cytomegalovirus early (CMV) promoter (Thomsen et al. (1984), Proc Natl Acad Sci USA. 81(3):659-63) or the SV40 early promoter (Benoist and Chambon (1981), Nature. 290(5804):304-10) as well as inducible promoters such as the tetracycline-inducible promoter (Dingermann et al. (1992), Mol Cell Biol. 12(9):4038-45). An engineered nuclease of the invention can also be operably linked to a synthetic promoter. Synthetic promoters can include, without limitation, the JeT promoter (WO 2002/012514).
- In some embodiments, mRNA encoding an endonuclease is delivered to a cell because this reduces the likelihood that the gene encoding the engineered nuclease will integrate into the genome of the cell. Such mRNA encoding an engineered nuclease can be produced using methods known in the art such as in vitro transcription. In some embodiments, the mRNA is capped using 7-methyl-guanosine. In some embodiments, the mRNA may be polyadenylated.
- In another particular embodiment, a nucleic acid encoding an endonuclease of the invention can be introduced into the cell using a single-stranded DNA template. The single-stranded DNA can further comprise a 5′ and/or a 3′ AAV inverted terminal repeat (ITR) upstream and/or downstream of the sequence encoding the engineered nuclease. In other embodiments, the single-stranded DNA can further comprise a 5′ and/or a 3′ homology arm upstream and/or downstream of the sequence encoding the engineered nuclease.
- In another particular embodiment, genes encoding an endonuclease of the invention can be introduced into a cell using a linearized DNA template. In some examples, a plasmid DNA encoding an endonuclease can be digested by one or more restriction enzymes such that the circular plasmid DNA is linearized prior to being introduced into a cell.
- In another particular embodiment, genes encoding an endonuclease of the invention can be introduced into a cell on a self-cleaving recombinant DNA construct. Such a construct can comprise at least one coding sequence for an endonuclease and at least one recognition sequence for the same endonuclease. When expressed in a cell (i.e., in vivo), the endonuclease recognizes and cleaves the recognition sequence, resulting in linearization of the DNA construct.
- Purified nuclease proteins can be delivered into cells to cleave genomic DNA by a variety of different mechanisms known in the art, including those further detailed herein below.
- The target tissue(s) for delivery of recombinant meganucleases of the invention include, without limitation, cells of the liver, preferably hepatic sinusoidal endothelial cells or, alternatively, progenitor cells which differentiate into hepatic sinusoidal endothelial cells. Target tissues can also include, without limitation, cells in the circulatory system, preferably hematopoietic endothelial cells or, alternatively, progenitor cells which differentiate into hematopoietic endothelial cells. As discussed, endonucleases of the invention can be delivered as purified protein or as RNA or DNA encoding the endonucleases. In one embodiment, endonuclease proteins, or mRNA, or DNA vectors encoding endonucleases, are supplied to target cells (e.g., cells in the liver or cells in the circulatory system) via injection directly to the target tissue. Alternatively, endonuclease protein, mRNA, or DNA can be delivered systemically via the circulatory system.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are formulated for systemic administration, or administration to target tissues, in a pharmaceutically acceptable carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (21st ed. 2005). In the manufacture of a pharmaceutical formulation according to the invention, proteins/RNA/mRNA are typically admixed with a pharmaceutically acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier can be a solid or a liquid, or both, and can be formulated with the compound as a unit-dose formulation.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding the endonuclease, are coupled to a cell penetrating peptide or targeting ligand to facilitate cellular uptake. Examples of cell penetrating peptides known in the art include poly-arginine (Jearawiriyapaisarn, et al. (2008) Mol Ther. 16:1624-9), TAT peptide from the HIV virus (Hudecz et al. (2005), Med. Res. Rev. 25: 679-736), MPG (Simeoni, et al. (2003) Nucleic Acids Rcs. 31:2717-2724), Pep-1 (Deshayes et al. (2004) Biochemistry 43: 7698-7706, and HSV-1 VP-22 (Deshayes et al. (2005) Cell Mol Life Sci. 62:1839-49. In an alternative embodiment, endonuclease proteins, or DNA/mRNA encoding endonucleases, are coupled covalently or non-covalently to an antibody that recognizes a specific cell-surface receptor expressed on target cells such that the endonuclease protein/DNA/mRNA binds to and is internalized by the target cells. Alternatively, endonuclease protein/DNA/mRNA can be coupled covalently or non-covalently to the natural ligand (or a portion of the natural ligand) for such a cell-surface receptor. (McCall, et al. (2014) Tissue Barriers. 2(4):e944449; Dinda, et al. (2013) Curr Pharm Biotechnol. 14:1264-74; Kang, et al. (2014) Curr Pharm Biotechnol. 15(3):220-30; Qian et al. (2014) Expert Opin Drug Metab Toxicol. 10(11):1491-508).
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are encapsulated within biodegradable hydrogels for injection or implantation within the desired region of the liver (e.g., in proximity to hepatic sinusoidal endothelial cells or hematopoictic endothelial cells, or progenitor cells which differentiate into the same). Hydrogels can provide sustained and tunable release of the therapeutic payload to the desired region of the target tissue without the need for frequent injections, and stimuli-responsive materials (e.g., temperature- and pH-responsive hydrogels) can be designed to release the payload in response to environmental or externally applied cues (Kang Derwent et al. (2008) Trans Am Ophthalmol Soc. 106:206-214).
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are coupled covalently or, preferably, non-covalently to a nanoparticle or encapsulated within such a nanoparticle using methods known in the art (Sharma, et al. (2014) Biomed Res Int. 2014). A nanoparticle is a nanoscale delivery system whose length scale is <1 μm, preferably <100 nm. Such nanoparticles may be designed using a core composed of metal, lipid, polymer, or biological macromolecule, and multiple copies of the endonuclease proteins, mRNA, or DNA can be attached to or encapsulated with the nanoparticle core. This increases the copy number of the protein/mRNA/DNA that is delivered to each cell and, so, increases the intracellular expression of each endonuclease to maximize the likelihood that the target recognition sequences will be cut. The surface of such nanoparticles may be further modified with polymers or lipids (e.g., chitosan, cationic polymers, or cationic lipids) to form a core-shell nanoparticle whose surface confers additional functionalities to enhance cellular delivery and uptake of the payload (Jian et al. (2012) Biomaterials. 33(30): 7621-30). Nanoparticles may additionally be advantageously coupled to targeting molecules to direct the nanoparticle to the appropriate cell type and/or increase the likelihood of cellular uptake. Examples of such targeting molecules include antibodies specific for cell-surface receptors and the natural ligands (or portions of the natural ligands) for cell surface receptors.
- In some embodiments, the endonuclease proteins or DNA/mRNA encoding the endonucleases are encapsulated within liposomes or complexed using cationic lipids (see, e.g., Lipofectamine™, Life Technologies Corp., Carlsbad, Calif.; Zuris et al. (2015) Nat Biotechnol. 33: 73-80; Mishra et al. (2011) J Drug Deliv. 2011:863734). The liposome and lipoplex formulations can protect the payload from degradation, enhance accumulation and retention at the target site, and facilitate cellular uptake and delivery efficiency through fusion with and/or disruption of the cellular membranes of the target cells.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are encapsulated within polymeric scaffolds (e.g., PLGA) or complexed using cationic polymers (e.g., PEI, PLL) (Tamboli et al. (2011) Ther Dcliv. 2(4): 523-536). Polymeric carriers can be designed to provide tunable drug release rates through control of polymer erosion and drug diffusion, and high drug encapsulation efficiencies can offer protection of the therapeutic payload until intracellular delivery to the desired target cell population.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are combined with amphiphilic molecules that self-assemble into micelles (Tong et al. (2007) J Gene Med. 9(11): 956-66). Polymeric micelles may include a micellar shell formed with a hydrophilic polymer (e.g., polyethyleneglycol) that can prevent aggregation, mask charge interactions, and reduce nonspecific interactions.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are formulated into an emulsion or a nanoemulsion (i.e., having an average particle diameter of <1 nm) for administration and/or delivery to the target cell. The term “emulsion” refers to, without limitation, any oil-in-water, water-in-oil, water-in-oil-in-water, or oil-in-water-in-oil dispersions or droplets, including lipid structures that can form as a result of hydrophobic forces that drive apolar residues (e.g., long hydrocarbon chains) away from water and polar head groups toward water, when a water immiscible phase is mixed with an aqueous phase. These other lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases. Emulsions are composed of an aqueous phase and a lipophilic phase (typically containing an oil and an organic solvent). Emulsions also frequently contain one or more surfactants. Nanoemulsion formulations are well known, e.g., as described in US Patent Application Nos. 2002/0045667 and 2004/0043041, and U.S. Pat. Nos. 6,015,832, 6,506,803, 6,635,676, and 6,559,189, each of which is incorporated herein by reference in its entirety.
- In some embodiments, endonuclease proteins, or DNA/mRNA encoding endonucleases, are covalently attached to, or non-covalently associated with, multifunctional polymer conjugates, DNA dendrimers, and polymeric dendrimers (Mastorakos et al. (2015) Nanoscale. 7(9): 3845-56; Cheng et al. (2008) J Pharm Sci. 97(1): 123-43). The dendrimer generation can control the payload capacity and size, and can provide a high drug payload capacity. Moreover, display of multiple surface groups can be leveraged to improve stability, reduce nonspecific interactions, and enhance cell-specific targeting and drug release.
- In some embodiments, genes encoding an endonuclease are delivered using a viral vector. Such vectors are known in the art and include retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated virus (AAV) vectors (reviewed in Vannucci, et al. (2013 New Microbiol. 36:1-22). In some embodiments, the viral vectors are injected directly into target tissues. In alternative embodiments, the viral vectors are delivered systemically via the circulatory system. It is known in the art that different AAV vectors tend to localize to different tissues. In liver target tissues, effective transduction of hepatocytes has been shown, for example, with
AAV serotypes - In one embodiment, a viral vector used for endonuclease gene delivery is a self-limiting viral vector. A self-limiting viral vector can have limited persistence time in a cell or organism due to the presence of a recognition sequence for a recombinant meganuclease within the vector. Thus, a self-limiting viral vector can be engineered to provide coding for a promoter, an endonuclease described herein, and an endonuclease recognition site within the ITRs. The self-limiting viral vector delivers the endonuclease gene to a cell, tissue, or organism, such that the endonuclease is expressed and able to cut the genome of the cell at an endogenous recognition sequence within the genome. The delivered endonuclease will also find its target site within the self-limiting viral vector itself, and cut the vector at this target site. Once cut, the 5′ and 3′ ends of the viral genome will be exposed and degraded by exonucleases, thus killing the virus and ceasing production of the endonuclease.
- If the endonuclease genes are delivered in DNA form (e.g. plasmid) and/or via a viral vector (e.g. AAV) they must be operably linked to a promoter. In some embodiments, this can be a viral promoter such as endogenous promoters from the viral vector (e.g. the LTR of a lentiviral vector) or the well-known cytomegalovirus- or SV40 virus-early promoters. In a preferred embodiment, meganuclease genes are operably linked to a promoter that drives gene expression preferentially in the target cells. Examples of liver-specific promoters include, without limitation, human alpha-1 antitrypsin promoter and apolipoprotein A-II promoter.
- It is envisioned that a single treatment will permanently cause a reversion of exons 1-22 in the Factor VIII gene, resulting in a functional, wild-type gene in a percentage of patient target cells. If the frequency of reversion is low, however, or if a large percentage of target cells need to be corrected, it may be necessary to perform multiple treatments on each patient.
- In some embodiments, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and engineered nuclease of the invention, or a pharmaceutically acceptable carrier and an isolated polynucleotide comprising a nucleic acid encoding an engineered nuclease of the invention. In other embodiments, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a genetically-modified cell of the invention which can be delivered to a target tissue where the cell can then differentiate into a cell which expresses wild-type Factor VIII. Pharmaceutical compositions of the invention can be useful for treating a subject having hemophilia A, wherein the disease is characterized by an inversion of exons 1-22 in a Factor VIII gene.
- Such pharmaceutical compositions can be prepared in accordance with known techniques. See, e.g., Remington, The Science and Practice of Pharmacy (21st ed. 2005). In the manufacture of a pharmaceutical formulation according to the invention, endonuclease polypeptides (or DNA/RNA encoding the same) are typically admixed with a pharmaceutically acceptable carrier and the resulting composition is administered to a subject. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the subject. In some embodiments, pharmaceutical compositions of the invention can further comprise one or more additional agents or biological molecules useful in the treatment of a disease in the subject. Likewise, the additional agent(s) and/or biological molecule(s) can be co-administered as a separate composition.
- In some embodiments, the invention provides recombinant AAV vectors for use in the methods of the invention. Recombinant AAV vectors are typically produced in mammalian cell lines such as HEK-293. Because the viral cap and rep genes are removed from the vector to prevent its self-replication to make room for the therapeutic gene(s) to be delivered (e.g. the endonuclease gene), it is necessary to provide these in trans in the packaging cell line. In addition, it is necessary to provide the “helper” (e.g. adenoviral) components necessary to support replication (Cots D, Bosch A, Chillon M (2013) Curr. Gene Ther. 13(5): 370-81). Frequently, recombinant AAV vectors are produced using a triple-transfection in which a cell line is transfected with a first plasmid encoding the “helper” components, a second plasmid comprising the cap and rep genes, and a third plasmid comprising the viral ITRs containing the intervening DNA sequence to be packaged into the virus. Viral particles comprising a genome (ITRs and intervening gene(s) of interest) encased in a capsid are then isolated from cells by freeze-thaw cycles, sonication, detergent, or other means known in the art. Particles are then purified using cesium-chloride density gradient centrifugation or affinity chromatography and subsequently delivered to the gene(s) of interest to cells, tissues, or an organism such as a human patient.
- Because recombinant AAV particles are typically produced (manufactured) in cells, precautions must be taken in practicing the current invention to ensure that the site-specific endonuclease is not expressed in the packaging cells. Because the viral genomes of the invention comprise a recognition sequence for the endonuclease, any endonuclease expressed in the packaging cell line will be capable of cleaving the viral genome before it can be packaged into viral particles. This will result in reduced packaging efficiency and/or the packaging of fragmented genomes. Several approaches can be used to prevent endonuclease expression in the packaging cells, including:
-
- 1. The endonuclease can be placed under the control of a tissue-specific promoter that is not active in the packaging cells. For example, if a viral vector is developed for delivery of (an) endonuclease gene(s) to muscle tissue, a muscle-specific promoter can be used. Examples of muscle-specific promoters include C5-12 (Liu, et al. (2004) Hum Gene Ther. 15:783-92), the muscle-specific creatine kinase (MCK) promoter (Yuasa, et al. (2002) Gene Ther. 9:1576-88), or the smooth muscle 22 (SM22) promoter (Haase, et al. (2013) BMC Biotechnol. 13:49-54). Examples of CNS (neuron)-specific promoters include the NSE, Synapsin, and MeCP2 promoters (Lentz, et al. (2012) Neurobiol Dis. 48:179-88). Examples of liver-specific promoters include albumin promoters (such as Palb), human al-antitrypsin (such as PalAT), and hemopexin (such as Phpx) (Kramer, M G et al., (2003) Mol. Therapy 7:375-85). Examples of eye-specific promoters include opsin, and corneal epithelium-specific K12 promoters (Martin K R G, Klein R L, and Quigley H A (2002) Methods (28): 267-75) (Tong Y, et al., (2007) J Gene Med, 9:956-66). These promoters, or other tissue-specific promoters known in the art, are not highly-active in HEK-293 cells and, thus, will not expected to yield significant levels of endonuclease gene expression in packaging cells when incorporated into viral vectors of the present invention. Similarly, the viral vectors of the present invention contemplate the use of other cell lines with the use of incompatible tissue specific promoters (i.e., the well-known HeLa cell line (human epithelial cell) and using the liver-specific hemopexin promoter). Other examples of tissue specific promoters include: synovial sarcomas PDZD4 (cerebellum), C6 (liver), ASB5 (muscle), PPP1R12B (heart), SLC5A12 (kidney), cholesterol regulation APOM (liver), ADPRHL1 (heart), and monogenic malformation syndromes TP73L (muscle). (Jacox E, et al., (2010) PLoS One v.5(8):e12274).
- 2. Alternatively, the vector can be packaged in cells from a different species in which the endonuclease is not likely to be expressed. For example, viral particles can be produced in microbial, insect, or plant cells using mammalian promoters, such as the well-known cytomegalovirus- or SV40 virus-early promoters, which are not active in the non-mammalian packaging cells. In a preferred embodiment, viral particles are produced in insect cells using the baculovirus system as described by Gao, et al. (Gao, H., et al. (2007) J. Biotechnol. 131(2):138-43). An endonuclease under the control of a mammalian promoter is unlikely to be expressed in these cells (Aircnnc, K J, et al. (2013) Mol. Ther. 21(4):739-49). Moreover, insect cells utilize different mRNA splicing motifs than mammalian cells. Thus, it is possible to incorporate a mammalian intron, such as the human growth hormone (HGH) intron or the SV40 large T antigen intron, into the coding sequence of an endonuclease. Because these introns are not spliced efficiently from pre-mRNA transcripts in insect cells, insect cells will not express a functional endonuclease and will package the full-length genome. In contrast, mammalian cells to which the resulting recombinant AAV particles are delivered will properly splice the pre-mRNA and will express functional endonuclease protein. Haifeng Chen has reported the use of the HGH and SV40 large T antigen introns to attenuate expression of the toxic proteins barnase and diphtheria toxin fragment A in insect packaging cells, enabling the production of recombinant AAV vectors carrying these toxin genes (Chen, H (2012)Mol Ther Nucleic Acids. 1(11): c57).
- 3. The endonuclease gene can be operably linked to an inducible promoter such that a small-molecule inducer is required for endonuclease expression. Examples of inducible promoters include the Tet-On system (Clontech; Chen H., et al., (2015) BMC Biotechnol. 15(1):4)) and the RheoSwitch system (Intrexon; Sowa G., et al., (2011) Spine, 36(10): E623-8). Both systems, as well as similar systems known in the art, rely on ligand-inducible transcription factors (variants of the Tet Repressor and Ecdysone receptor, respectively) that activate transcription in response to a small-molecule activator (Doxycycline or Ecdysone, respectively). Practicing the current invention using such ligand-inducible transcription activators includes: 1) placing the endonuclease gene under the control of a promoter that responds to the corresponding transcription factor, the endonuclease gene having (a) binding site(s) for the transcription factor; and 2) including the gene encoding the transcription factor in the packaged viral genome The latter step is necessary because the endonuclease will not be expressed in the target cells or tissues following recombinant AAV delivery if the transcription activator is not also provided to the same cells. The transcription activator then induces endonuclease gene expression only in cells or tissues that are treated with the cognate small-molecule activator. This approach is advantageous because it enables endonuclease gene expression to be regulated in a spatio-temporal manner by selecting when and to which tissues the small-molecule inducer is delivered. However, the requirement to include the inducer in the viral genome, which has significantly limited carrying capacity, creates a drawback to this approach.
- 4. In another preferred embodiment, recombinant AAV particles are produced in a mammalian cell line that expresses a transcription repressor that prevents expression of the endonuclease. Transcription repressors are known in the art and include the Tet-Repressor, the Lac-Repressor, the Cro repressor, and the Lambda-repressor. Many nuclear hormone receptors such as the ecdysone receptor also act as transcription repressors in the absence of their cognate hormone ligand. To practice the current invention, packaging cells are transfected/transduced with a vector encoding a transcription repressor and the endonuclease gene in the viral genome (packaging vector) is operably linked to a promoter that is modified to comprise binding sites for the repressor such that the repressor silences the promoter. The gene encoding the transcription repressor can be placed in a variety of positions. It can be encoded on a separate vector; it can be incorporated into the packaging vector outside of the ITR sequences; it can be incorporated into the cap/rep vector or the adenoviral helper vector; or, most preferably, it can be stably integrated into the genome of the packaging cell such that it is expressed constitutively. Methods to modify common mammalian promoters to incorporate transcription repressor sites are known in the art. For example, Chang and Roninson modified the strong, constitutive CMV and RSV promoters to comprise operators for the Lac repressor and showed that gene expression from the modified promoters was greatly attenuated in cells expressing the repressor (Chang B D, and Roninson I B (1996) Gene 183:137-42). The use of a non-human transcription repressor ensures that transcription of the endonuclease gene will be repressed only in the packaging cells expressing the repressor and not in target cells or tissues transduced with the resulting recombinant AAV vector.
- Embodiments of the invention encompass the engineered nucleases described herein, and variants thereof. Further embodiments of the invention encompass isolated polynucleotides comprising a nucleic acid sequence encoding the endonucleases described herein, and variants of such polynucleotides.
- As used herein, “variants” is intended to mean substantially similar sequences. A “variant” polypeptide is intended to mean a polypeptide derived from the “native” polypeptide by deletion or addition of one or more amino acids at one or more internal sites in the native protein and/or substitution of one or more amino acids at one or more sites in the native polypeptide. As used herein, a “native” polynucleotide or polypeptide comprises a parental sequence from which variants are derived. Variant polypeptides encompassed by the embodiments are biologically active. That is, they continue to possess the desired biological activity of the native protein; i.e., the ability to recognize and cleave recognition sequences found in an int22h-1 sequence in a Factor VIII gene including, for example, the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 3-4 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17). Such variants may result, for example, from human manipulation. Biologically active variants of a native polypeptide of the embodiments (e.g., SEQ ID NOs: 19-21, 28-31, 40-43, 52-55, 64-67, or 76-79), or biologically active variants of the recognition half-site binding subunits described herein, will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%, sequence identity to the amino acid sequence of the native polypeptide or native subunit, as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a polypeptide or subunit of the embodiments may differ from that polypeptide or subunit by as few as about 1-40 amino acid residues, as few as about 1-20, as few as about 1-10, as few as about 5, as few as 4, 3, 2, or even 1 amino acid residue.
- The polypeptides of the embodiments may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants can be prepared by mutations in the DNA. Methods for mutagenesis and polynucleotide alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Pat. No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be optimal.
- A substantial number of amino acid modifications to the DNA recognition domain of the wild-type I-CreI meganuclease have previously been identified (e.g., U.S. Pat. No. 8,021,867) which, singly or in combination, result in recombinant meganucleases with specificities altered at individual bases within the DNA recognition sequence half-site, such that the resulting rationally-designed meganucleases have half-site specificities different from the wild-type enzyme. Table 7 provides potential substitutions that can be made in a recombinant meganuclease monomer or subunit to enhance specificity based on the base present at each half-site position (−1 through −9) of a recognition half-site.
-
TABLE 7 Favored Sense-Strand Base Posn. A C G T A/T A/C A/G C/T G/T A/G/T A/C/G/T −1 Y75 R70* K70 Q70* T46* G70 L75* H75* E70* C70 A70 C75* R75* E75* L70 S70 Y139* H46* E46* Y75* G46* C46* K46* D46* Q75* A46* R46* H75* H139 Q46* H46* −2 Q70 E70 H70 Q44* C44* T44* D70 D44* A44* K44* E44* V44* R44* I44* L44* N44* −3 Q68 E68 R68 M68 H68 Y68 K68 C24* F68 C68 I24* K24* L68 R24* F68 −4 A26* E77 R77 S77 S26* Q77 K26* E26* Q26* −5 E42 R42 K28* C28* M66 Q42 K66 −6 Q40 E40 R40 C40 A40 S40 C28* R28* I40 A79 S28* V40 A28* C79 H28* I79 V79 Q28* −7 N30* E38 K38 I38 C38 H38 Q38 K30* R38 L38 N38 R30* E30* Q30* −8 F33 E33 F33 L33 R32* R33 Y33 D33 H33 V33 I33 F33 C33 −9 E32 R32 L32 D32 S32 K32 V32 I32 N32 A32 H32 C32 Q32 T32 Bold entries are wild-type contact residues and do not constitute “modifications” as used herein. An asterisk indicates that the residue contacts the base on the antisense strand. - For polynucleotides, a “variant” comprises a deletion and/or addition of one or more nucleotides at one or more sites within the native polynucleotide. One of skill in the art will recognize that variants of the nucleic acids of the embodiments will be constructed such that the open reading frame is maintained. For polynucleotides, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the embodiments. Variant polynucleotides include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis but which still encode a recombinant meganuclease of the embodiments. Generally, variants of a particular polynucleotide of the embodiments will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein. Variants of a particular polynucleotide of the embodiments (i.e., the reference polynucleotide) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide.
- The deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the polypeptide. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by screening the polypeptide for its ability to preferentially recognize and cleave recognition sequences found within an int22h-1 sequence of a Factor VIII gene.
- This invention is further illustrated by the following examples, which should not be construed as limiting. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are intended to be encompassed in the scope of the claims that follow the examples below.
- Recombinant meganucleases (SEQ ID NOs: 19-21), collectively referred to herein as “F8R 1-2 meganucleases,” were engineered to recognize and cleave the F8R 1-2 recognition sequence (SEQ ID NO: 7), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence, and more specifically within the F8A1 sequence. Each F8R 1-2 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 1-2 meganuclease binds to the F8R1 recognition half-site of SEQ ID NO: 7, while a second subunit binds to the F8R2 recognition half-site (see,
FIG. 2 ). - The F8R 1-binding subunits and F8R2-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R1-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R2-binding subunits are also highly conserved outside of the HVR2 region. The F8R1-binding regions of SEQ ID NOs: 19-21 are provided as SEQ ID NOs: 22-24, respectively. Each of SEQ ID NOs: 22-24 share at least 90% sequence identity to SEQ ID NO: 22, which is the F8R1-binding region of the meganuclease F8R 1-2x.27 (SEQ ID NO: 19). F8R2-binding regions of SEQ ID NOs: 19-21 are provided as SEQ ID NOs: 25-27, respectively. Each of SEQ ID NOs: 25-27 share at least 90% sequence identity to SEQ ID NO: 25, which is the F8R2-binding region of the meganuclease F8R 1-2x.27 (SEQ ID NO: 19).
- Recombinant meganucleases (SEQ ID NOs: 28-31), collectively referred to herein as “F8R 3-4 meganucleases,” were engineered to recognize and cleave the F8R 3-4 recognition sequence (SEQ ID NO: 9), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence, and more specifically within the F8A1 sequence. Each F8R 3-4 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 3-4 meganuclease binds to the F8R3 recognition half-site of SEQ ID NO: 9, while a second subunit binds to the F8R4 recognition half-site (see,
FIG. 2 ). - The F8R3-binding subunits and F8R4-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R3-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R4-binding subunits are also highly conserved outside of the HVR2 region. The F8R3-binding regions of SEQ ID NOs: 28-31 are provided as SEQ ID NOs: 32-35, respectively. Each of SEQ ID NOs: 32-35 share at least 90% sequence identity to SEQ ID NO: 32, which is the F8R3-binding region of the meganuclease F8R3-4x.43 (SEQ ID NO: 28). F8R4-binding regions of SEQ ID NOs: 28-31 are provided as SEQ ID NOs: 36-39, respectively. Each of SEQ ID NOs: 36-39 share at least 90% sequence identity to SEQ ID NO: 36, which is the F8R4-binding region of the meganuclease F8R 3-4x.43 (SEQ ID NO: 28).
- Recombinant meganucleases (SEQ ID NOs: 40-43), collectively referred to herein as “F8R 9-10 meganucleases,” were engineered to recognize and cleave the F8R 9-10 recognition sequence (SEQ ID NO: 11), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence. Each F8R 9-10 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 9-10 meganuclease binds to the F8R9 recognition half-site of SEQ ID NO: 11, while a second subunit binds to the F8R10 recognition half-site (see,
FIG. 2 ). - The F8R9-binding subunits and F8R10-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R9-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R10-binding subunits are also highly conserved outside of the HVR2 region. The F8R9-binding regions of SEQ ID NOs: 40-43 are provided as SEQ ID NOs: 44-47, respectively. Each of SEQ ID NOs: 44-47 share at least 90% sequence identity to SEQ ID NO: 44, which is the F8R9-binding region of the meganucicase F8R 9-10x.70 (SEQ ID NO: 40). F8R10-binding regions of SEQ ID NOs: 40-43 are provided as SEQ ID NOs: 48-51, respectively. Each of SEQ ID NOs: 48-51 share at least 90% sequence identity to SEQ ID NO: 48, which is the F8R10-binding region of the meganuclease F8R 9-10x.70 (SEQ ID NO: 40).
- Recombinant meganucleases (SEQ ID NOs: 52-55), collectively referred to herein as “F8R 11-12 meganucleases,” were engineered to recognize and cleave the F8R 11-12 recognition sequence (SEQ ID NO: 13), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence. Each F8R 11-12 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 11-12 meganuclease binds to the F8R11 recognition half-site of SEQ ID NO: 13, while a second subunit binds to the F8R12 recognition half-site (see,
FIG. 2 ). - The F8R11-binding subunits and F8R12-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R11-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R12-binding subunits are also highly conserved outside of the HVR2 region. The F8R11-binding regions of SEQ ID NOs: 52-55 are provided as SEQ ID NOs: 56-59, respectively. Each of SEQ ID NOs: 56-59 share at least 90% sequence identity to SEQ ID NO: 56, which is the F8R11-binding region of the meganuclease F8R 11-12x.56 (SEQ ID NO: 52). F8R12-binding regions of SEQ ID NOs: 52-55 are provided as SEQ ID NOs: 60-63, respectively. Each of SEQ ID NOs: 60-63 share at least 90% sequence identity to SEQ ID NO: 60, which is the F8R12-binding region of the meganuclease F8R 11-12x.56 (SEQ ID NO: 52).
- Recombinant meganucleases (SEQ ID NOs: 64-67), collectively referred to herein as “F8R 13-14 meganucleases,” were engineered to recognize and cleave the F8R 13-14 recognition sequence (SEQ ID NO: 15), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence. Each F8R 13-14 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 13-14 meganuclease binds to the F8R13 recognition half-site of SEQ ID NO: 15, while a second subunit binds to the F8R14 recognition half-site (see,
FIG. 2 ). - The F8R13-binding subunits and F8R14-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R13-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R14-binding subunits are also highly conserved outside of the HVR2 region. The F8R13-binding regions of SEQ ID NOs: 64-67 are provided as SEQ ID NOs: 68-71, respectively. Each of SEQ ID NOs: 68-71 share at least 90% sequence identity to SEQ ID NO: 68, which is the F8R13-binding region of the meganuclease F8R 13-14x.13 (SEQ ID NO: 64). F8R14-binding regions of SEQ ID NOs: 64-67 are provided as SEQ ID NOs: 72-75, respectively. Each of SEQ ID NOs: 72-75 share at least 90% sequence identity to SEQ ID NO: 72, which is the F8R14-binding region of the meganuclease F8R 13-14x. 13 (SEQ ID NO: 64).
- Recombinant meganucleases (SEQ ID NOs: 76-79), collectively referred to herein as “F8R 15-16 meganucleases,” were engineered to recognize and cleave the F8R 15-16 recognition sequence (SEQ ID NO: 17), which is present in the human and canine Factor VIII gene, specifically within the int22h-1 sequence. Each F8R 15-16 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each F8R 15-16 meganuclease binds to the F8R15 recognition half-site of SEQ ID NO: 17, while a second subunit binds to the F8R16 recognition half-site (see,
FIG. 2 ). - The F8R15-binding subunits and F8R16-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. F8R15-binding subunits are highly conserved outside of the HVR1 region. Similarly, F8R16-binding subunits are also highly conserved outside of the HVR2 region. The F8R15-binding regions of SEQ ID NOs: 76-79 are provided as SEQ ID NOs: 80-83, respectively. Each of SEQ ID NOs: 80-83 share at least 90% sequence identity to SEQ ID NO: 80, which is the F8R15-binding region of the meganuclease F8R 15-16x.14 (SEQ ID NO: 76). F8R16-binding regions of SEQ ID NOs: 76-79 are provided as SEQ ID NOs: 84-87, respectively. Each of SEQ ID NOs: 84-87 share at least 90% sequence identity to SEQ ID NO: 84, which is the F8R16-binding region of the meganuclease F8R 15-16x.14 (SEQ ID NO: 76).
- To determine whether F8R 1-2, F8R 3-4, F8R 9-10, F8R 11-12, F8R 13-14, and F8R 15-16 meganucleases could recognize and cleave their respective recognition sequences (SEQ ID NOs: 7, 9, 11, 13, 15, and 17, respectively), each recombinant meganuclease was evaluated using the CHO cell reporter assay previously described (see, WO/2012/167192 and
FIG. 4 ). To perform the assays, CHO cell reporter lines were produced which carried a non-functional Green Fluorescent Protein (GFP) gene expression cassette integrated into the genome of the cells. The GFP gene in each cell line was interrupted by a pair of recognition sequences such that intracellular cleavage of either recognition sequence by a meganuclease would stimulate a homologous recombination event resulting in a functional GFP gene. - In CHO reporter cell lines developed for this study, one recognition sequence inserted into the GFP gene was the F8R 1-2 recognition sequence (SEQ ID NO: 7), the F8R 34 recognition sequence (SEQ ID NO: 9), the F8R 9-10 recognition sequence (SEQ ID NO: 11), the F8R 11-12 recognition sequence (SEQ ID NO: 13), the F8R 13-14 recognition sequence (SEQ ID NO: 15), or the F8R 15-16 recognition sequence (SEQ ID NO: 17). The second recognition sequence inserted into the GFP gene was a CHO-23/24 recognition sequence, which is recognized and cleaved by a control meganuclease called “CHO-23/24”. CHO reporter cells comprising the F8R 1-2 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 1-2 cells.” CHO reporter cells comprising the F8R 3-4 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 3-4 cells.” CHO reporter cells comprising the F8R 9-10 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 9-10 cells.” CHO reporter cells comprising the F8R 11-12 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 11-12 cells.” CHO reporter cells comprising the F8R 13-14 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 13-14 cells.” CHO reporter cells comprising the F8R 15-16 recognition sequence and the CHO-23/24 recognition sequence are referred to as “F8R 15-16 cells.”
- CHO reporter cells were transfected with plasmid DNA encoding their corresponding recombinant meganucleases (e.g., F8R 1-2 cells were transfected with plasmid DNA encoding F8R 1-2 meganucleases) or encoding the CHO-23/34 meganuclease. In each assay, 4e5 CHO reporter cells were transfected with 50 ng of plasmid DNA in a 96-well plate using Lipofectamine®2000 (ThermoFisher) according to the manufacturer's instructions. At 48 hours post-transfection, cells were evaluated by flow cytometry to determine the percentage of GFP-positive cells compared to an untransfected negative control (F8R bs). As shown in
FIGS. 5A-5G , all F8R meganucleases were found to produce GFP-positive cells in cell lines comprising their corresponding recognition sequence at frequencies significantly exceeding the negative control. - The efficacy of PCS 7-8 meganucleases was also determined in a time-
dependent manner - As shown in
FIGS. 6A-6F , the % GFP produced by a number of different F8R meganucleases was relatively consistent over the time course of each study, indicating persistent cleavage activity and a lack of any substantial toxicity in the cells. Other F8R meganucleases exhibited some variability in % GFP expression over the time course of the study. - These studies demonstrated that F8R meganucleases encompassed by the invention can efficiently target and cleave their respective recognition sequences in cells.
- Meganucleases F8R 1-2 and F8R 3-4 were tested for the ability to cut and cause insertions and/or deletions (indels) at their recognition sites by T7 endonuclease assay. HEK 293 cells were transfected with 200 ng of mRNA encoding each nuclease. Cells were harvested at 7 days post transfection and gDNA was extracted. This gDNA was used as a template in PCR reactions using primers F8R3-4f.357 and F8R1-2r.467. The resulting PCR product was then analyzed using T7 endonuclease to reveal the presence of indels (
FIG. 7 ).FIG. 7 illustrates an agarose gel loaded with PCR/T7 endonuclease reactions from HEK 293 cells that were mock treated (Lane 1) or treated with F8R 1-2x.15 (lane 2), F8R 1-2x.27 (lane 3), F8R 3-4x.43 (lane 4), or F8R 3-4x.70 (lane 5). The lower molecular weight bands inlanes - To determine if cleavage of genomic DNA by F8R 1-2 and F8R 3-4 meganucleases could stimulate an inversion of exons 1-22, we first transfected HEK 293 cells with 200 ng of mRNA encoding either F8R 1-2 or F8R 3-4 meganucleases and harvested
gDNA 7 days later. The gDNA was analyzed by PCR using primer set H1R/H1F to detect normal exon 1-22 positioning and with primer set H1R/H2/3R to detect inverted exon 1-22 positioning (FIG. 8 ).FIG. 8A illustrates an agarose gel loaded with H1R/H1F primed PCR reactions from HEK 293 cells that were mock treated (lane 1), or treated with F8R 1-2x.15 (lane 2), F8R 1-2x.27 (lane 3), F8R 3-4x.43 (lane 4), F8R 3-4x.70 (lane 5).Lane 6 contains a control PCR using untreated human cell gDNA template.Lane 7 contains a no template PCR negative control.FIG. 8B illustrates an agarose gel loaded with H1R/H2/3R primed PCR reactions from HEK 293 cells that were mock treated (lane 1), or treated with F8R 1-2x.15 (lane 2), F8R 1-2x.27 (lane 3), F8R 3-4x.43 (lane 4), F8R 3-4x.70 (lane 5).Lane 6 contains a control PCR using untreated human cell gDNA template.Lane 7 contains a no template PCR negative control. The presence of PCR fragments inFIG. 8B is indicative of successful exon 1-22 inversion using F8R meganucleases encompassed by the invention. - To determine if cleavage of genomic DNA by F8R 9-10, F8R 11-12, F8R 13-14, and F8R 15-16 meganucleases could stimulate an inversion of exons 1-22, we first transfected HEK 293 cells with 200 ng of mRNA encoding each individual nuclease and harvested gDNA at
day 2 andday 8 post transfection. The gDNA was analyzed by PCR using primer set H1R/H1F, which detects normal exon 1-22 positioning, and with primer set H1R/H2/3R, which detects inverted exon 1-22 positioning (FIG. 9 ).FIG. 9 illustrates an agarose gel loaded with H1R/H1F primed PCR reactions (top) and H1R/H2/3R primed PCR reactions (bottom) from HEK 293 cells that were mock treated (lane 1), or treated with F8R 9-10x.38 (lane 2), F8R 9-10x.70 (lane 3), F8R 11-12x.56 (lane 4), F8R 11-12x.69 (lane 5), F8R 13-14x.3 (lane 6), F8R 13-14x.13 (lane 7), F8R 15-16x.14 (lane 8), or F8R 15-16x.85 (lane 9).Lane 10 contains a control PCR using untreated human cell gDNA template.Lane 11 contains a no template PCR negative control. The presence of PCR fragments in H1R/H2/3R primed PCR reactions (lower half ofFIG. 9 ) is indicative of successful exon 1-22 inversion using the F8R meganucleases encompassed by the invention. - This study demonstrated that F8R nucleases encompassed by this invention can lead to the hemophilia A specific Factor VIII gene inversion in HEK293cells. In addition, the described method can be used to determine the efficiency of F8R nuclease-mediated Factor VIII gene inversion.
- HEK293 cells (2×10{circumflex over ( )}6) were transfected with mRNA (5 μg) encoding F8R11-12x.69 or F8R13-14x.13 nucleases, respectively, using a Bio-Rad GenePulser XCell according to the manufacturer's instructions. At 2 days post-transfection, genomic DNA was isolated from cells and inverse digital PCR was performed to determine Factor VIII genome editing. Genomic DNA isolated from untransfected cells served as a control.
- Genomic DNA was digested to completion with restriction endonuclease Bell. Digested DNA was circularized using T4 DNA ligase and analyzed by inverse digital PCR using the Bio-Rad QX200 Digital PCR System according to the manufacturer's instructions. In normal human genomic DNA, the BcII digest generates an approximately 21 kb fragment encompassing the int22h-1 repeat in intron 22 of the Factor VIII gene as well as an approximately 16 kb fragment encompassing a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- In inverse digital PCR, the two circularized BcII fragments described above are amplified with primers flanking the respective Bell sites. Primers U1 and D1 bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer U3 binds upstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1. All primers bind the genomic DNA in opposite orientation to conventional PCR and generate amplicons only when the BcII fragments are circularized.
-
U1: (SEQ ID NO: 88) [5′-CCTTTCAACTCCATCTCCAT-3′] D1: (SEQ ID NO: 89) [5′-ACATACGGTTTAGTCACAAGT-3′] U3: (SEQ ID NO: 90) [5′-TCCAGTCACTTAGGCTCAG-3′] - Inverse digital PCR of HEK293 genomic DNA with primers U1/D1 yields an approximately 0.5 kb amplicon that can be detected using a TaqMan probe while PCR with primers U3/U1 does not generate an amplification product.
- Upon successful inversion of the genomic fragment between int22h-1 and its distal copy, the U1 primer binding site, which is located on the inverted fragment, is reoriented relative to the D1 and U3 primer binding sites. Now, the U1/D1 PCR fails to generate a PCR product, while the U3/U1 PCR yields an approximately 0.5 kb amplicon which can be detected with the same TaqMan probe.
- Genomic DNAs from HEK293 cells and HEK293 cells treated with F8R11-12x.69 or F8R13-14x.13 nucleases, respectively, were analyzed by inverse digital PCR. Only the U1/D1 fragment was amplified from genomic DNA isolated from untreated HEK293 cells, while the U3/U1 PCR did not generate a signal (
FIG. 10 , mock). Using genomic DNA from F8R nuclease-treated HEK293 cells, both U1/D1 and U3/U1 amplicons were detected (FIG. 10 , F8R11-12x.69 and F8R13-14x.13). The U1/D1 fragment was still amplified from genomic DNA from F8R nuclease-treated HEK293 cells because the nuclease treatment generated a mixed population of cells with both edited and unedited genomes. Since digital PCR allows parallel analysis of hundreds to thousands of chromosome equivalents, the Factor VIII gene inversion efficiency could be calculated. Out of the total number of Factor VIII genes detected by this assay, 4% and 30% showed an inversion as a result of the activity of nucleases F8R13-14x.13 and F8R11-12x.69, respectively. - Inverse digital PCR detected Factor VIII gene inversion in HEK293 cells treated with nucleases F8R11-12x.69 and F8R13-14x.13. In addition, using inverse digital PCR, the editing efficiency could be calculated. Depending on the nuclease (F8R11-12x.69), up to 30% of the detected Factor VIII genes in HEK293 cells were edited. Importantly, this study demonstrates that Factor VIII gene inversions can be induced by DNA double-strand breaks within the int22h repeats. Both nucleases target recognition sequences within the int22h repeats and potentially introduce up to three double-strand breaks per chromosome.
- This study demonstrated that F8R nucleases encompassed by this invention can lead to the hemophilia A specific Factor VIII gene inversion in normal wild-type human T-cells. Normal human T-cells (1×10{circumflex over ( )}6) were transfected with mRNA (1 μg) encoding F8R3-4x.43 nuclease using a Lonza 4D nucleofector according to the manufacturer's instructions. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing. Genomic DNA isolated from untransfected normal human T-cells served as a control.
- In this long-distance PCR, the genomic DNA was amplified between primers FWD1/REV1 and FWD3/FWD1, respectively.
-
FWD1: (SEQ ID NO: 91) [5′-CCCTTACAGTTATTAACTACTCTCATGAGGTTCATTCC-3′] REV1: (SEQ ID NO: 92) [5′-CCCCGGCACTTGAAAGTAGCAGATGCAAGAAGGGCACA-3′] FWD3: (SEQ ID NO: 93) [5′-ACTATAACCAGCACCTTGAACTTCCCCTCTCATA-3′] - Primers FWD1 and REV1 bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer FWD3 binds upstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- Long-distance PCR of normal human genomic DNA with primers FWD1/
REV 1 yields an approximately 10 kb amplicon while PCR with primers FWD3/FWD1 does not generate an amplification product. - Upon successful inversion of the genomic fragment between int22h-1 and its distal copy, the FWD1 primer binding site, which is located on the inverted fragment, is reoriented relative to the REV1 and FWD3 primer binding sites. Now, the FWD1/REV1 PCR fails to generate a PCR product while the FWD3/FWD1 PCR yields an approximately 9.7 kb amplicon. PCR fragments are analyzed by agarose gel electrophoresis and visualized by ethidium bromide.
- Genomic DNAs from normal human T-cells and normal human T-cells treated with F8R3-4x.43 nuclease were analyzed by long-distance PCR (
FIG. 11 ). Only the FWD1/REV1 fragment was be amplified from genomic DNA isolated from untreated normal human T-cells (lanes 2 and 5). Using genomic DNA from F8R3-4x.43 nuclease-treated normal human T-cells as PCR template, both FWD1/REV1 and FWD3/FWD1 primer combinations yield their signature ˜10 kb and ˜9.7 kb amplicons, respectively (lanes 3 and 6). The FWD1/REV1 fragment can still be amplified from genomic DNA from F8R3-4x.43 treated normal human T-cells because the nuclease treatment generated a mixed population of cells with edited and unedited genomes. - The F8R3-4x.43 meganuclease was able to generate an inversion of the Factor VIII gene in human T cells by producing a double strand break within the int22h regions, and this inversion could be detected by long-distance PCR.
- This study demonstrated that F8R nucleases encompassed by this invention can lead to the reversion of the hemophilia A specific Factor VIII gene inversion in hemophilia A patient T-cells.
- Hemophilia A patient T-cells (1×10{circumflex over ( )}6) were transfected with mRNA (1 μg) encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases, respectively, using a Lonza 4D nucleofector according to the manufacturer's instructions. At 3 days post-transfection, genomic DNA was isolated from cells and long-distance PCR was performed to determine Factor VIII genome editing. Genomic DNA isolated from patient T-cells transfected with mRNA encoding green fluorescent protein (GFP) served as a control.
- In this long-distance PCR, the genomic DNA was amplified between primers H1U/H1D and H3D/H1D, respectively.
-
H1U: (SEQ ID NO: 94) [5′-GCCCTGCCTGTCCATTACACTGATGACATTATGCTGAC-3′] H1D: (SEQ ID NO: 95) [5′-GGCCCTACAACCATTCTGCCTTTCACTTTCAGTGCAATA-3′] H3D: (SEQ ID NO: 96) [5′-CACAAGGGGGAAGAGTGTGAGGGTGTGGGATAAGAA-3′] - Primers H1U and H1D bind upstream and downstream, respectively of the int22h-1 repeat in intron 22 of the Factor VIII gene; primer H3D binds downstream of a near-identical, inversely oriented copy of the int22h-1 repeat located about 0.5 Mb upstream of int22h-1.
- Long-distance PCR of normal human genomic DNA with primers H1U/H1D yields an approximately 12 kb amplicon while PCR with primers H3D/H1D does not generate an amplification product. Conversely, long-distance PCR of genomic DNA from patient cells with the hemophilia A gene inversion with primers H1U/H1D fails to generate a PCR product while the H3D/H1D PCR yields an approximately 11 kb amplicon.
- Upon successful reversion of the genomic fragment in patient T-cells between two inversely oriented int22h repeats, the H1U primer binding site, which is located on the inverted fragment, is reoriented relative to the H3U and H1D primer binding sites. Now the H1U/H1D PCR yields the 12 kb amplicon, indicating a reversion to the wild-type configuration of the Factor VIII gene. PCR fragments were analyzed by agarose gel electrophoresis and visualized by ethidium bromide.
- Genomic DNAs from hemophilia A patient T-cells treated with mRNA encoding F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nucleases (or GFP as a control) were analyzed by long-distance PCR (
FIG. 12 ). Only the H3U/H1D fragment could be amplified from genomic DNA isolated from patient T-cells treated with GFP mRNA (lanes 1 a and 1 b). Using genomic DNA from F8R3-4x.43, F8R11-12x.69, or F8R15-16x.14 nuclease-treated patient T-cells as PCR template, both H1U/H1D and H3D/H1D primer combinations yielded their signature wild-type (˜12 kb) and inversion (˜11 kb) amplicons, respectively (lanes 3 a and 3b: F8R3-4x.43; lanes 4 a and 4b: F8R11-12x.69; lanes 5 a and 5b: F8R15-16x.14). The H3U/H1D fragment was still being amplified from genomic DNA from F8R nuclease-treated patient T-cells because the nuclease treatment generated a mixed population of cells with edited and unedited genomes. - F8R meganucleases encompassed by the invention were capable of inducing a reversion of the inverted Factor VIII gene back to a wild-type configuration in hemophilia A patient T-cells in vitro, and this reversion could be detected by long-distance PCR.
Claims (14)
1. A method for genetically-modifying a Factor VIII gene in the genome of a mammalian cell to generate a reversion of exons 1-22, wherein said mammalian cell comprises an inversion of exons 1-22 in the Factor VIII gene compared to a wild-type Factor VIE gene, said method comprising delivering to said mammalian cell a lipid nanoparticle composition comprising a nucleic acid encoding an engineered nuclease having specificity for a recognition sequence positioned within an int22h-1 sequence of a Factor VIII gene, wherein said engineered nuclease is expressed in said mammalian cell;
wherein said engineered nuclease cleaves said recognition sequence and generates a reversion of exons 1-22 to a wild-type orientation in said genetically-modified mammalian cell.
2. The method of claim 1 , wherein said genetically-modified cell produces a functional Factor VIII protein following said reversion of exons 1-22 to a wild-type orientation.
3. The method of claim 1 , wherein said recognition sequence is within an F8A1 coding sequence of said Factor VIII gene.
4. The method of claim 1 , wherein said F8A1 coding sequence has at least 95% sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.
5. The method of claim 1 , wherein said nucleic acid is an mRNA.
6. The method of claim 1 , wherein said engineered nuclease is an engineered mega nuclease, a TALEN, a zinc finger nuclease, a compact TALEN, a CRISPR, or a megaTAL.
7. The method of claim 1 , wherein said engineered nuclease is an engineered meganuclease.
8. The method of claim 1 , wherein said mammalian cell is a hepatic sinusoidal endothelial cell or a progenitor cell capable of differentiating into a hepatic sinusoidal endothelial cell.
9. The method of claim 1 , wherein said mammalian cell is a human cell.
10. The method of claim 1 , wherein said int22h-1 sequence of said Factor VIII gene has at least 95% sequence identity to SEQ ID NO: 3.
11. The method of claim 1 , wherein said mammalian cell is a canine cell.
12. The method of claim 1 , wherein said int22h-1 sequence of said Factor VIII gene has at least 95% sequence identity to SEQ H) NO: 4.
13. The method of claim 1 , wherein said recognition sequence comprises the nucleic acid sequence of SEQ ID NO: 9.
14. A method for treating a subject having Hemophilia A comprising genetically-modifying a Factor VIII gene in the genome of a target cell within said subject to generate a reversion of exons 1-22, wherein said target cell comprises an inversion of exons 1-22 in the Factor VIII gene compared to a wild-type Factor VIII gene, said method comprising delivering to said target cell a lipid nanoparticle composition comprising a nucleic acid encoding an engineered nuclease having specificity for a recognition sequence positioned within an int22h-1 sequence of a Factor VIII gene, wherein said engineered nuclease is expressed in said target cell;
wherein said engineered nuclease cleaves said recognition sequence and generates a reversion of exons 1-22 to a wild-type orientation in said target cell, thereby treating said subject having Hemophilia A.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/691,648 US20220193267A1 (en) | 2016-05-03 | 2022-03-10 | Engineered nucleases useful for treatment of hemophilia a |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662331335P | 2016-05-03 | 2016-05-03 | |
PCT/US2017/030872 WO2017192741A1 (en) | 2016-05-03 | 2017-05-03 | Engineered nucleases useful for treatment of hemophilia a |
US201816098660A | 2018-11-02 | 2018-11-02 | |
US17/691,648 US20220193267A1 (en) | 2016-05-03 | 2022-03-10 | Engineered nucleases useful for treatment of hemophilia a |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/030872 Continuation WO2017192741A1 (en) | 2016-05-03 | 2017-05-03 | Engineered nucleases useful for treatment of hemophilia a |
US16/098,660 Continuation US11278632B2 (en) | 2016-05-03 | 2017-05-03 | Engineered nucleases useful for treatment of hemophilia A |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220193267A1 true US20220193267A1 (en) | 2022-06-23 |
Family
ID=58739354
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/098,660 Active US11278632B2 (en) | 2016-05-03 | 2017-05-03 | Engineered nucleases useful for treatment of hemophilia A |
US17/691,648 Abandoned US20220193267A1 (en) | 2016-05-03 | 2022-03-10 | Engineered nucleases useful for treatment of hemophilia a |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/098,660 Active US11278632B2 (en) | 2016-05-03 | 2017-05-03 | Engineered nucleases useful for treatment of hemophilia A |
Country Status (8)
Country | Link |
---|---|
US (2) | US11278632B2 (en) |
EP (2) | EP4019628A1 (en) |
JP (3) | JP2019514397A (en) |
AU (2) | AU2017260426B2 (en) |
CA (1) | CA3022801A1 (en) |
DK (1) | DK3452583T3 (en) |
ES (1) | ES2905791T3 (en) |
WO (1) | WO2017192741A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3526323T3 (en) * | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | MODIFIED MEGANUCLEASES SPECIFIC FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME |
US20200299658A1 (en) * | 2017-11-01 | 2020-09-24 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US20220119786A1 (en) * | 2019-01-10 | 2022-04-21 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified transferrin gene |
US20220195407A1 (en) | 2019-05-07 | 2022-06-23 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
EP4069729A1 (en) * | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
WO2023070002A2 (en) * | 2021-10-19 | 2023-04-27 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
WO2009095742A1 (en) * | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
AU2004208031B2 (en) | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
DK2662442T3 (en) | 2005-10-18 | 2015-07-06 | Prec Biosciences | Rationally designed mechanuclease with altered dimer formation affinity |
WO2009059195A2 (en) | 2007-10-31 | 2009-05-07 | Precision Biosciences | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
DK3211075T3 (en) | 2008-07-14 | 2019-01-21 | Prec Biosciences Inc | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF |
EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
US20160045575A1 (en) * | 2012-12-07 | 2016-02-18 | Tom E. HOWARD | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED cDNAs, COMPOSITIONS, METHODS AND SYSTEMS |
ES2886194T3 (en) | 2015-01-06 | 2021-12-16 | Univ Yonsei Iacf | Endonuclease targeting the blood coagulation factor VIII gene and composition for the treatment of hemophilia comprising the same |
US20200299658A1 (en) | 2017-11-01 | 2020-09-24 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
-
2017
- 2017-05-03 WO PCT/US2017/030872 patent/WO2017192741A1/en unknown
- 2017-05-03 DK DK17724672.5T patent/DK3452583T3/en active
- 2017-05-03 AU AU2017260426A patent/AU2017260426B2/en active Active
- 2017-05-03 CA CA3022801A patent/CA3022801A1/en active Pending
- 2017-05-03 JP JP2018557839A patent/JP2019514397A/en active Pending
- 2017-05-03 EP EP21204497.8A patent/EP4019628A1/en active Pending
- 2017-05-03 ES ES17724672T patent/ES2905791T3/en active Active
- 2017-05-03 EP EP17724672.5A patent/EP3452583B1/en active Active
- 2017-05-03 US US16/098,660 patent/US11278632B2/en active Active
-
2021
- 2021-10-08 JP JP2021165964A patent/JP2022025081A/en active Pending
-
2022
- 2022-03-10 US US17/691,648 patent/US20220193267A1/en not_active Abandoned
-
2023
- 2023-08-15 AU AU2023216779A patent/AU2023216779A1/en active Pending
- 2023-12-07 JP JP2023206612A patent/JP2024028886A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3452583A1 (en) | 2019-03-13 |
AU2023216779A1 (en) | 2023-11-09 |
EP3452583B1 (en) | 2021-10-27 |
AU2017260426A1 (en) | 2018-11-22 |
DK3452583T3 (en) | 2022-01-10 |
JP2024028886A (en) | 2024-03-05 |
JP2022025081A (en) | 2022-02-09 |
ES2905791T3 (en) | 2022-04-12 |
JP2019514397A (en) | 2019-06-06 |
AU2017260426B2 (en) | 2023-08-31 |
US11278632B2 (en) | 2022-03-22 |
WO2017192741A1 (en) | 2017-11-09 |
US20190142973A1 (en) | 2019-05-16 |
EP4019628A1 (en) | 2022-06-29 |
CA3022801A1 (en) | 2017-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220193267A1 (en) | Engineered nucleases useful for treatment of hemophilia a | |
US20230201317A1 (en) | Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases | |
US20240002796A1 (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
CN105874071B (en) | Methods and compositions for genome engineering | |
US10758595B2 (en) | Treatment of retinitis pigmentosa using engineered meganucleases | |
EP3704238B1 (en) | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PRECISION BIOSCIENCES, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JANTZ, DEREK;SMITH, JAMES JEFFERSON;BARTSEVICH, VICTOR;AND OTHERS;SIGNING DATES FROM 20181119 TO 20181120;REEL/FRAME:061825/0872 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |